var title_f5_2_5152="Cutis marmorata telangiectatica congenita - leg";
var content_f5_2_5152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutis marmorata telangiectatica congenita",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reticular, red patches with areas of atrophy and ulceration are present on the leg of this infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5152=[""].join("\n");
var outline_f5_2_5152=null;
var title_f5_2_5153="Beraprost: International drug information";
var content_f5_2_5153=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Beraprost: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dorner (JP, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2677576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Beraprost Sodium",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3123370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Prostaglandin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2677577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pulmonary hypertension",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2677579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Primary pulmonary hypertension: 60-180 mcg/day in 3 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2677580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 20 mcg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10481 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5153=[""].join("\n");
var outline_f5_2_5153=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369711\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677576\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3123370\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677577\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677579\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821221\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677580\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10481\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10481|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_2_5154="Hyperpigmentation";
var content_f5_2_5154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperpigmentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmentation following sclerotherapy",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: New Zealand Dermatological Society Incorporated (DermNetNZ.org). Copyright &copy;2009 DermNet NZ.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5154=[""].join("\n");
var outline_f5_2_5154=null;
var title_f5_2_5155="Petroleum gauze";
var content_f5_2_5155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Petroleum gauze",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 305px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAExAdQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDvEBJBqUqe/SmjjpUiMMYPWuQ6iMA54p4U5FBHXim7jtoEPY4FIGyaQKzUMpXFUK47OWpwBJqOMEGrIbOBQ9AWoijGKm4C4700KN1MIIbHap3K2HdaPpSjGOetJjimIcADzTscYFNXj3p5xnpg0gG7SRTkUY96VgccVGGwcZoGPdcU5SNuKjDZHNA60xEuFwKTHFNXryacaQwwAM03dkcUpUt1NOWPCZNVcmw1Rz70vfimjG/IpQShpDF60E4HvSd6XvyKAGEMRwKBxxUwIximMuenSi4WGZ5oDHNLt9KQrgUhi8MetLkCmDinhcgZpDQYzzTDHkU7JWl6g0AIka45PNMK4big8dKTJpoTAnFNLDPFOIyaayimIByaXOBzSJx0prEnr1pAKW4psbHf7UFMpmmoecUILk7MAcUj4IBFIVyKco+SgZGowal4IphIo3cUAKx9KYWNJkk08g7c0CImyaZnB5p7H0pjZHTmqEOBNNZqOaYetMVxd1MY8048dBTSKADtzTGHPSpUAJ+albaTgUr2HYrnijk1M0fGaaPei4WIDjPNFK4+Y0UXCxZ3nFKvqahUnHNSjpSsO45s+xoC5wDS5ULyOaVWJNOwrjwdoGOtMf5mxUjIMZJqIjLUhhgk8HpUiZPA5pY17VMoAXpzQ2CQioe5p/lcZ3CkZsHpTeQSc8Uhj2jODkc1CCckYqbeX6Ujj5cnrTuKwsJAIzVg7TVRT8tPBwnPWpZSHOSB14qHHepY/mPJ4qWVVCDFNCZWTr7VMBzio1GTUmMY55piGsCKeg3LTWOQaEY4osFyUgbcDrTHGeAaUOOlOGGbHalsMgb5TxTgdx5qV1GOlQ9SQOtUncQ8dM0HnGKbtPrThkdaBCY9KVQSaeBxmmkYPNIY8gAcVCwyaecEZBNRsaVh3AcGnFjTN2BxRkmiwXFK7hQvpSqMd+KXb3FAEb1GDkYqZge9RkbTQJjkUmnNHxTkIxT26UDSK4XBppGT0qRyM4pDxQDGsAAKhxtOasEZFRYweaBDgcr0oQ/eFPAytNAG8UDIm5FKp45FOdcE0gqiRo6nFSAZWmMMU5Tnikxoibr0qPHrVk461FIfSmmJjSOKbjvTs4FI3PSmJDQMmjAp4Ximk+tLcYEcU3PpS7sn2pQBmlsC1DdhagZqmf2qI4PNSVYjPJop5UZop3Cw5FzUqoRyKbnt2pQSCKpXEBVjzQpK8HpT8+9GQxpkjlG5OKaqn+KpUyo9qMgrzUsaFQ8cU/Jxmo0FPGaLDHFunFN3dRS5U9xUeQCf0pDROnA6U2QkjilTJA9KUggnAoGRgEAU93XbyOaRgcUjRk9OaQAj4xipM7lGDUKoc4A5qREPHrTFclCcZpMn0zTjkD5jSA4piGkcccU3kCpM89KQ8mncVgDjB4xTweMihYgwzmjbgYI4FK6HqG7A9aTGMY707jGB1pQcdaQDMYpPmNSNjqKaTiqQhMnGAaRc4waMZOe1KOKAFVfyoKjOetIW5p/GKTGiFo+4phJ9KtcY5poUHpSHYgGSBgU4EipCoXmmH2oSDYac96RxinZGacw4piIlNPZzimHApycc9qQCEHrTetPYjkgUxj6U0JjvamHB4NOU0j9OKTGiQAbeKhPDCpUb5aik60AK55NRjipCA2KbsPWrFuKelC0h6UIRnmkwQjqajK8YqywHWowATyaSYNEASmsMVZbgYFQ4y1FwsIDSMPXrUhTHSkYUXCxAQRSEkCp0TdnPSoZVweDSbKSGFiRUe4ipCOKZjmkkNsQk0Uh+tFVYm5ZA4BNGc/hQjDdg1KiqFJxVEkQyDT1HNUNa1FdLtjKy7m6AetcNea/f3bsVm8uI9FWhJvYTko7noN3qVpaj99Oit6ZrGuPFdqjFYlLn1rhJJQ+d53P1OTTQ23jBXAzxyDWip33M3V7HZP4tkzhIEP41Cvi+5LH5I8Zxg1ye4lQeGB79CtLKX2fuju29eOlWqSM3VZ1R8WXO/BjRT7ipE8VTqF3ore4FclA7bAPMZpD2IzmpEYFt5/dFTzz1NP2SBVZHZL4vfaP3Kkjrg1PF4wikXJgbd7HrXENIdwWQNk9GXg00OWywX5B1Ze1L2SD20jvovFto5w8bqe4qwviuwyUYSL3yRXnwY7fnAbd69aCRwAd6d1I+YGl7GI/byPSovEWnDlpGB7cVYTW7BjgToM15WCQWwMHvGxpyE8BGbIGcY4PtSdBdyliH2PW/t9rJgLPGSe26pI3Rxw6kexryMSvksjiIjswzUi3syOF8xlb0/hNL2L7h7ddj1xio75pCQTXlf9pXS5V7hwOgaM5A+tPTV76NOJpT/tj/AAoVFle3R6tG4FOMwIxtrytNc1AZ8u5dx3ycY+tL/wAJBqLBS106uCMLil7Fh7eJ6fkYpdwxXldx4gvpWCyzSBcdV6fjUkeuaiqL/pDZPQZ5P4UexYe3ien8A+1CgE15mniLUcHbcYYDneOlPXxRqKHDyKGOMccGn7KQlWiemttIwKYR9K86i8WX6kCRozn25FTw+KrxCrNCsqE/epeykivbRO8wD1pM8VxZ8YTclY4mBHAGciki8YP5QEsIaTuBxS9nLsHtY9ztScj3pA5AwK5GHxehwJLfBPQhsA/nUkHi+ISHzLeXZ6jnFJ032Gqse51ZJNJiuePiqzI+RZGz6ChfFdkCQyyqR2K80uSXYfPHudB8ufenE9MVzg8U2W0+Ysik9DjipR4isiMq7gj/AGeKOV9h867m5KgxmmIuO/FZUGv2FwP9eFPT5uKsDULUn5biM/8AAqXK1uHMmXicZpmeaiWVWGQw59DUn0p2C9x468U16GO3FNzkZpWHcfH+VJJ0pokCkljgDqfSuS8QeJ/mkt9MYF16v/hTUW9ES5KOrOtklSKPdI6qo7k4qlJq9kg/4+EP0NecT3l3ON0zO6c555J9uar8OZBmVFGSV654rZUe7MXX7I9BbxNp28r5jcf7NQnxNZ8lBK4HoK4XDEBny0ZGOnt6ilVRvGcRZwVJJH51XskR7Znav4ugBwsTE+5qI+Lo0OXt2Hpg5zXG+YcHmMqOrZ64pwYK+IQ0eR1YkgD2xR7KIe2kdgvi2B8FoHUepYYFWLbxPYStgl0H94jiuFJHIEe/HfOCT60yWVMspdnYdkHSpdJFKtI9Zt54riMPDIroe4OakYcV5x4Svnt9SjgBcRScEN616Pu44rCUeVnTCfMhi7gOKimHNSg1FJUF3Iwue9RycdOaeTjpUbc9aYiI5zRSk0UwL2wevNIGKsM0HOTikYfLk0yTlfHU25Yo1cLjnmuJ3gqQjYHriuj8X3KvdlVIyoxXMlpPmA2MG4IrWktDCq9R5LIuX2uM5PrUkbnYSjAA9N1RbAznAZHIxluhp6ovCyLtTHJHUGt7HPccrgynkRsBjk8GpN3zKNuJAfvDo31pHBKAzKrjP3zxxQhDscOZUA4xwf0qhEhk2FvNVWGP4DgCm4IVT8rqfXBJFJGR5RWIZB6ofz701FVpV8vKPjOX/kKLCuTgBjhCHQdVY420isny7JQj5wY/X/GonxJuM25W6EKB39albYQAduV+645oC5LGC0uEAjPYnv370x2ZziTiVjjCcD/PFRKDh2Yeapzg5wR+FSqGZkTfuGPuDgigdx8qsHRJFC9w38qRvmO5i0iH7vbbTIUMYZo3IBOV83n8qkBb5UDOGxkrjg0AK+5VVWUbOuQMtihE3him6QA8bjnb9abgo7BQsTAdz9786AqMvzhldjx2GetACJFgBgybicFP/rVIypnCM0TgdT3z9aSYOpCzIi4XO4Dk0xfliLhGkV+hYdKAFzvUh1JYnkjgc1JlyVU7XGOq9f0qNSzthF3e2MD/ADikdFUu2RFnjGTuoAcqPtZ43VCeqHB/nTAULLyUOMiTJHX2p0kQynmoVYfdfaf1obO5pMm4XGDkEAYFAhGkVkYSEsTn5uQMdOtGWVVDMvl5Pzdx260BGMQTIx1CDIz6inIgLFokAPRg4wBTARcoHaJM5yCSAenFNdlR41+Zz12kfKMD1pyxnbhnYSMRwvQ09Yi0rZURMBxx+tAiNdwZ3ULF2JweePWnHHyAqyv1Bzx0oXOGMiF2zw4O0YJ9PwoLbnVQ29P9nr19aAFjYLuLEyjgMQc4I570qSFYkCSFFJHynPNJIwKOVPlNg8E/hTQcFVICsvBc57cdKBivMC4wGQ454z7+lNjn2xhtrPGcYJGD3pXkZmYnMpGQuU4GP/11GcBR5bMeeY+xIHpRYLkwdRKcZlbAGdvHNIJF2/e2uekY5701iFdjJ+7Kj5dgC4wP/r06ZSdgYIqZ44BZgPelYLjl8zzAGJiOPvY5PPakEoVSAshJ6Mep5prAK7eWHk2/3zkLgVH5hRVBlYrnlVQjnrxmiwXsXVvrmBlCz7D1ATmtO28T3yKq7w591rn4x97y4G2YGQ/UnrRIwG1JHCY/5ZqeBUuCZSm1sdlF4ukKjzbdeOCQ2P51M/iu1WMsqOzf3R/jXBkoMhA8p+vAqyvmK4yqrxnPT8qXskV7aRt614yRrWSOKFkZhg85NcpDKsrb2VijDGepHbFNvkZuQfN5wG9KfatIskaoVGOx71Sgo7Eym5bk0EYaFXDuFBG0bf61MiyM6s4jfGMBeuenamZYN80a7yeo5AGaFZPOTy9yHHUoecGqJH/IFy6usgPQLxS7ijqcq0jDAAye/pSDzPKkWJA688EEUwlCFUqVwSGLE/KcdKAHb1QSeYCH5wgUf/qp7szxqWljdR/AF56e1NQuu/yisoPfsvHWmF49qHDF8geo9O1AXFYkIwnfZnBwuRxUbDeiGPCR/wB7oTUsQxJtDLK7D5vlJqK44x5m4kHiNeg570hojspEt9RhkZyzhx905GM165C26NW7EV44/wAp/dRhSDkN616xo8rzabA7j5igzXPVWp0UWXQwHU01/wBKRlwM0bhj3rG1ze4xsUxhnpT2I6mm7gMjGakoYR64zRSb8dRRTA8t8R3V7e65NOs80MUZITy2K5pdP1TxQkyxw3csqk4CzKHz+fNdM9vJdXax20arNKcAYyfwr2LwJ4D0/SI0u7oLdX7AMWYfc9qdKLaIqNJnCeHfhfqeu2T3us3a2Mr8xqIt273IyMCqGt/CXWdPzJbXNpcL/skofyPGfxr6Gqlq9p9rsnRfvgZWt3eK90xSUnqfKV3pt9aTtBcW0vyZ+ZBux+X0qoqlU3KuUJ+bPbvmvarWxbzp7jG1oyVJ9/SoD4Zju7SV5IIf3hyGZASD9a5fr6i7SR1f2fzLmjI8aXZvzGGIUdc5/SnpsaIHLRsxwQh/Guy1PwkqMwaJs9mjbp+FY0vh9lICyhR3LoQ2e3IrtjXhLqcU8PUj0MeJjK+DhSq/e7U5mQBiXZlbpjPHpU9zp13AXaSOSdRypBz/ACquchUGI9q/f67hitE09jFprcU7osFpNyDJ2KeSO1IxChnt2AUdmbgYojUF22plQo++3X8RUcio5SNFbcWwQuCAfzzVCJAASmDtlJ52n72PapS+0uX/AHbKeDj/AAqKZW83a0WwqBnnPvUaCMIuYJSAwAcZUH8KQFlC/BeMMM4Z+eg7ik80hmzukXHykZGcckVBC6iTLSCQqPu8jqfyqVZ8ofJk2BjyCcHr0osFyTzNsY4Qo3Hzcle/WnJIsvyqxkHXYTxg+gqNAk3MIBkwWxuAp2Y8u0zHepIQjGBj/wDXQMeCF3GJvLJ/hbn/AD3pNxJCAFWyTgtwff2qMqUKM0Q2n+NgenXP86CdrkNulA4HX0zQFyQ7Q+S+1R3i6DFLJuSEFtrIerMuSR1piMyg7NoUgArnOMn060+Nt8m61UnCn5mIOfwoAitJPtWWgBZMcKw6fXNORMj5pNkrcYA6802SQM0gmG1ycbQvXtU0jAhY/LwBkBx24/nQArKyuFdfL75Py8mkeU7cnLk556D0qDcu+SUCSRD8oweuB6GpmyFiR3AjHIRG5HHcUCuLucFQzqq8ksPvdMU1H2gllDp/tfKTgURKpYi1+cgAElcY/A0gjLqR5rozY3bQcH+lAEgbb5f75jjnZg8cevSo5CpJfKxqMZ3E88e1PBKzKQgifB5bjJ6d+KZKwDOZSJHOfmHAHbtQAxipiiUqS3AyeQe/1p8qOxXe6ykcHYTxz70+RnEa52tH7KN3A/OnqxUt5BUEDpIMk4HvTArNEfLBjm2Kx+4c880OgdkD5iYDO4AHvnipskqpIBYfebng46gUhVgxJAnxzz/CQO9AWI1VmiA2l03cMeOp7igRgynyw8i4wc4HBPbFLHguo3ndkZVe/HpT9v707j5AyMYBXtQBEv8Aq2IcIp/5ZZOTz3/WpGDSsNsUUbJnLMSQO3egqPKUnAXIy+DmnuMlGkld4iOAi9ee9ICtLsUyFpwCSckd/pgUsY3H9zGxXGSfvE9qkwdisscYGf4iB3+tNEn7ws8wyBztU4FMQ4KWVdzlE3fcHBIz6VKCnn/JmUDsR93NRKclCqOz8ZduhHtUqt8rCUPAAMkAdRj2oAoX4h8vDI6v6LnFQWITlWQ47nFWLiSQRgKyFD0J6ioYI5XZt0ikEjGOntQxk+ELSrFcSBOpBSp3LPEu9UdBkY4Bxj2pN2Zh5kSD5R83OCcUgERCsWCOSPlAx7f0pAA2nfvPkr/DjdzxQQzJGfOwmRgF8Z4+lSxhllAYpITjcm48VE/AYeUysOi8YHP/ANegBQqStypj4Gdq57+9OjjbypFhDBB1BGMc0soZ2XJV48YKBMAH0NK0aqH81Mbjxs4wMd+9A7DNuSFGIwARuLEc+9NIjRHQFS3JL46VMC8mwlw6j7qbsfmKYy5UglYUP3uv5UgKU4Z0LGU7B0HH9K9F8KXMUmkwIjDcq42k81544RgPLUAYwCGzmtrwy7pcwLyvzYNZVFc2pOzPQeWHrTCKkGe1IR3rnOkbtB60hQHpxUi8rilKhTUstFZoznvRVwbSOaKQzoNC0T+xtPtrgWl5cXkzb5ZLQLvjXHC/N1B9jXQ2+oSNewHzL62hJzIt3blRwOm48c+1YOm+I9T1SSZbHR3iuCFjR5ZgiRJj15PJ9B+NbGgQ3P8AaEzX1nIQE/eSyx4AcHomSSwPPIrX/CY/4jqIZVmTdHkr64xmn1ia94m0zRLEXF3OuGGUQHlq8c8W/Gecb4tMVYweNyjn86p1EtN2Ty31PW77Tore8kNtcW8YuOJIJWADn2FY2qTWum2pS9vkt1zgQIQ7H8PSvnSTxhe3t0JbmWV2Zgflc10tq1zqUy7FlllYZ29T+NYToqerRvCtKOiZ31x4x02Bj9msjMc/elb+gqlJ49iYMTo9i5PbaRj9ayh4WviB5j28ZIzgyfpxWlp/hC5sIF1B0S4k3hIIsffb1APXFNRihSlNkq64biFrmfwnCLZeWkDNGAPqay4tX0e9uil3o7RQk4DwzbiPwYc16Zo/hz7VcJqPiKUSBFBis3z5cJ9SDgE/pVXxPouk32pwbIbcAfM7wYBcD+EkZxx6VTSjqxJylojhZ9E8KXwbydSMJ7iWMrj8VqvN4JtZAI7HUbOYsCRsnAYjHvWtqukaDaTOFSVMZwiuSWz0znoBWPDeabG7CGFmlPyks+cj04qVXXSRToPrErXngG9ttPkvJLiB7bONzMH2n0+WuafS50IWJVmjycjdx6cV6LaaRq+t2oFrBILRTlY0wqZ+mevvWxaeELG2jY6m8oZRlgqEkH8K0Vae5m6ENnoeKPaXMJkZbYxoowcgnge9RFcSKY9zSL1+YEcD0617jbeFNJvEVjdtEjDIUqxP0OakbwT4Zjspbt5JpwmQNoVCx9uK1jXfVGMsOujPCSN0jbowuCP9UM+/Q1Nb2k5twsVuzA8gqhBHPevYpfA/kWK3TTC2MmBHFt3O5PQcVDf+EYtOtfO1DUgkrDKw8BvxpPE26DWFv1PKVt5opiRDLKpGCAhXqemcYpY47oo5t4XiVycqc5/lXf2GhTagZJklSHTov9ZdzfKg9h6n2FN+xxXVw1voUL3AQfvLqYYUe+Ow/Wl9YfYf1ZdzhVs7oAEwvu3dDjHSli0a7a4eRoi4fB2owAU13U1hZadNtumNxcf3Tnr7KP60+4meC3WWaOKyhP3dw+Zvov8AjU/WJdh/Vo9ziH0bUIVTdaMYiR8wAZvX1pklhdxgs9rdyRejqRjJ9a9C0mLWL/59K055F7XFyAB+AOB/Os/V9O12G6KTkSTMclIlzj/vkYqvby6ol0I9GcFJHIiOWHlbj/qmznr1zinuy7j5O8kbixfGPp613I1DXNLUCZXaI8FJEyPyYVO+s6TdJs1bw/YSlh94ReWT+K4q1WXYh0H3POmkDwsXIAJJUKN2aVM/KCqgjnd1A4rvp7XwbcLiPT7u2c5/1c+cZ9NwNYWq6bYmQCyurl4gCNk6DI9sqf6VftYkOjIwI3DPuO6QcZMeT069aeQfLXaxCMRwzjPXoaknt7mHc0UL9+UJYH6jr+lFravdSILW3uJrgfMdiE4wOuMZ/SqUk+pDjJboj2xO6uo8pwMnc2AOfam+aj7lYvKwO3epz17j8qsSW10JNs0E4JHG1dueO/SkW0uFKq0alQecgAjA9aXPHuPkl2IwFVwFl84/3OeATTZGTy3cZj38bcE96tx2crPsii2gYA2tuOKsQ6PqMiqkenyO5wCyxMSw+lHPHuP2c30M77sg3gxjacOefYcUgbmRgpnUE9AR2retvB2uHds0i7KEDg27Yzn6U/8A4QzX8/PpdyjNwWMLbRz3J/nSdWC6gqU30OfZTH5JUxvjny+44prbi0m0eRjgmQgE8dBXdp8NNfaNZYorfnJzHOuR+NDfDTX5NzXCQA9i064H6ml7WI/Yz/qxwLeXGq4IY4B24+Y4GfSiMShSUjKIeAnBzx613U3gDUh9++0yMrkZNygIFMj+H8QUte+I9NiQnJZZy34cKKPbRH7GRxnJkBncOR/Aj8CpRHuSQxgt15c7gPautTw/4ejn8tPEdvJ/e8qBmAz6kkCtOHwh4ZucCXxKgVupOwAc/wC9S9vEfsJdTy27VVIzEN6859fpTI/mVyqSgZzjpz/WvXU8BeF5k/c+IvPYdgwxUH/CKeGBcfZIvEFoZzng3ScfpUyxCXRlRwzfVHmjNseJlnIkwAFk5JwfenKxWNy4WYd93BPNerJ8L7e6dDBqVi+37hEm8j8gKkPwluIg3/EyxGeqwRAk/nS+safCxrDf3keTOkSMNgKMV+8X6c9BQjTfvEQmQEnDDBIr1Rfh/BaLnfcXODyHj2tn8Kpap4YvbWRTZ+HGuNxGN7Bcn2yetYvGq9lFmywDtdyR5tIMvGPLk3Hq23IHHrmpI2w7AFJGO3qGHP511f2rT7W4kt/EOj3ukdt/lbgD7kV0ei+BtC8QRM+ia/O0g5LKykFf93qKcMZzOziKeC5FfmPMlKFNzeYsgx/FwOaW5JBBkO/HIU8E816hefCe9gRmiv7aWMfwvEcn261z+peC9Ws7kRJp00oxlXhUDP8AgfatXXS1sZRw7el0cV5U5QZVVyewztq3oWI9ThSRmYb+3T8a059Fv4pNsttdo46qygH+dZ97Z3cMiu8EgjB+YdOPwzWUsQnpY2jhba3Or1TxNp9ipXzkeQdga5HUfGkspIgm8sZ42jFRp4Pju7c3ce9gxztzyKpSeFoGYrmRG7ZrlnVa3OqFNPZmjZ+Op0wJ2jlA74wa3LPxvZzECYKo9jXDSeFXDFRJz2OKqT+HbqJuQCfYYpKqu43SPZLbWNOuIg8d1Fj3ODRXjA0a4xxuX2zRT9shexZ6HoXja+jdInvr+0AP/LpbicN9R1Fer+CvGUt1vttTS6ZGYmK9nh8lXXsNp5HNeMabeTQAxoGZOCojhQEH/eJFdtodwsskbeXNEMDcLgjOe/Q9M0Yaq5OxFamkrlzxj8MNZ167e7/t2OVG+5GyFcDsM5xXJ2vwT1Oa6eGW7gJX7zLyF+p9a9N1LXL8WiQaYQHOFBHQe9dN4cvtOt7VNPS+SW8TmXIKsznknB966YRV7Iwk3Y8vtfgvo+jLHLql/d3Uhb5YoVCDP1NdXY6Jb6ZFGY7IpHI2IrdPvSEd2Y810Wp+JLGzQtcyo7ozYjUHcCOmQenWvPrvxjq+r6rGljBHMFbKRsvA9yfpRL3nuOPurY72K6hii2XVrHI8XLDg7W7KPWpbQy3U8hkbyGGeMD92AOgyOPc1geFjPqk3n3rRv5TF32rhRgDA/TP5V10Fs8tmizRKPNLFtvBQHp/9emk+gNrqQGBNQUyTXwkg3YAU4U4rE1a307TZhPAUkkxjgj5fyqzr+lx2FlNNHcFYwP8AVEdT9a4W4h80gSPKQTkDPauarGTurK/c6aUoqzu7dircLda5qZt7GEEu2Bnn/IrrdN8B2umW4m1SeKSQkAqAEX6ZwTVLQrmTSXcWRhDOu52dMkD0BrZufEslyFSa3g8vPIzz3pUsPCK97VjqV5yfu6I6GzisbWFVtJ0hOOzAiqniHWtN0awEt9P5i56lQ5rLsNRtHYG4t2Ccn5TkY/SuE8dNLrmrxxR5WxRuY84yB7VXNNKySI5Yt3bZvH4o6BHGEiCFF+VVKFiR6niqtx4q06ONdS1rT7a2sWy8UeCss3plSOlQR+FNCmWJoRbRyKobdcAglu2CBxWd4h8OteQST6tFHPLCPldZ9wZe2B6/nWcpVU9X/kaxjSa0X+ZRb4pWtxfz3MWks0pwLaNXO5COh47/AErI/wCEqa4vZJtfs7qWcnKW6Z3SfU9QPwrR0XwxpkkyzEPEV7K5jOP613mi6Ho0199rvmgSOIAJmQDP4Ue+5KI701HmRx+kxeJ/Gd3FC2nz2GkxkFQ4Kxxr7ZIyfoK7rUtOuNM0yHRtCM32iZhvIwDjuxI6D8ar6texahfNbWdx9js0+QMGIB96ns/A+lRxtPNrVzJPJgiTz9gH4A5NXHnbaS+dzOfIrNv5WGWPhCOwi3zXqiZuHcKCUP1Jq5beHpNPdZ4rmK+ac7I2kjVgjdj9MZ/Ss260yK1IWx1q+ZiQBgjafXknNSWMMaOGkvr4KT8reZlieOcE4HWrU5Xty/iZuEWr834HQjTNaXa0F7bKWHIaI/zzUMtv4rt0/d3FlcYzjghvzIqq+o2VvCqQi+uSCMiS5Kgj8DUqeJooFAisAg95/wD61ap/1cyaOd1GDWokkkk8LWs078mdVEsh98E/0rlbueyhbN1p+ppdfxCTagz6D5K9DuPGW18Q6erjP3hclf6U5fFqyeWfsTqVOc+cHyPxFAanlyRC+bdDb4UdWZ+B9WPFK9jI0ojhjjkI7xtuH5ivSNQ1i21GN47jTIyHzgiYqfxwK57ULCGSJBatNHGOqEjGfXgDP40PyBeZzk1k0CK0rQhj/CHDN+QqIQJJKk6zT21zF/q54G2utaL2zRP8hLe5XrUAs5i5zjk8bTU3GW31DULiMJfPp2pgEEPcxNHIfYshGfxFTrr1xbBRB4W8PsFHXcT/ADFUBpsjH/WEU9dKLdZmJpaD12NeDx9rVuQE8O6ZGo7RTBTj2rm9Z8VeMNRlb995EeeEhuNg/StFNITOHbNTDTYFPA/OnzMOU4oweI55Nx1a5hJ7i6c1s6dHrdsAzeINWdh2Sdgv610C28aEbQPypxQZzjPpS5mPlRWW/wBZaIp/al+VPBzcGsafSFlkzcSTkd/3rc10ir35qC6iE3yNnnjik2x2Ryd1p2iwJi4mdV9POb/GsG4j0+4LDRtM3sOPPnJCj6ZNdrqHg62vFbN1IpPTcAwqrB8PbAAebe3D49Dgfl0pknms/hueaRmubnbg9c7VFV5tJtrZTtv3kYDpGP617NF4Q0iMDKM+ORubNXYtE06IDy7eMYHpTuKx89yQ3JYNG9wE/wBokn8alht9nzRpK0x7kcV9BHT7QdII/wAqj+yWwORGnp0BouFjyHQ9c1jS5FKQXPqCd1dra/F/X7OKMTRO0fIO5SSD25xXTPbQFiQo9OgqCW3h24IGDxyKE7bBa5X0T44XEkvl3kW4Hjd5XzJ/iORXpGja7pS2R1m/1S1urp0LoFcYjX0A7GvAfGMdrbava7IAHcfejXBb24rMvIjJaCXR52ChtzwsApPrj3p8z3FyrY1fib8QtY1rUTHDeyxWyP8ALDC21SPQ+tc4uvXsDQ+UrSK3DEwjd9NwAz+Oa6Pwd4RHiPWIt8qrAB5kjsNuxe55/lXsfkRWduU0eEQW1ooRflBLHrlvU9zWPNpzSNVFt2ieKReOPGenQiHThdGIrgbrZnOD7nOKv6B8UPHSXKQoJJmAOITbAnA5JwOa9z8LeM7S8ja0vo1guk+ViigK/wDhVrVLbTr9iq6LBM7DPmYCke+4c5q+enFXTJ5KknZo8jX4m6lebX1RvK2kgugGAfTGOK07LXLDUkkV5I2WRSpYnp3z+dM8eaHBHfLbz23kmSIbdnBP59a8y1HQdT0uQ3NipmgU/ej/AIf94dqmS5+o17p69o9pFDEBBOhjPQEdK0XtLK4QrPCu/wDvgV4OviXULdNsUp3oeR0xWnZfES6hZVuGJHfHak3OK2GuVnqVzotm2UWXntkc1VOj7AAzLOmOh61gWfxC0+Z1+0lQMAdK6Cw1rSLwL5N1knPB7VPtCuUcnh2wmQP+8jOOVBorSjxsHlbXX1DCin8hXfc85029WHlYpS/Bw8O8N6gYzXSLeJJI8yWrWdtIcwxO2Xj9j7VgabqpsLxZ7u03QZO6GIfOc+hHTnFWb2/tViWS/n+ztIMgspI/SsMN3NK3Y7HQL4XMwjBXK8ktxW34pEdttmmSWK6kUGG4T7rDuCK80svKERuftcEyhhhYZHz7E46CtEXOoa1drGsk1xI7YVQzEZ6d67k7nNsFzJc6vfpaWnmSSMduBzz3/Wu8i0yPw5pkOnWwEmq3xVHYD7mff261Polhp/gjTTLcN5uoOvzY5x7CovD9xcavqdzqk8TCKNGjiIHCsw6+/FNtLT7wSb1Ol8MGxsNFaUyr5bSOOfY4x+VWz4itiH8qKeRl54XA/OuaZJL+dpo/LjtlIU7W5d8YzgjGaZrj/wBn2q2turSXk/A3MWbn/PSs5VJpe6aQpQb94z9Z1+41OWaMoEi6YHP4VUt4hErSS9vX1z/9arN1pbaWtut5gTSIZWA7HOMVRDG7nwMrEDkjH+fWhJ/a3CTj9nYv2bjLOEwjDk568j/CoLgEE/dx6ZHt/jU00ixoArKcDHH41lXM7SXLMM7cnAFAkjShnRIMuMNt9Pcf4VkjMl1uPQVP+8fO8kDHGaLWHoScHPekMtxqVRuBnAqO9TKnDDjnA6U7Dbc7hgk96hldY0IZ0BPqRQBDZJvuAucFjg1oyv56pFEoIGSWx71gveKCViY57tUSvID8rsQfeqFc6q3gCwyFShC9cjrjOOajvYdix8gLuwT+feueV5Afvn3BNTedJjG4igVzQuCgclW4PIqFWf1PH1qqHb1OKkLEjqaQ7lkPJ2JpvnYyCee+ah3sM8/zpucnPJNMRKWBxzilRsng59aZhto5x+NCh+Pl49c0AWfMI+lGSfWoSD0wM4qaJTzlgoA/u9aAK8q5zkUoUquFAwOelSGIu+ARjPpVs2v7kt0B+73zQFijESc5H6VKo289SKkjiGTuOB646U5Fzg87T+dAEJOCcgcU1+1SS8k4GKYVOODSGIeATTSRnningAD3ph+9nB60hhvGf8ahkbc3HXPWpsDHTFMjUGX2BzSAmQPgc1IIzUy4xwKcwxjnFNiIQvrStGO/SnFsfSjOaQEezIPaoXhPPerYGaR+4HJpoCg0bY6Dn3qNoyTVwKT2xTSgB6ZpiM9vAr+JIXvEvUsjbEgSfxZx2NZmpfCue1tDMl1Z29tBl2nBLPM2B8vXrn6V6n4Mgtn065M6jKyZB3HjK1yPjXV2vgbWJgsSZUKgOCemT/jVNpISi5My/DGn3em3KabHBie9iE0Z3r+8Uc7dxxjvwM8ivTNOOkppQiu0a1kR8ypMfmDn371wuoMLvTUjtnxqOlBbiB1PJT+ID6HB/OsXx9d+I9Z1ZYrUeZIFXZDFkbcrnoe5BqYuLV2rjkpRdkzofEPhWxuppL7QtWtldWyUkkCgH054qpZ+JtZ0BAGVnjUjzEC+bEc9wy8jNebat4R8cMVe70u6ljTkoiEr+IHWmaCPFOk3L21pJqC2wO6W0C7CQepCMP5c0nSSd1oUqzatLU9n1fUbbxRaFrqzQIIS8UkbZfnvjHQV5NfxvY3RRLvbKvAY8Bh6Gu0TxNa6aI5nsru7nIO+W2jAwhHKSA4yc9PSuf1L7Be3a3umyxXdu/MtscCRR349alp/E2NSi1ZIp2mo6TclI9T02088jDMq7d/uCKk1HwtorQrcf2NfNHJyGt3DD8jUut+CY5L20fQbmOW3u0DKHPKE/wAJ9Dnik8J6xqWkO1teQl7NMkqzYZB6jPX6VE21sXBRe5BoHhTwlc3BGopqcEOMnMGdv1K8gfhXTxfDnQGbz/D8k93bgZ3Wt9ll+q4yK1vg5c/2pqWv6q8e7a6pFvUnavOcYH8q1fEfgqz1jUmvdHLWV99/5Q0LbvVTgVpCLlTvYzbip2uc8mk2dsoiOjXFwR/y0a4bJ+uMUVdZfFdgxt7pUupF/wCWs0O5mHuR1+tFcrU0/wDgHYlTa2/E5OG8srySCOXSbme4aJkdY7d9zMc7T8vGRxnHpXRaJ4a/syOPWtYjS08niG2u8YZuxweRVWx8My6nZQPY61dR3DYjaCCPDxv3BJIxj1NWPEHg+58PvZzX+tDUbSTCyDUWLPE3coVHI9jXTRjyrna+Zx1Hd8qZfTTdZ1XUkuJbfw3qUSjn7HceWyg93GMNWzbSR6LZy3dnHDb2xJVW2/PIRxkE9s54rOtrqCPTSunWv9n6UePNYbZrr3x1x7VrWWlxJbnUNcRRAg/0a1ds9O57En0rW6ei+8lJx1l9xj6Pod54iu/td9I0VmW++/3pPZa9Bezis9OFhYlYAwK7u6jHLfWsjR9cN/qSefGkFuOI1IyQ3bntU+ow3t7eTtb7jaKDG6qQrMR6H0q42UfdJkm37xlwiz0m6QtIL10yCI3y6n1CdOnoa29H0yPzjqVzGRM/zKrHcUz2471PoOmWtraq0dukchJ3HJZvxJH6UNf2umwSZlJWP5fQFyTwPUmnGNtZEylfSJx/xAcPraIo5EYUkEHPf8Ko2saWsELnKnrn15HrUM269vLi6mlO9yWOT7cYH5Uty8k0CJHyEB4yMnJJzWbfUtIpTStM55GM9TRDFGhZpWU4BqBxMp2lNvse1VJY3DbsMT7c1Nh3Nh541UhNuB/ntULzptypGQcHmsh1kHOHA9SKjCM54+b1NOwuYu3GogLsj3Egk/Ss2WV5W+ck/jVm3sZJ5MRxEk89K1INIWM/v2VD3CjpTFqzFhiZuvStCCBv4QTWqI4IV/doGPTLdqIZZEJKnH0OKVxpGcYHXkqRUbLye/4V0BuSyMshDu/OT17/AONUJIwcgLnJoGUgtPHBFW47Mvz61KLBuoBI74oAoAf5xTwuTgda0I7TkAkAVZiswvzZVx6A8/lQBQji/ibn0qYRDJwOPWpzGc9MAe1KiAd+9AFSeFUAKrye5qEqOh61o3S/IDjp+tVp49jL1pAQ23cgdeKvEkxqONoGOnNUogPnUgYNakRG1B1A6+lAyAQHHA4PcjH6dqgZPmwMexrTuWDHIA5GCfXp/hVGTnn0piRVcAHpnFRHk8VO/X2qHGeAKQxh4zQfb9adjHWm457VIxreopIeZhTm2jqabDjzOKALy/Shz6HpSdx2ooYhm7tinBsimsvPrSHge9IY8de9I4yBxg0R5JqZgAKaAgPAznikJ796HyTURJBpisTQ6gLKOZGbYJhtD5OFPqcVNLoulvaTNaanFNIEy0q4YE49+nOP8msTUnCwkuTj27Vgzyt5W2CRhjp8+MUvMrfQ2Ht5LgwG3llg1Bxs8uRepxyFI6g+nvWRc3Os6VfGWaQxMOpTgH6Y70zTfEF3p1yslzBFd4Od7HDL9DXWzeJrDxMqQSLaWcSr83nYEjn2PSs7O2jNU1ez1RSs9b1ie1WczzTJ14mYEVJP4l1S6RY4NOkmkUY3Tjzdp/GorbR9S0WcXlj5s2iznD+UwZk98eh9at2+t6tBcmKGSFrR2wpkwCp9OOtTGU76/kOcYW0/M5nU7p7ezle6tZUdAPtEcYGGyfl4+tc3Glta3jR39oYXIDhg+SQwyCrdR1rrfE99PDNNDeRQK9zGQWT+I5BHPTtWP4wgtLu3snhvY3kWIA5X5lAPH14rTnMeQVvEiaUDCkV1PaPyHbaXT346/kKp6jq9lqhafTLoCcKQ0b8HHvmueu7qSRdjlGSMYU4wfrVXTBDqmqLDNFGV6GUfeH0xUuMZaj1ifQ/wMeL/AIR1zCoUSOSR3BFegtqNoLv7O8oWcHG1gRXhVhoHiPQ9Ht5dMaK4gUb4kKtHMoz1DLnP4rVyb4lafGLeLxlY3YVDtkm8rIX/AIEhyfxH5V00pcseUwnHmdz20XtqScXMPBwfnFFeET/G7QLaVofD/hW4vbFDhZgm3ce/GD7deaK25zOxXsvE0ei6peTQwRTXEkQDxRFnVD9G5JHSnw+M7JrlNQ1eO6vbtBhFuRtiiHoEB5/GsLRvFEQJW4sbW6ic5IOVZP8AdJ6/jXX6ZqfgwTyXlxaATQqJIop0KAyA9DztI+tcMdUlc75KzvYtaHq2o628moiNEmU/JPefLEo7BFxya1reON5Xu7rUxqUsfJyDsU+wNZ17ql9rtur3F1ZtCOVWIjKg/wAOB1ps9uPsyQwOsY/iIOKJO2goq+pCl1O8906lndsudp5rTtfEv2IBreafzSMuWTIHtzUFpaWNlAzveLG+PvHsff2qtqOqI1vLGDBcu0XDRZOOf58VnJtSTRrFJxszo9G8atPqE1pckRSzr+6YnCqx6Dn3rr53tbCyWKUq7qhAzjlj1PtXgutstkYbibSbhSVB+aQAf7wxzUejX9/q12ZHLx2kPRGLMCfqTWkMROStYznh4LU7O4n3ybFICrxx0PakXegVsn8KojdggA8dx2pzO6L8zHp0rQyLkl5I4Csdw9/8+9PW9PdYz9VB9f8AGssHI6mnoHweTn2piNUXQPBjj6nGBiiW47+WmR6rWUJCvU1NFLuGCcUASPcSvyzEDPAFJudu+KXaCFP3ienbFWIYC4XgbRzyaQyKKGSUhVPWtS1tk+ZCpzjk9eeadFbqsRDtjjp+X+NRxgxSkBifcn60APeLYcbR0qhINpNaErjzMgk8dqa4hZAJnCgD8aSYNFaCcoMZ4PUZq7HdSbG2sQGByAfWs6VYQB5bEn35qxbsrIORVXJsKqgEgZ5OeTT1YqeuD60hIB6UqjLdqLjsTCVWXa45P8QpywHblDkGoWHPUH6GkDEdKLhYWTO4j8OlNuFGEIHOByfXFPLHb/jUMs3GCR6UCsQqhV8nvWii5+UZLc9D25zVMOMemKsq20I3HzDjnNAWHTDa3vzVSY8dalkmBHXmqksgNAyJ2xzUTOeMU1354pnXrSAeX9DTGYgdcUjEDrgVE0q9zSAR2J71Lbf61R3IqsCCw549alsMyTlz06CgDU28ClxxSk8AUhbg0mwSEIzzmmEge/ekZuaYTikOxKhxn1pWbNRIaXHNNAKTxUDHmpmXgY6fWomyR61QiIWI1O4itGUlZG+YA4OBya6m3+HHh/yVnQTTcbgrMOfasTw+zLrtoxHAYg8Z/hIr0fRry2lQ26DyZ4/vRNgEe49RVRhGTtITnKK90wm8CaJNEv22ytwB0EabSPx6msjW9C8NaKQLXQYri4xwJNzD8q6/Xtb0zTreT7df20DqNyh5BnP0rzfVviFNqNy48M2fmynCtOeg+h70pqlSQ4+1qsvWv9p2sF5dXM1vpcckY8uBU3Enj+AnA4yPSvMrjVbvRBNH9ge73yFkm3/JjPTAzXVQeGPEuvziTUnkt4z14JJHsK0tS8Pa1o8EKafaJeWoO0rLgOfwz/KufmlLZaG6hGO71OCtPEVzfyFbjSw/ynIEHAPqaybgnZLMLWaNWXAZnBH4DtXdE3MEU0txYGzK5DKCWAB4JPbFcVrsi2VveKuGD8oAc1MrtoqLSTOUu5i5MQPJ61peH4BDcRCPcrE5yayLZ9vLAHd6jvWxpkxWRM4zg4rZqyOe92ekyX+sXMCXEU7THYEVNwQqB024qsl/BcSR2etROLnORcXSeYP91xzuT9R2rK0jUQNqk49Pard7MEnXo27nB71nTm72ZU49j0GCDXEgjXQP7Ls7HHEBjVQh7hSvDL3DdeeeRRXH2Nrrxgzp+o/ZrcklY1ulUD8D0orpV+xiYMMUN1DHBGiJP0aOQASH3BPBrfh8C39zaPJpirOyjJhknCH6crXLw+OfD2sKBqFukLHq0XBB+nSuk0e8VFL+G9dgmJHEczhXHthuPyNc6ab1Ol3t7rJYdBv7SxRxpN2k6khgrAgfTpms+S78nm8S+tm/6axn+YrUtrvxcZ2e9imNueBLCgCn64zn860TJrKWiO0MnkPlVNwFw3rjd1rVO+pk1bqc0L2CYFI7uJ2x91zg/rVnwt9qtRLdi+soUibcsLygSN9F70t7aTPnztMjbP8AEsIP/oNVZvDl3f6fJNBZzWsEagm6Y4Bx1Cr37VMlrdIqMnazZ2dvqWj38UkusatYQIzHaGyZF/TpUK6dpsZJ06986Jzu3r90/Tv+dcNoekJev9murox3S5wdoIdfUD168fzqRdF1mNpGtJI1hU4CsfmP4DOPxxULlvzWNPea5bnbm3PIVs9hzUD2LM/zyDH+zXFS3l9aKRItxIw4yqFV/PNVZPEd9GhLW820cEhs4/SrVSD2ZLpT7Hf+TEgODlgeSTTHZRnBxk9u1cFH4tYcN5gb0IFXIfEolwAMeuRV3RDi10OtdQVypGfrUSuOmRWGusGQAoyH6HFRvq0aAl2Qt3+bP8qBHUxThcAtkVope2qIMSdK87l13I/dI7n2FU3126UnNs+098gfzouhqLPUP7VtkYjzH49BUL6vGzgpu9Oa8yOs3bcwyQL7M2TT01y/i2h0hOTwwbrSuh8rPSWvSQST15pgYMcsevqa5O311nTbiLcBk/Mp/rVmOSZ4/N8m52Hu0ZAP6U7pCszpwY+Pm/WpUmAGFNcysGotEZUt5RDjO/Y2PzqJXkz85BPfDGnuSdcJj1ponyw5xXMCSZeY3dT/AL9OF7eKfuhvyosFzqjKNgJYU3zxgYbI+lc0dTusY8oD3xSpqd4vQRY9MZpWC50bylgOtWtLtIrqQrdSFMjCDOOfU1zUOszo2WhTd+lEmq3T8rtQfniizHobdzH9kZ1mkxgcHHU02OVpQnIyeMEjI61zjXksrETSO31PFEF2RCixkgjinYm5v3UjI+D64FVXm5xms9Lh2xuYnBp8knfNKw73JnmI6dRVcXDsuTkGo2kBON3NCK8hwisfwpXYEiMSpPvSSSfLjvUws7lYsmFgvqcCoXtph1jJ/EVLuNCuNiKgPzt19q07GLZGKybbzDcYdMEepxW5Iz2kaNNEVVuh6015i1ZMw+XrUZzTBdCXAijdyxwNozmrw0rV2z5emzEj1IA/nRbUClz+NROSDxxVi40zW4wWbTSEHVt4P8qj061klk87Vd1jZ5wqtzNMfRFxn8aOth9LkcbAHmpd4GM5Aq5PDctC39m6ZBp1ofv3WoybpSPZT0/Ks+W3cjNx4i0rB6iK2J/kBVWsTd9iUvkttBGKjCsWxtOc4xjoaiS00QSq15rVzOoPKW9qEz+Jqcah4csiFtIb517+ZsJP4tnH4VSE2Fnvj1C02L8xkAXI65OK6jxcbeERhf318eFijG5iaxLbxfoVrKkiaQYpFwQyqjnPrzj9KS58VWxfOmzyW24ZlliiR5JCfQuRtH51M4KStcqE3F3sTaT4AuNQkN54haMFjlYAgbaPcmu5sdDsLKJUtreNQo4CoFH6V5yvjyysz+9g1K8cfxz3cY/RTUU3xZnmxHpGmPLJ0Cn5h/47miKpU1tcbdao97HqsjGA/u/Lxj7jNjn2/wAKoytBPJJvmjhdQBlyCefTP6GvKdT8WeLLyJZr2S00SDkK+wl8/rj8cVxesXss8Xn317qupHd8hRsRk9vfrnoKqVdLZEKj3Z6t8SJ/7L0O6cXKSSNwW3DcD1HT6V4pq+s22qacpeFI5gP4cdB7+tXZrDWb9ljvraG1tinmHDMWI7Zzyc1h3kKadbzLhVd+PoPauWTV9Opurta9DmppfLY7CeuBzWjp0xj+dxkjjBNY5V5XKx5yT36VosxtYAAAAep9a6JbWMUbUFyWfK5HfGa1V1vWzo09vosVnJLn5lnjDPj/AGSa455/LTcxkYt0CnmrGm6rcRzB4mdCp4zWKTTujV6qxy+oa3rEd3It0skcwPzLtK/pRXsS6pDPDC9xplpNLsG6RkBLH8aK1VVdjN0meItoF4BkLj8afbWOoW8gdLhEI/266WeQ4Ac5I71VLKeOa6lTUtzllVa2Om8JeNL7Sma3vwj20g2s8UhBHvjpXpOj/EPTjaJp2pM0tmG3LIoDYz2IPUV4XKvGQuahCTI26IhT6Zp+xSVkJVm3dn0Z5Oi6n+80e/ijlIyBC+PzQ8j8M1Yh8TvpWnXFjrykBY3MNxuO0nqAfx9q+a31S5tGAlOP9rtV6HxVcbcC5ckjH+syPyNYui18LNlWT3R6XY6vaXck0ml3LSXIO4l4SiLj+4TwTntW/Z+MNT04GK4dnikZnbcoOSe9eK2evXkaBZbuaX8hx6Vq2niry4hbz2zTW/vKQy/Tj9Kx9nUjsjX2kHuz2VfGWnTKsV3YKcAZkRsNjH3vTNS3A8MXqyJo9/ZSSnDOZXB8rnG4qOuM15JFf+GrpkMkV1E5GHDMMfXIGfwpqaDpksQOm6s9vLvIykjIcH/gIqOSS+NXLVRfZZ6BfeFdOuLrY2rWzlhkPbqr7jj2xiktvhsBb/aLjVAYd/l+XbY3k+mWIAriY/DM8hAfxC8ikYJeTJ/xre0exn02ZZtN8VMl2h27WUlQvp2/OpiorRJlOpJ7s3Yvhh9qMiJfrbSK5QROGkfPoSMDPToKlj+FP2XHnX9xNITyltFgD6u3GfpXS+H76dk/0rWXlnUjDKdqnByeME1rXviCJI2JaYuM42KOOegJ9s8+9a+zi1uSqskzy7VvBdzC22CXAzgB5CzfpxXNXmjm0DLOk00oOMr90V63deKY0VhBp0rMerscv+eePwqlF4qtQyiXSlfPcrgDPesXFrRO5uql90eSxwqkgYCQL3HGR+FdXYTaRFH5l9oVzJC/3f8ASZEP8q9GM9lfWbSW4sY3A5Tau4fTNU5NAsZZIYbe7smlck73GOvvxz6VSjJ6EymrHGR69aaVel9E02G0LD7t2TNg+oJGRWxbfEPxAoCtqEITssVsh/Uirdz4S05pPIubjEpbhDEVGfYk80n/AAiGjadIPNedZj90FNo/AmrinHYzlJS3MjVNd1TVI9s2p3RjB3BFGxc/QACs4QTSYJuMMP4lyCfrXT3ukW9qCY9NkmGcbzdhufcLUH2a2ih8x4rZCf4C8hI+tVyp6snna0Ri77dJAZLhPMHYyf0zU7XSj5mY7f7w6VfRdP35ntYs9mRj/WmTx2AO5N6j8DTsLmuRw38MkeY50Yf71SecG6pn3xTdL0qXV7jydJszM4++y4AH1Pb862Z/BdxZlZJbizWUc+W92B+hNOzFdGRvXuCKcH3crS6ikcUiRO9hG/cR3Sc/XLVmzXOnQHbPcwrz1F1Gfyw1AWLUjbWw3Q1Yh2nBGQMViza1oSja+sWsY64kmQ4/HNbdlGbz5bL98MZAjO7g9KevUkUlY85znPSnC4iOAxx9avp4Y1mYZi025Yf7yD/2annwZrsgJOmlR/00uUWlcLMqW7WqyGR2VvbPWtCPWLWBT5USA/nUA8G6ouRIumREf370f4UL4SuwfmvdCT1zd5o+T+4fzQs+vF8gnI9MVG3iAYwI4uOxFPbwrIud+reHl9c3dVrjQrWLiXXvDQP/AF8k/wAqLvs/uYfMqXOoPPL5hK7vZQKmk1a+ltzE8weM8bX6VE+lWCjJ8Q+Gx/28tTl0ZJf9TrHhyQe1/j+dJq+6/AcXbZ/iVbSeazO+C4kjk65jfGDVldZ1FGBXVb5Wz/z1yP1qT+wJj9y/0FiOw1AUJoV24O650Ve3GoqKVvId/MVPGXiKE4jv2kX+7LGGJ/ECrFr4v1NBi1SC2k2ktLIoZzgdAew9qpSeHpR/y9aSx/7CSf4VF/wiU/LfbNNUn01BKNfP8Q08vwLF5f32oxbLm9ZwTkhUAFV1hgYENMoYerVSuPCd7njUNLx/tX60628P3lvzJqWjuAcgNchgPwHWlouhWr6ll7cbCVuYwPUEGs25EUL/AOtmnk7JGvH4k8V1tpeX9vEkTahpYVM8wFAefQ4qVtdtLNcajcW90XYnH3ifTtQ5oSicifJnUIbsWpxko8Tb2Popxj8a0LPw54auQjX/AIlNsrAbisykE/j0ruYLa5vbBNQnSOztSwMayBlaT6Dd0qWR49xSeC2Kk/wtjA69MUct9Ww57aJHLWvh/wAJ2lywtLg38KKPMfzFZnJPABz09fqK2Pt9lCnkaelvCWQjOVGD9B3pk0ljFOJVs7ZG29chsAkHjjr2rI1fUIViAcwtuzuDHaO1S3GPYNWYNzbajqdwGlu5Y1ySY9m/dg9j05q1Be6dpksT30UjxgJuJI/9B6msnV/FcKRFI7iwCg8W8O5iTnpx1rFfTtc1i4U3Cppsb8hWGHI/3c8fiaz9NStDZ8S+MILi9uLxv3avnyoj98L0GcV59d3cupTHy43fd6DpXR6noiWDoIrWe4Qr80swJOfw4/CqccMm3CxktjhVXGKaet3uFuiGahpyaVo1uCqNdSfMWU8gVgXQ+1lEUuG75PFdOmnzO7vNtCbMfe5B9a569vLPTpHQzrLIeCEGcfiaqMtPMGlfyM/ULl4oNlm6g9GYNzVq3LW9jGx++wySetRafDa6vcNFCJY0UZMjc4P0xS6jBd2soSZQQgwrKflI9am6bsUu5dtdevbWLyl8tlB43DOPaisfcDywDH1zRT0FdirLPc/NDZzlT0Z8KP8AGrMNnIXO90Uj+DDZz6VfQO7ExTFN/O3+n0qTYhwZSyv93ORnofyr2VZHjNtlO8sQkgZ5v3a9Ylyu/wCrdqZqVpFdur2NpDp6jjEUrTE4/iOa0FiRAIyG8vGck9Ppx1qVYAw+0Qq2fTqG6ACpcIt3Y1OSVkcXf6FfSysyzi6VePmOB78dKwrrS7uAk+Sy/QV6iLZJFEYclieAOVGDzUcsUjOBIkcbryrnOKPZJ7MFVkt0eTgOhwvmI/f5iP0py3l2jYE7pj1Oa9KvNPt7mRnvYhIh6SHsOwzj9ayrrwxbtbnbG6kYAffxz7VLpSWxSrRe5yS6xdx8O0cnuVq7b+I5oGUtER/uP/SrV74YmiRRbyCbILbsjG3+eax5dLvIWctbSYXgkjI/SocWt0aqSezOtsvHUKcSQyDPUgZrWtfGWlscifYeuHUjmvLig5OcH0ppTkDaQamyZWqPbLTxlblsxXkZ9gwrXg8atjAkVgfUg189bPm+YdKcu9FyjED2NTyRHzs+ko/GiN99UP4Vdj8Wac4xPEu09wa+Y1uZ14WeYH/fNSC/uxkG6nH/AAM0vZoftGfS02taJIw8u5MB/wBtMj9KE1jTVYN/bMPHTKNXzOb27I5uZiD/ALZqNppWbJmkJ92NHs13H7Rn1INb05zga7br7bGx+VX/ALdaTRfN4jswo6AkjP4V8oR3l0h/d3Eqj2c0kl1cS/62aR/qxo9mu4e0Z9UX93p1raGS88TaZbxDp5kq7j9FHNcbq3j/AML2e4Jq91fOOgtrc4P4tgV4EVweQPrjmjvxzQqa6sbqvoj03Ufio2CNMsJP96eX+ij+tcze+PvEF0SVu0tx6RIP5tk1y2Ac9qUL7YNWoxRDnJmu3iHXL0iGfV9RkQtnYbl9uf8Adziq941xDOwlZ3z3Yk5FO0RC+pRoZFjLArvIBx+dd03hu1hs2ur7UpBGB6KAf0pTqKC1CEXJ6HB225mOyIFmGB3wa3F8M6rLaRz3Cx2Vm3S4u2WKPHsTy30ANM1LWrKCJYtKtm85TzcSvuz9FxxXPXVxPeS+ZdSySyAYDSMSQPQZ6VKXNraxbm46XH3fkQymOGUXBH/LTaQp+gP9a3dH8catpjQ4dJRD9zK4I/KuYb3peQBzxWllYzu73PdbP4xaFeaYseq6VfWWpAY+12DhV/FRjNcpq3j03crmLVbxlJ4MpfJ+vFeaqM0DkYPWp5FcfOzsJPEG85a/kGf96pBrNiVAk1G4J77VP+Fcbgg89KUDuMD6U7ITbOvOs6W3W6ujj/Zx/SopNZ0sDh7tvpXJnn60Yx709CbM6ltc0wfdS7J+opo17Tuf3F59d4rmNvcfLRgY6c+tGgW8zqhrumMcst8v4g1Yj1fSWG43dyp9GXn+VccV465HtRtzyvT3o07Br3OzXV9JHIvrgH/dNTR65pWRm/n/ABQ1wu0EYxz9aCuPvdPaiy7D17nokepaVJ92/JJOeWAq1HNYvjZeE+nzCvMdueg496TZgjHB9qLR7C17nqijBJivcA+oNbmga3qWkTLLZzWUjrypmgDkH2zXi0MlwjDyppvwJq7BrOo254nLH0cA0nCEt0Pmmtme1ar4q8VarL5l3qm9uxAwF+g7VlSahrYO5tUdAO+7pXCWPjG4hwLqASD1RsH8jWzD4v0q4XbcpNH7MmR+hNJ0oMFUmi/N4j1SVmV76VgDgMBjNFusupyqrXLvKf77cVENQ0O8iCx3cKdhn5SPzpgsnDZtLmN88rtfrWbo2+E0VW/xHQWXh3UrOeK903y/tULb0JwRn1wanvvFPii1kJv2kDE/eZOtYkep6zp6jbI+z8xTo9Ym1KT/AEufKKMlWPX2rDknf3rM2Uo/ZNzT/HGqzuIhbCeRjgAKRWlqGqObYSzxrG/QhTkVHomq2hh8lYYh6lVxn2rD8Z3K+clrbjAUbmFYTppzUUjSM2o3bKGp6yxtJ23Y8z5QM9q5Axq8i7STI3pRfzs7hM8VseE9MN5fxs4O0Gtp2px0Ijeb1PR/hzo8en6cbmfa0knIDDpVfxnbKxMmBzzXUWunyPbqUJWNB61ieKlYWDDnJ4Ncsk1FNm8Wm2jzSSMbjxRRN8shA5orZJkto1VZWV8bAw6HPf8Azmnh2BXejBSDkleW/LtioVZWQLI3zckE8gmnzP5YdThgclgvP4V7J45NHkbniZBvPyszcDnpj6VICr7NnEw52/3vSqxwVXb5gfBKrjGPbn6VY8wyysJNyMmPm25yAM0yS3uO8pckKg7IFHTnmouUQsse8gcSMfXiq65SE7QTGF7KAck/X+lTpJ5eNz71XJMYkz/L6UwHkMUXzLhTAfvAHOMUwWrCUvC0su3g7vl5JqWJ8uzQjIAA2ZyB69aI3/dszSSJORuOOB6DPai7FZMrBDlpUHlKTgZznp/PNQTRI4MU4bzTxnPU8Zq2xRiFeIIeMyHOcD9O9STA/uxJIjw4zlUCkZPXOKrmJ5TCu9EsZlKvbqowD+7A3Zzxz6dKxZ/CXmFzZztIo+6G/wAa7CFVZZZYtig87WbJOPpTGjj2osbMWzgDaCAepqXCLKU5R6nAy+Gb1EzE0cvOCoyDn05rMl024iwHhdCOcsK9PfmRd6iOUDdvIJHOPyoO1wzufOQtw/UjH1+tQ6K6MtV2t0eTvER98FffFNEZA7EfrXqa2qyQqmFCNgYLfe9Qf0qlPoem3AzDABKRuKA4PsO9S6L6FKuuqPONmcbTu9qXbz/dOPSu5m8LWrM4LyQtuwuBkHHqaoT+FwsWY5WZ+OSBt59/wqXTkUqsWcps65796XbgAdq6K48NXcIG2WJ05yQeOKqnRL1XPlwMxHdPm/lUuMl0LU4vqY5QN6n2JpoTGeq1sLpF24O6B8jkjIHtVhfDd7gK4jUH3HFCi+wOcV1OeKc45HvTimOpGPUV0a+GLlmYCVW2kA5UjqasReFHZdxuokU9A6kH2xVckuxPtI9zlUVhh1HQ5rR1XWLzU44lunXbGoUKi4z7n3rR1Xw8LK18xpJPM44IGD3rBZMHBGPfFRKNnqVGV1oRbc9AAaQjk7qmx2JLD2pQhxxyPSkMrEHbjtSEAEYOfatK1025unUQQu2ehNWH0K+DbWiz6EEEnjNVZi5l3MYjk54pQpwOPxraHh/UhGJPsjGMjOeKdF4evpHVURQx5AYjFFm+gcy7mKF5+XmjaO4Oa6uHwq6sRfSmPH/PMZJ4z3rTg8KwRQh2zKpwAC4B59h+FUqcmQ6sUcEUPGRgUqRkt8gya9Hh0iyhkAhhHmfMQ7EFfpzV4WtosrGaFR82MRYG7APtir9iyPbo8sMDlSSrfULxUgtLgIMwyBT0O3rXqKQxpAfKSMxkYGeCvP8A+qgwwbgVcyyBzjCjGccjNP2HmL2/keZR6ddSn9zbzS4GcKhNH2C4BJeCRMeqkV6iIYjKRNiPpngHPHtUZt1SPBiDxFeCFOSc0ew8w9v5HnK6NflFY2cqo3RmXAP41NFoF87fu4w5xn5TnivRTCEdSXUuCW25JI4/+tToo45pmZSsJULuZx6dsij2KF7d9jgh4Yu9rtNJEhHReTn8hjvVuHwpKPLNxIfLY4GzGTXXjZHE2zEsZB+bBz1/zzTvJiZ0IdjLk7cIBjgVXsok+2kcxF4Ysy+FllzhTiXC5B/GrI0CzjtiRbRygZG/J65HfPvW+sLBgZUG8bSCp7+lO8pTHlP9HYA4QjPfv2quSKFzzZjHRtPWZT9nQAk5bAKqcdO4q3HoNosr5sopdxwpaPGBjriteRGUDzM7DnLBRk8e1SQACWUwSvGCcN5nynpSduwK/cxX8N6aYsvBGJMAgCM88nj0/wD1U9/CtlFKryWYWPJ+VccjsQBitlpVFuV2KzbR8/Ldz2/rTCAjhg8bSEsQpGO3Q0rIq7KlvolgJWFqhAG3PmS4+vGSM002VrDEcwsDg87VfJ49fr6VoCTz3PnlUBCnOzg9OO9ME5WJlhClcHGUB9O56f8A1qlxT6DUmupR8q5tC3kvAm4HG+3VyB1yCMYNUHiuJvNkmnR5ONziPA6elasgijnBLLJKxO4FT8vHY1VvNzxFs+THnjGRu49R+FT7OO9i1Ul3OcvdHSEvMsxkwCTxir+geII9MYBrd3XuVYZ/lUt+2bOQkZ+UkrknPvXMjk1x4inFu1jroTlY9Yb4kaetjDb2lveQtjMsjhTuPthulU7/AMWaXe2Dx+ZMZjzlozya80J5qWJuRWMqamtTaMnF6HWaYbEWu65kTzHYsR6e1FYkX3BzRWqaStYhq5qRoy4cuCoH3guCPr+VSx7g2FkZGcgkfwt3NMXLdCTuOAR19Px6VMFLZTb8xUnB+6cn9TivQPPY6NVJHLA5HA+VgTzkHv8AQVJkkbnfc2Dhz8x54GQaj2uzvuV8DcQpPzY6ZX261IpK4A5wVyRkdB/FTESRxgfIskmM/wCr3FgQB1HamRxFRkOOFCjCbuT2bP1pCSigEAfKBtb7pJPVae8m4h3OAXOGc4xgeg7UCFb55DuCtksSkffHf/JpI44zCwaMnAGNrZ2nPGeP601uYsFQflH3uByeoApZWIkDZ43Ehs4GFHGVpiHMpcgMZHUbuA2QR68/402OONbgum8ZAU+YB8vHPrxxSbQVKMpxhFwx45OcqKeJCOd7D7xBI5HYZWgBjRo0SnzSsh6bQRnn1A/rTpQH2g7ApJG9zg5HH+TTiQsqq/JUgbQcngZyOwpoVTgBgX2hSSMkbj3JoATyx5xDJDKOAu1uSRzwRmmCKb7O7JGypzleOOfXFTFRncoVsBm2qcrxwMNQFRsAKDtKqSARg9Tn1p3FYq+WftCld5Y5PzYIHGOCDntTGzvAnV48KpJ25B7/AJVcBGQzYUYLj5tqk57HrmpG+ZjuJOGxlzkgYPQc5o5hcpmRiNYCAiNG2SGIb1xUys58uPerKCCQpGcY/Opym22UZIDjOSBhsnsMZFNMBE3mbjn5htblgB7Z6fjVXRPKyCDaXzbqWJUnYxB6n0z70oi3O4lGJNxICpjOAcfzqQxEON6rn5RwOoPY9cVGQohKsgPB+X+ID69+nrRoLUY7KkO0WvzcAyZJGDzwMetPeQP80m6ZNpODyoyeR+VDbmdY/MZgHxtB+U8d+cUsZXzAYt2EXJDdRk/j607BcWJWk3tCmxg+CAuRgDjOabmMKFAcyEDIBAAJ5zimyIpEnmSfMHOGUEg8ewx+dNRWQqRINqlRkdfXgg/0oAj1iB7y3aNyFUZwcAcD+dcfb+HrmSdlJ+QHBYg13LIqvkOkyYYHqe/QnGaUBlkfa/kPu+6Xxke9ZypqTuzSNRx0RzVt4XiWMyPIcYzgnae3/wBetCPSbCGZPJt8SBujHdnH6VpcOFDBjJ8vOeBz/nmnS+btAcGMEMN+Bj8BimoRXQTqSfUJI1DhJURE2DgLjBPrinRKQjeQokTLHe4yB2/kf0qOMsJZPKCtllycEfXH+FRFl8sbX2kD7pXBPP8A9f3qyCcxxqwMDkPuCsMAbsdvWnSAbFWW3EaFeflzjJ/SoZ5M4VgyuWbDbhjpj0+nFEcmyZmwCzKoO0554+tAEoLKH8n94BkqTghRxx+VKFjGFBMc+VBOQAeP/r1TUO1uwjWIIARzgZ5H41YkZ2jj/wBHKhXXDAEjp/n8qLgkPkErf8fChI8YK4zzu/DPakhc/P5IMilm+Z1zjA4609YwjncTKCBnaNuOfp/nFNdgfM/evCoLDDZCmpuVyiMV5+8HOwEDjd7VNIHJbzYXSM7uNnJ9/ekE6FQRkZ29emMcY4+tMlaRFT7Th8A4Yuef5ii4co90YuRGocA8BsDbgcdOlIqv5OQ/JwpQ5456gUnm3MjSLbkBQx3bDkdD3x6+1LG4EXJb5NpO7oOOnX+lFw5UAw+ChaHhjvZtuDnoPxqQRutwTPtIDDaQx+Y4OKSaZ7jPnhnjKsCAFIIz+HtSLPJEzpCrDLYIODgY49aLsfKhyxYXKSMhYElcnA57+lOARclowIzuLkDqec98VVeXdGEk3BwAdxx2J7fj6Usr3PlrJIGkjBZVVjjI7cD8qVxpIuxsqu4gkHAA5bGPpUXmEQESbZAR97qc5quJRNMoO+ORtrZG78PX86BJP5TRRrvjAbqBng+uKQy+6YKPuRnO4hduMD3oRjvZnDxhtuPL53cehNUvlMivGrId2T84wCRz0zikPmIVM6b0dRuJBDZz1zj+VAFzfIYWaKNSpBAZ05Az60rTLIypC7GTfyD8yg4GfaqkFrKxZoo1IG7hsnHpnnFPO4oFAXepXLeo/LmgCWZmjkzfCJlCr8q4XHI9KckmYZNkgij3EEbuOlV3jnhYScEiPldu7Iz3GaaUVblmmlQMWBzjaRx+eaQybzIUkjFuWTOC0hOM8f8A1qp3GzDkyidzjAVuR75qZ5P3K4bMQwckDJ5P49agdsNsj+aTBAGDgDPocdKAKd15jWzBxjKHP5VzAPNdK+VYgqMjIbH/AOuuacfOeMVyV1sddB6MUGpYuTUC1btl3EGsUbM0YF/diitOxtd9uDiiiwXJBFNEFCFinUkN98Y7U4giUtC2CMDDtjbxjipI5NimSPLBT0x16UrRxucBSXfqg4Awef1rvOGwjLvi2zhw7EANjIbv1/GpTvACyDETKR+7bcfbj8aHL5WOUKm3gFQT19KfFJGspljRnUjnIwSBjGO9MQtvJIJJGtkZwTjJXJGB6Htn3phz5JmMsKMEI5K7uT6fnSyqohy7hVC4CjrkmkPlkxxhcsG6ZBPGfypiBPL+UKhkmDAElj29qaEw4EylTsxu6sS3bmpi7SkCcHpwAMYYg9wKPMVZTnEgPK7yTgD3/GgViHzF5KBgNxJ6K3A4xzRsEcSbnVQQEIz8x5zVmSGZbctFIxUr820cHJ/wqBEVmUQKWcncxyCDjjp3ouFiNcs+BnLKzbOmM9OTT8MkwDPGpBHDYwu0d/zp5UPNIJ28o8AeSvXHJ4pUURwuAh2OCRkYIycdAaLhYZHGzxD91uBQLk/KoJPalYKJPMKnhyVZ+vA7DvSNG0bohk8wE5CFWHGKVUzOu0eU6oTntzzQAgD4G1Cu5VTJHX6DtSlxG26QsrfORg5cHGPWpCdzkzybgXzuB3YwOmMjHWoljuFgHk5WIgAMu3PJ75oESKpOwA4yUB2jOR1weuKZngqobKqxwOo59alCxmVSpZ33fMhYDJAx6+1MZ1c7XVLZQBhSvXn3/GgB6kgtkqF3D7pwOB3NRfI8QU42hRhc4AyeoPenLIAWMiee4ZiDkgcD0FOK9ChjPK5Vcnb/AIU7gRssZOSQV3OQT0/Fab9nVcAg8hQAxx+X/wBeptzuR5UBBZWIfccnnpjH+c0ABJj5yeUMjO3k8D3ouKxXaJdgZmK8OQWzj05UU9IAHVCX3b1wpHJwP4aeeI+NwUrhWHB5OcE1OBlwAeNxby8deO5x/nNO7FZFUQAruJbdsOeRu69/SofKHmMAA4DtkDBU4H941cSMSAASKcqo2H5cc5PJ5NMkALMXZSRvYkkbfQcf560KTBxKvlsISDgjy1AA4xk+vekdA2ePlG4ZxhDge/erzRvhf3cm1tgDuvH/AAGmMGwxBJYqxDdXOT6DpRzBykCI4kBZpFYbAOcHB9PWm7DtJ6FlOW6sfm7jtVvH73G0r+8UbTyzYH6VGCQm1c/d+4D833u5o5mHKhPsy7vKdmcBmAUkHHHrRHEiFSONoUcKOM+ueDUhJDn03twp+Tp35pCFdcKN2RGMt2/3aV2OyGmOMfvCidW/ebfbkFanGQAgkcfMoCnlW4+nH41XBG88tuw5B/jFSqQrZYEkMoO3p0/i5oGIqsgwGbCqSApAI5/vd6cclyzOzkMQWweOO471DhWQ714CgDPK9e1Ss4EpPzBwzHn74+XtzQIUnEcXzbc4OdoG7n86jWJFYBgp4bgjLYz3FPJBAwB0QHZ1/wCBUmU8rDfNw5wvAH40AL5ZZ9x27t44T+Ljue1R+WvlkJEgkAByG+7g/Tn86l+ZSWUsV3jJAOBx3HeoY2PkEycZUfwkjOew7UAOkUuMSM0qhiuWbAA/n+lI9srt5nlhR8pIBzu7dQBVhwAw37925gMnnp/e7UBhznPRRnpj6+tFx2K0cSxRFFjjKkMMNn+fSleBAwxtADgjPBGQOBnrUjuq42Asp3AsqHb+K0MxDAKGAymeNwbj6cUBYjID5Dnd8mQNoRhz+X4U9C43gNJyTwpKnGP7vekY4hGF2Ltbj7ynnt3zSqrl8IGG5zgc5OR2PYUAMdSVJPA+TO05P1J7U2GNI9zLkNtILbzt4OetOCsQV2MzKqYAPTBxz605k8xN2CTucbiDj/vmkAjW6PMd+4szj7x+Zsj1pFjCgKEJ2qCwyex79jThFIHBKFNzJwR9445z6UhVzF5aoCAGG0DKqc+uOaB2E8pV+YRhW+ddwXk/8BoUAAkqM4VsKQT9TnpTgds2W2gl/vdG5Hb2pSrLESxATYQACATz3IPNAWI/LUIxVl2AMN2MqCOcAVBc4AYHK7ieDy7cA/gOKt5UuzblU7j+8YYwCOwNU3Zdp2sQDgZHJfgjr2pDKE8aCUEJGGHGF5IB9+/WufliJkY471vurs6/L0IyEPT8a7OLw5aMqsY85HWsKseY3pS5Ty0QnPStDT7dncKBXof/AAjFmf8AlnirNr4ftbdwyrmsvZM19ojP03TMWi8HNFdXDbxiMAA4FFaKJPMeVR3UywB7eCURkDAC9KlFyZmAit3ZpFJLsOck544FMaJZNrr/AKxdx44yQMY/T0q/FsLEXBCAN8vfGB3raxzieeRI6XUnyg5UcLjA6Y/GiPzJISLeJDkY3biF6+vHNNMgWJgYYZeM+bk564/lSyIVjiCyrJEXBKLn5cDpTsxDn8uGQBUMjl8soy2OPbOOlSW6idn6QDbjDknnriqrBWkWSGNQqpvy7FtxPPSnRsSLh2nS2JOPlJAIAOetGoaE8MlpGZVdUJJJ3CUY447/AFpFyIIokfZC235l5Az16j6VDBcNHb8QxmQrgTFWY88d6luY52ePznXyyRgL9B246UagTzJEs6tHJJIMkkhc7iB05xnpToFluJXMWwKFHyoNpGeT1PWoS0aXEb2iP5gTcw6H9OmeaQ7biSR7iRYSr4VXJy2KV2Fh+5VXE4MkmWYZOMdqcVdEQfKA5A2n09c1XEoS1ES2zlyv3+uAc81MF2iOQSF49xLbOuR747U7hYliCSvm2EhZVLBlIOM+1Ej4mfzS58vrsIyQPbj1FRRJHNcSGF44okAzuyW9famB4HVvMn8xwCVyoC88fXtRcLEgZ47c7VSRGXADD5hk+x9qcISZolVkLA5+YfdA9ePUUy8kngiSMhXjbAGSQoGO2RSRFJZf9CQbgpLEsAFJ56Y/pS5kFiRv3jlmRIyF+/ksCTz1/Olikj+diBOpY/MoJxjH+NNjdWdw8gVuCADkkgU9GkhsQroCG+VcP8wyTz16UcyCzHbHCAROqA4/ix36GmERSLGYlYT8ttLbs4GB/KmSbUlR5HE5DnAxjHTr+lOfDSbwwijGACx3jjk0cy7isTMSSwuF/dkBAEAGCeefypkYIUnyklAJYMeQMfSmwSoy7DHIT8xDIufzyKV42iiKOoCnaNqvgg98gGnzILCmLKAK6gHaNuOR6/SkQLI6+SpiA3MWJyCfxp7lA8SQqxmJLbeh6egOe3elPmF3W4YxHYPlce49BzzTuKw141dmMrquCMCIDBxSDzFtj+6V4wpAPl/N1780wymKSRirsct8xbhTjgce1KYmSGJ5JQHkI+6ASRzQA50UGMebvcsCEIOBwOuOKQffzHEkMoH3uSBk56/ialtiJ2At4VXcS53H5uvPTpSFDHcOLp3fGAFDYIxz/SncLDCqb2LM8q7ifMRs9vWkUSi0CoQsQwMbgCefep1LqglSMxxkE4JyMfl9aRoo3VAgleYMBtUg4x/LrSuFiF/KZ8w535b5Scc/njrTmDCYC5DbAwIPHy8e2PfmlnUl1jugF+Tk9Dz+FLHhDKVMUK5P+u/i46AUXCxCiOsDCOUMhGcsRnr+NSOsZkUBijh8nJOG4FMPlFEyXyzKMJjH19uDSB3RkDHfwSSx2nrgYOKdwsTku7HzW8wALkBuhz7UkbCNXEc2xCT8zCmQRySSs0HmqGbnneTgHnjtmmbwi4kj3zYAO5to5J65+lFwHvmTbuR2JK/MTw1PmYnCAIy7TlEHzD354NNffDKgDoBlmKA7uAP/ANfanRK0jqkMZGAozGTnBwfalcLDPnMjFGU/Nn96vI4p7KGiPmF1dgAXXADcmk3Md3nAPKAxAzjgcEHNIxl8oFF2LlRlw2BxyR2ouFgcHGzKDruRcBmo8oPKdhwQF4lIO38xUczxDa1uGyVYhw/H4fjUhkZrnZcMAvABT7xPWgLDmVSr75CGGQXjXjr7Y/yaY0cqINsyg5UgbuTTvmFsWiSTySP4xkdfpxTXaNUxiRpCwH3xgHH+FFx2GhSJECJJHJg9WyOtA3PMSy+aob5juwRkYpWc4UyMPL2EnIIPXHelgZ5JH+zqQAQAc5Jxnk/pRcLD4VkFsyLKyQ44j69/XFR7NxG4Oj78hi/Az7U0yokJEnzTbSck4BGf/r1IlwWRFkl5LAbA24fl2oADCBLlttzwC3zEEEfUU0QRsjhj5SDOFC7j09RSYEsoEQCnaMFWOcZ/D6VKreXJIbgmSQybRkYA49s0XHYYqfuAUgGOCG7+lOjSCN1EbM0hJ+9HxSEgwOVfYAPmG8AdfQmmuwyu0IMMMscjPAoAcUIk3XJkDcFQBjPHQ1n3CztHmPauc8sMkAHjoatl1gO4/vCVyFVgRgH1qGSVJhKGlVSSeCTn9KQGdOI1JWBwx7nPI5r1DTlzaQZwcoMnr2rzWRkOFiU4H8RXrXoPh1hJpFvt42rtIJzjFQ9y47GkV/Q0saDOMdKGI5KnqelIDhTzg1QIkOPaimg5HWioLseQqpJU24czBe+ABzwRj8amLIodblm3kk5ADdR0OT0rMbWrWaMYktRkYUlwpHPualh1vTImeIywyFskntkj2I960M7F0mf7OAokFtjGV4PU+tOaVYZEO+Rzlj855z7j1qKO8hkRd0mIvlwjNuH1HPNOkazMitDchiNxyFKkH607isOguJnl8y3YxHYAFUEY6dScVI1xGQxuJFllJbG05NRxxm5LOJyz/LhZCoxj3PWozD8jbQh3McGQg8+2DxTFYu/bbh4kt2GU44OCR19Oac00FtcKyusxG5uMkqD2zjIqGWG7RY4pjEOVw3lYPTs2BUEeyF22JLIhRiRIMjGfUEUgsaCtJNcObZQNrKMAnOO4yefSmGWNI5PN+ZyWOWYcduc896q7TIzOCII1cE5xjjtznj8aRZES3ZUCsTnDgn1HbpQBfjllAjRg4g3DJyQCCB2PvUgdTg2fzzBcgMo7n8fWs9mMUqtM6um4kIrAkDHpnHajzZWkK2c/lDYPmkIz2449qALcgErSTSyQxlWI27tvQEe/PNJFNIkKqXcRPjLBdwwffFU1ktvJkW6JefLAyLhgRx27dqfEXdY8s6QZXIJK/hjvTEWpdqOspWNslmVdysGwOOAevBp0Qe4mfyYFBG0AInOM/hUEhEcoa1zv2kjI255/Gnw7ZzIZ51Q787ZDjHB6Y+tIBssaJGTLFC0vJXKlccgHFS3EcjRwoH3Q7lwHHHTrnn9arCVhAY0+cY5kCjjnHXNTlHSVJCEYB84BHJ7dKLAPiMRkzbCUEIPmzuHJz0596T5XkkMwPyszAK33u2cHFQRT7rg+SBbD5SQjkZ78knr1p63BiRjMBJKd21pGOf8ACiwFgJILbaqs8WAB2wST3xQ6oksYEucsT8oLce+evSo4pp/LhaRyyFlxk8D6AmgMXcCzjBChjlWGQee31osBNhpirKwhcJuLEYTJHGRUSbUkldmWUEgbowCB+f0qSSVjO/nMVKlACM5PPsBUaXrYkzBvTLYySD07elLlQXGxy3UVniGIeQQ2Wfhevp2pJplRkRZfvtkwA4ycd8jOKHmeK3YtIQjbQUU9/wBKQzQyMix7yCWYb4wo9OpPTIp8oXHxvJJKPOj+zqU4bbgDJx9acrTxO+wRzSEn5tuegPqOKaCiT4n8wEqvyr8w7ep9aW2aTbI9nuVG3HnjB7f1o5QuWEci0XM8nA+aNZNoGSe2Ka0qzMqojo5JJ3ZG4+lRmWE+UrAl8rnP9MHPc1K7SHi5LFNpJXqAPXsaXKFwlWSGVVuFcKAACy9T6nn6VG11NNHIyu0ak4wpwf1qcERSyLarwzLkjkqP1qEg+WzSSP5mGw2QAORnnNHL5hcjM0QcKISJ1YfPznpx16Uy6uLtJEN4s/l7RkEg8Z9BU5leVEQBfKVl5AyTx61GiRrIHtnDOqcKM5xn/CjlGJA81w072hlUDI2GXaB/jTnllkgCxwoAqhmwDk8/3sc06Ly2Zze7sEtg8enX24pytNFakQuVhABDM2MjnjFHKAeS0IRoxHMxLExhznP+NO2yC4Zpoig4wxB79MYHH5UwyCWRPKUCfLgHGcnnnjtnPOaly6yD7QN7HZuBbGOfftn+dHKgGRvJHGIxErbg2Gz3+vWowzJ5YeUH5htAdspx3GMU9BmBxAwWLDZ2j3oaSJ4EXDlwyrjzSVPHoPajlC5DHLIohWMSuMsAyNgn6cUzzSt1KLwzAs2QrjPODjnB/lU88cwEf2hFRMMSsa49effilttwkb7Kdy7gCdvIPPrmjl8wuVoHY2cjIshQA8FgoHPYZqWaUbY1MWXDLuZSR1HBocRiNvtKkSYPz5Cjr/j2qziVYB18sbSH6ZGPXHFHL5gVZGEUiM8kt3HtO7a+7jPPvSwSxGSUs0ivu4D8Z644HB/OpJyolxbsRKNw5OOc9hzTZflmLXWZGO0hWkxRyhcktrmPynEkXmOc/wC1z7ntmoBOsaI2IS5Iwrbxjjj6mprGNpIv3MirENwIjOSOOCPWomdUhAKFgMfMMsc5P5d6XKh3FjMhmVr2M7NucCMEj/OKI3cMyWCIcMCQeWI9ealSJo5o5Mq5wwGeM9cetR7nkdxGIoywU9Dx7ZOPanyoBow0b/amVZOeGQkZx60ssk5iVpG/dgqV3EnP071KhEO9UCNHuI4y2OD6dahnjd4fMJJTGTHuAxye2aLICmZJYbkmF97upAUZBHXgZqtJ9qHmgzKpzk5zk/iK0BJIskfkuUJPLAkkZGc1XlIil/fOJpCoO7dxxijlFczftM4gVvLUqvAZePWu6+H1+0tpcW0ybZIm3EZz1rkJJC++Qs0cS5AU9CRjtXTeAWX7ZdIF58sHj1zUtWLido2GBK9TTeo5pzoAARkU2JGL8cgUNjSLUUa7BuHNFSqnHUfnRWRtY+Ompe4ooqyDRtPuitzQ+r/QfzooqyWbY6L9B/OrVp/qJf8AdNFFMzZ0Kf8AHlb/AO8v8xWUf9W/0f8AmaKKbBDbP7v/AAL+hqR/9VH/ANcj/OiihCJrT/Xp/uP/AFqKb/j6X/dT+lFFCGLaf6v/AL6/pWtrv/IEH+8P5CiigSKWmf8AH+v+5/7Mai1j/j6uf9//ANkNFFAdCwv/ACCof9ykt/8Aj/H/AF2NFFNbi6FvV/8Aj6h+qf1qJelz/un+lFFR0Ke5Vg/1sv8AwGs+6/5CDfU/zooqyS3qXSD/AH1/rWpZ/wDHpL/v0UUMFuYV3/x9r/vp/wCgmtnVP+Pdf91qKKGJFG0/10n++P50S/6t/wDPeiiq6iJx/qbf/dT+tR3X+rH+4f5UUVJQ+x6n/fNRSf62X6n/ANCFFFD2Bbl+9/49bb/fqrF/x8Qf7o/nRRQA+/8A+PyX/rm38jWDL/x8W/8AvLRRR1GdHN/rYv8Agf8AM1Fp/wDx83H+8n86KKBEM/8Aqj9D/MVZH+pi+qfyoopMfUoXP/H8v0Na1t/x/wA3/XSiimwRRf70n0b/ANCWtOf/AJAA+i/yNFFLqPoVbz79v/wL+lRxf8hGX/gH8xRRSWzBlSD7tx9TVyH/AI9G/wB1f5miimIhtv8Aj+T6N/KrF7/qR9E/kKKKBizfdH/XV/5Gsx/9af8AdX+dFFHQRZX/AI95/wDeX+Rqq3+q/wCAL/IUUUMaJNQ/49pvp/Wt7wJ/yFrr/dP86KKiRcdzuZOlSQ96KKhmi3JxRRRWbNT/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5155=[""].join("\n");
var outline_f5_2_5155=null;
var title_f5_2_5156="Magnesium glucoheptonate: Patient drug information";
var content_f5_2_5156=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Magnesium glucoheptonate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/20/16708?source=see_link\">",
"     see \"Magnesium glucoheptonate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2110224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Magnesium Glucoheptonate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low magnesium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to magnesium glucoheptonate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Good mouth care may help. Ask the doctor for a drug to help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Oral solution: Mix with water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12032 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-B6EAAB5947-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5156=[""].join("\n");
var outline_f5_2_5156=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110224\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019040\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019039\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019044\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019045\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019047\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019042\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019043\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019048\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019049\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/20/16708?source=related_link\">",
"      Magnesium glucoheptonate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_2_5157="Calcium gluconate: Patient drug information";
var content_f5_2_5157=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcium gluconate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     see \"Calcium gluconate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"     see \"Calcium gluconate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6026083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cal-G [OTC] [DSC];",
"     </li>",
"     <li>",
"      Cal-GLU&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12855597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put off or treat soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low calcium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3869669",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hydrofluoric acid burns.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3869667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Abnormal heart beat or high calcium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take iron, zinc, or folic acid within 2 hours of this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695813",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 hour before or 2 hours after a high bran or fiber meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Soft, brittle bones (osteoporosis):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11306 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5157=[""].join("\n");
var outline_f5_2_5157=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6026083\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12855597\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014150\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014149\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014154\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014155\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014157\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014152\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014153\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014158\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014159\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=related_link\">",
"      Calcium gluconate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=related_link\">",
"      Calcium gluconate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_2_5158="Vitamin B3 (niacin): Pediatric drug information";
var content_f5_2_5158=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin B3 (niacin): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6951?source=see_link\">",
"    see \"Vitamin B3 (niacin): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/53/26452?source=see_link\">",
"    see \"Vitamin B3 (niacin): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Niacin-Time&reg; [OTC];",
"     </li>",
"     <li>",
"      Niacor&reg;;",
"     </li>",
"     <li>",
"      Niaspan&reg;;",
"     </li>",
"     <li>",
"      Slo-Niacin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Niaspan&reg;;",
"     </li>",
"     <li>",
"      Niaspan&reg; FCT;",
"     </li>",
"     <li>",
"      Niodan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Water Soluble",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Adequate intake: 2 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6951?source=see_link\">",
"      see \"Vitamin B3 (niacin): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Formulations of niacin (immediate release versus extended release) are not interchangeable. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adequate intake:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-5 months: 2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-11 months: 3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recommended daily allowances:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 years: 6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-8 years: 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-13 years: 12 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     14-18 years: Female: 14 mg/day; Male: 16 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;19 years: Refer to adult dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyperlipidemia: Initial:",
"     <b>",
"      Note:",
"     </b>",
"     Routine use is not recommended due to limited safety and efficacy information: 100-250 mg/day (maximum dose: 10 mg/kg/day) in 3 divided doses with meals; increase weekly by 100 mg/day or increase every 2-3 weeks by 250 mg/day as tolerated; evaluate efficacy and adverse effects with laboratory tests at 20 mg/kg/day or 1000 mg/day (whichever is less); continue to increase if needed and as tolerated; re-evaluate at each 500 mg increment; doses up to 2250 mg/day have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pellagra: 50-100 mg/dose 3 times/day (some experts prefer niacinamide for treatment due to a more favorable side effect profile)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recommended daily allowances (RDA) (National Academy of Sciences, 1998):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;19 years: Female: 14 mg/day; Male: 16 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnancy (all ages): 18 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactation (all ages): 17 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dietary supplement: 50 mg twice daily or 100 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Many over-the-counter formulations exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyperlipidemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release formulation (Niacor&reg;): Initial: 250 mg once daily (with evening meal); increase frequency and/or dose every 4-7 days to desired response or first-level therapeutic dose (1.5-2 g/day in 2-3 divided doses); after 2 months, may increase at 2- to 4-week intervals to 3 g/day in 3 divided doses [maximum dose: 6 g/day (NCEP recommends 4.5 g/day) in 3 divided doses]. Usual daily dose after titration (NCEP, 2002): 1.5-3 g/day;",
"     <b>",
"      Note:",
"     </b>",
"     Many over-the-counter formulations exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sustained release (or controlled release) formulations: Usual daily dose after titration (NCEP, 2002): 1-2 g/day;",
"     <b>",
"      Note:",
"     </b>",
"     Several over-the-counter formulations exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release formulation (Niaspan&reg;): Initial: 500 mg at bedtime for 4 weeks, then 1 g at bedtime for 4 weeks; adjust dose to response and tolerance; may increase dose every 4 weeks by 500 mg/day to a maximum of 2 g/day. Usual daily dose after titration (NCEP, 2002): 1-2 g once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If additional LDL-lowering is necessary with lovastatin or simvastatin: Recommended initial lovastatin or simvastatin dose: 20 mg/day; Maximum lovastatin or simvastatin dose: 40 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Lovastatin prescribing information recommends a maximum dose of 20 mg/day with concurrent use of niacin (&gt;1 g/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pellagra: 50-100 mg 3-4 times/day, maximum dose: 500 mg/day (some experts prefer niacinamide for treatment due to more favorable side effect profile)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Studies have not been performed; use with caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Contraindicated in patients with active liver disease, unexplained liver enzyme elevations, significant or unexplained hepatic dysfunction. Use with caution in patients with history of liver disease or those with suspected liver disease (eg, those who consume large quantities of alcohol).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, timed release, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 50 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, timed release, oral: 250 mg, 400 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 100 mg, 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Niacor&reg;: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Slo-Niacin&reg;: 250 mg, 500 mg, 750 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Niaspan&reg;: 500 mg, 750 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, timed release, oral: 250 mg, 500 mg, 750 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Niacin-Time&reg;: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or milk to decrease GI upset; administer Niaspan&reg; with a low-fat snack (do not administer on an empty stomach). Swallow timed release tablet and capsule whole; do not break, chew, or crush. To minimize flushing, administer dose at bedtime, take aspirin (adults: 325 mg) 30 minutes before niacin, and avoid alcohol, hot drinks, or spicy food around the time of administration. Separate administration of bile acid sequestrants by at least 4-6 hours (bile acid sequestrants may decrease the absorption of niacin).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of hyperlipidemias (FDA approved in adults); adjunctive treatment of hypertriglyceridemia in patients at risk of pancreatitis (FDA approved in adults); to lower the risk of recurrent MI in patients with hyperlipidemia (FDA approved in adults); in combination with a bile acid sequestrant to slow progression (or promote regression) of atherosclerotic disease in patients with CAD and hyperlipidemia (FDA approved in adults); has also been used in the treatment of pellagra; dietary supplement;",
"     <b>",
"      Note:",
"     </b>",
"     Niacin may be used in combination with lovastatin, simvastatin, or bile acid sequestrants for treatment of hyperlipidemias in patients who fail monotherapy; combination therapy is not indicated as initial therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F201016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Niacin may be confused with Minocin&reg;, niacinamide, Niaspan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F201014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, atrial fibrillation, edema, flushing, hypotension, orthostasis, palpitation, syncope (rare), tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, headache, insomnia, migraine, nervousness, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acanthosis nigricans, burning skin, dry skin, hyperpigmentation, maculopapular rash, pruritus, rash, skin discoloration, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Glucose tolerance decreased, gout, phosphorous levels decreased, hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, amylase increased, diarrhea, dyspepsia, eructation, flatulence, nausea, peptic ulcers, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Platelet counts decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic necrosis (rare), hepatitis, jaundice, transaminases increased (dose-related), prothrombin time increased, total bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased, leg cramps, myalgia, myasthenia, myopathy (with concurrent HMG-CoA reductase inhibitor), paresthesia, rhabdomyolysis (with concurrent HMG-CoA reductase inhibitor; rare), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cystoid macular edema, toxic amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, hypersensitivity reactions (rare; includes anaphylaxis, angioedema, laryngismus, vesiculobullous rash), LDH increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to niacin or any component; active liver disease, unexplained persistent increases in liver enzymes, significant or unexplained hepatic dysfunction, active peptic ulcer disease, arterial hemorrhaging",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with diabetes mellitus; niacin may increase fasting blood glucose (monitor glucose; adjustment of hypoglycemic therapy may be needed). May elevate uric acid concentrations, use with caution in patients predisposed to gout; large doses should be administered with caution to patients with gallbladder disease, jaundice, history of liver disease, diabetes, unstable angina, MI, renal dysfunction or heavy alcohol use; niacin may cause small increases in prothrombin time (use with caution in patients receiving anticoagulants; monitor closely)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatotoxicity may occur and may be more common if extended release product is substituted for immediate release product at same dosage; do not interchange extended or sustained release products for immediate release at same dosage. Cases of myopathy and rhabdomyolysis have occurred during concomitant use of niacin with HMG-CoA reductase inhibitors; risk may be increased in patients with diabetes, renal failure, or uncontrolled hypothyroidism; monitor all patients receiving both medications for clinical signs of rhabdomyolysis (muscle pain, tenderness, or weakness) and serum CPK and potassium.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2914257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Niacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Niacin may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.  Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concurrent intake of hot drinks, alcohol, or spicy food may increase flushing and pruritus (avoid around the time of niacin administration)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5943163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Water soluble vitamins cross the placenta. When used as a dietary supplement, niacin requirements may be increased in pregnant women compared to nonpregnant women (IOM, 1998). Animal reproduction studies have not been conducted. It is not known if niacin at lipid-lowering doses is harmful to the developing fetus. If a woman becomes pregnant while receiving niacin for primary hypercholesterolemia, niacin should be discontinued. If a woman becomes pregnant while receiving niacin for hypertriglyceridemia, the benefits and risks of continuing niacin should be assessed on an individual basis.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood glucose, serum uric acid, periodic liver function tests, platelet count and prothrombin time (if on concurrent anticoagulant), serum phosphorus (if predisposed to hypophosphatemia). Treatment of hyperlipidemias: Baseline: Liver enzymes, uric acid, fasting glucose, and minimum of two fasting lipid profiles; repeat 4-6 weeks after dose is stabilized; once LDL-C goal is reached, repeat every 2-3 months for first year and then every 6-12 months if no sign of toxicity develops and dose remains stable. Monitor CPK and serum potassium (if on concurrent HMG-CoA reductase inhibitor).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Component of two coenzymes necessary for tissue respiration, lipid metabolism, and glycogenolysis; inhibits the synthesis of very low density lipoproteins",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vasodilation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: 8-10 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and extensive; &ge;60% to 76% of dose is absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass effect; niacin in smaller doses is converted to niacinamide which is metabolized in the liver; niacin undergoes conjugation with glycine to form nicotinuric acid; nicotinamide, nicotinamide adenine dinucleotide (NAD), and other niacin metabolites are formed via saturable pathways;",
"     <b>",
"      Note:",
"     </b>",
"     It is not clear whether nicotinamide is formed before or after the synthesis of NAD",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Single dose studies indicate that only certain Niaspan&reg; tablet strengths are interchangeable (ie, two 500 mg tablets are equivalent to one 1000 mg tablet; however, three 500 mg tablets are",
"     <b>",
"      not",
"     </b>",
"     equivalent to two 750 mg tablets)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Immediate release: &sim;45 minutes; extended release: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine, with &sim;33% as unchanged drug; with larger doses, a greater percentage is excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/53/26452?source=see_link\">",
"      see \"Vitamin B3 (niacin): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Transient flushing of the skin and a sensation of warmth (especially of face and upper body), itching, tingling or headache may occur; if dizziness occurs, avoid sudden changes in posture and notify physician; notify physician if taking vitamins or other products that contain niacin or nicotinamide; do not change brands once dosage is stabilized; report signs and symptoms of hepatotoxicity (nausea, vomiting, loss of appetite, yellow skin, dark urine, general feeling of weakness) to physician",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Nutrition, &ldquo;Cholesterol in Childhood,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(1 Pt 1):141-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/2/5158/abstract-text/11345978/pubmed\" id=\"11345978\" target=\"_blank\">",
"        11345978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;ASHP Therapeutic Position Statement on the Safe Use of Niacin in the Management of Dyslipidemias. American Society of Health-System Pharmacists,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(24):2815-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/2/5158/abstract-text/9428952/pubmed\" id=\"9428952\" target=\"_blank\">",
"        9428952",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Colletti RB, Neufeld EJ, Roff NK, et al, &ldquo;Niacin Treatment of Hypercholesterolemia in Children.&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(1):78-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/2/5158/abstract-text/8516088/pubmed\" id=\"8516088\" target=\"_blank\">",
"        8516088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daniels SR, Greer FR, and Committee on Nutrition, \"Lipid Screening and Cardiovascular Health in Childhood,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(1):198-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/2/5158/abstract-text/18596007/pubmed\" id=\"18596007\" target=\"_blank\">",
"        18596007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine,&rdquo; National Academy of Sciences, Washington, DC: National Academy Press, 1998. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegyi J, Schwartz RA, and Hegyi V, &ldquo;Pellagra: Dermatitis, Dementia, and Diarrhea,&rdquo;",
"      <i>",
"       Int J Dermatol",
"      </i>",
"      , 2004, 43(1):1-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/2/5158/abstract-text/14693013/pubmed\" id=\"14693013\" target=\"_blank\">",
"        14693013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al, \"Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(14):1948-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/2/5158/abstract-text/17377073/pubmed\" id=\"17377073\" target=\"_blank\">",
"        17377073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuna AA, &ldquo;Safe Use of Niacin,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(24):2803.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/2/5158/abstract-text/9428949/pubmed\" id=\"9428949\" target=\"_blank\">",
"        9428949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo; May 2001, www.nhlbi.nih.gov/guidelines/cholesterol.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12642 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5158=[""].join("\n");
var outline_f5_2_5158=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200983\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200984\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054368\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443901\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054361\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200962\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200948\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054372\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054371\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201016\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201014\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054376\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054360\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054359\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299759\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2914257\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054379\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200958\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5943163\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054367\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054358\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054374\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054375\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054366\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12642\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12642|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6951?source=related_link\">",
"      Vitamin B3 (niacin): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/53/26452?source=related_link\">",
"      Vitamin B3 (niacin): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_2_5159="Assess aspiration risk";
var content_f5_2_5159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Prudent limits of targeted depth and length of ED procedural sedation and analgesia according to presedation assessment of aspiration risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 771px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Higher-risk patients are those with one or more of the following present to a degree individually or cumulatively judged clinically important by the treating physician: potential for difficult or prolonged assisted ventilation should an airway complication occur (eg, short neck, small mandible/micrognathia, large tongue, tracheomalacia, laryngomalacia, history of difficult intubation, congenital anomalies of the airway and neck, sleep apnea). Conditions predisposing to esophageal reflux (eg, elevated intracranial pressure, esophageal disease, hiatal hernia, peptic ulcer disease, gastritis, bowel obstruction, ileus, tracheo-esophageal fistula). Extremes of age (eg, &gt;70 years or &lt;6 months). Severe systemic disease with definite functional limitation (ie, ASA physical status 3 or greater). Other clinical findings leading the&nbsp;emergency&nbsp;clinician&nbsp;to judge the patient to be at higher than standard risk (eg, altered level of consciousness, frail appearance).",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Procedural urgency: emergent (eg, cardioversion for life-threatening dysrhythmia, reduction of markedly angulated fracture or dislocation with soft tissue or vascular compromise, intractable pain or suffering). Urgent (eg, care of dirty wounds and lacerations, animal and human bites, abscess incision and drainage, fracture reduction, hip reduction, lumbar puncture for suspected meningitis, arthrocentesis, neuroimaging for trauma). Semi-urgent (eg, care of clean wounds and lacerations, shoulder reduction, neuroimaging for new-onset seizure, foreign body removal, sexual assault examination). Non-urgent or elective (eg, non-vegetable foreign body in external auditory canal, chronic embedded soft tissue foreign body, ingrown toenail).",
"      <br>",
"       &Delta; Procedural sedation and analgesia terminology and definitions:&nbsp;see \"Preparation for procedural sedation in children outside of the operating room\", section on 'Definitions'.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Green, SM, Roback, MG, Miner, JG, et al. Fasting and Emergency Department Procedural Sedation and Analgesia. A Consensus-Based Clinical Proactive Advisory. Annals of Emergency Medicine 2007; 49:454. Copyright &copy; 2007 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5159=[""].join("\n");
var outline_f5_2_5159=null;
var title_f5_2_5160="Liver transplantation in alcoholic liver disease";
var content_f5_2_5160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Liver transplantation in alcoholic liver disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/2/5160/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5160/contributors\">",
"     Scott L Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/2/5160/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5160/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/2/5160/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5160/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/2/5160/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial reluctance to transplant patients with alcoholic liver disease, it is now clear that transplantation offers an excellent survival advantage in appropriately selected patients, equal to that for other disease indications. The original reluctance stemmed from the perception that the disease was self-inflicted and from the possible presence of alcohol-mediated damage to sites outside the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. There was also concern that compliance with postoperative recommendations would be suboptimal and that recidivism would lead to graft failure. Opposing opinions and accumulated data have addressed these reservations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/3\">",
"     3",
"    </a>",
"    ]. Liver transplantation appears to be cost-effective for alcoholic liver disease, albeit possibly less so than for transplantation for some other indications such as primary biliary cirrhosis and primary sclerosing cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the shortage of livers limits the availability of liver transplantation for patients with advanced liver disease. An increase in mortality related to cirrhosis in recent years is troubling and underscores the need for more formal programs to reduce alcohol intake [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/7-11\">",
"     7-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review liver transplantation for alcoholic liver disease. Other aspects related to alcohol induced liver injury are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link\">",
"     \"Pathogenesis of alcoholic liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=see_link\">",
"     \"Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY OF LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;End-stage alcoholic liver disease was responsible for 18 percent of all orthotopic liver transplants between 1992 and 2001 in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/12\">",
"     12",
"    </a>",
"    ]. The first large experience with liver transplantation for alcoholic cirrhosis was reported from Pittsburgh, where survival among 42 patients was equal to that for other forms of liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/13\">",
"     13",
"    </a>",
"    ]. Similar data have now been accumulated from several other centers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/14-21\">",
"     14-21",
"    </a>",
"    ]. In one report, for example, actuarial one-, five-, and seven-year patient and graft survival rates among 123 patients were 84 and 81 percent (one year), 72 and 66 percent (five years), and 63 and 59 percent (seven years), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/19\">",
"     19",
"    </a>",
"    ]. Without transplant, five-year survival is as low as 23 percent. Full integration into society is likely following liver transplantation in appropriately screened and managed alcoholic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important determinant of success is that clinicians caring for patients with end-stage alcoholic liver disease consider transplantation as a potential option and refer their patients early to a transplant center for evaluation. With progressively increasing waiting times until donor organs become available, delayed referral may prevent the patient from surviving the evaluation and waiting period [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early referral for liver transplantation is not always accomplished, in part because of active alcoholism or a perception among referring clinicians that transplantation is not a viable option. However, it is unclear how often patients who are transplant candidates are not being referred for evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/2\">",
"     2",
"    </a>",
"    ]. In a report of 199 potential liver transplantation candidates with end-stage alcoholic liver disease, only 41 (21 percent) were recommended for referral, and only 15 (8 percent) actually underwent transplant evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/25\">",
"     25",
"    </a>",
"    ]. The main reason for not referring patients was active alcohol use. The likelihood of transplantation for patients with end-stage alcoholic liver disease was significantly lower than for patients with other forms of end-stage liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful transplantation in patients with end-stage alcoholic liver disease depends upon careful patient selection. Transplantation is generally performed in patients with advanced disease as determined by the MELD model. A randomized controlled trial comparing patients with Child-Pugh stage B alcoholic cirrhosis listed for transplantation with those randomized to usual care (in which transplantation is generally performed in patients with Child-Pugh stage C cirrhosis), found no survival benefit from early listing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consensus has not been achieved on optimal selection criteria, particularly in determining the minimal duration of alcohol abstinence and predicting the likelihood of recidivism. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Predictors of recidivism'",
"    </a>",
"    below.) Transplant centers have developed their own criteria but several common themes have emerged [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/21,27-30\">",
"     21,27-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22743?source=see_link\">",
"     \"Ethical issues in liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alcohol abstinence and psychosocial factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sobriety and adequate social support are essential. No absolute interval of sobriety is required because some patients who are otherwise suitable candidates will not survive a six-month period.",
"   </p>",
"   <p>",
"    However, a period of six months of sobriety is used widely for predicting recidivism and also allows for hepatic recovery from ongoing alcohol-related injury [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/31\">",
"     31",
"    </a>",
"    ], but accurately determining which patients are abstinent can be difficult. One study that included 40 patients with alcoholic liver disease who were admitted for an assessment for liver transplant found that 38 percent of patients had urine tests that were positive for alcohol (20 percent)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    illicit drugs (30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/32\">",
"     32",
"    </a>",
"    ]. However, only 3 percent of the patients admitted to using alcohol.",
"   </p>",
"   <p>",
"    Three small studies are frequently cited to support the six-month rule's ability to predict post-transplant drinking [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study followed 73 alcohol-dependent patients for an average of 25 months after transplantation and compared them with an equal number of age- and sex-matched nonalcoholic liver transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/33\">",
"       33",
"      </a>",
"      ]. Among long-term survivors, three of seven alcoholics (43 percent) who had been abstinent for less than six months before transplantation resumed some drinking compared with 3 of 45 alcoholics (6.7 percent) with greater than six months abstinence before transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/33\">",
"       33",
"      </a>",
"      ]. This study did not incorporate a formal diagnosis for alcoholism and relied exclusively upon self-reported data.",
"     </li>",
"     <li>",
"      Another study concluded that pre-transplant drinking predicted post-transplant drinking based upon data that two of seven alcoholic patients who drank after transplantation later admitted to drinking within six months of transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/34\">",
"       34",
"      </a>",
"      ]. Patient selection for transplantation was based upon strict application of the six-month rule and the patients who reported post-transplant drinking retracted earlier claims of abstinence before transplantation.",
"     </li>",
"     <li>",
"      A third study retrospectively reviewed 24 alcoholic patients who underwent transplantation over a nine-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/35\">",
"       35",
"      </a>",
"      ]. Most patients reported 3 months to 12 years of abstinence before transplantation. However, three patients were actively drinking at the time of transplantation. While they denied post-transplant drinking, indirect laboratory and clinical data suggested ongoing drinking. Only one patient who was abstinent for more than six months resumed drinking after transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data underscore that the evidence behind the six-month rule is limited. Most of the studies were small and poorly controlled. Furthermore, they demonstrated the difficulty in obtaining accurate information on pre- and post-transplant drinking. Finally, other studies have found that relapse rates were reduced with longer duration of abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the limited evidence, the six-month rule greatly impacts the selection of alcoholic patients on a transplant waiting list. Most liver transplant programs (approximately 85 percent) and about 40 percent of third-party payers in the United States require a set period of abstinence before transplantation (usually six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In addition most require enrollment in an alcohol rehabilitation program such as Alcoholics Anonymous, while also considering other factors such as functional level, employment, and social support. Many centers also require patients to sign a contract agreeing not to drink and to remain in alcohol rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some centers randomly check blood alcohol levels (BAL) in patients on the transplant waiting list. One study looked at 134 patients on the transplant waiting list [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/39\">",
"     39",
"    </a>",
"    ]. In that study, patients were considered to have a positive screen if they refused to submit to a BAL check within 12 hours, if they had a positive BAL, or if they reported alcohol use. Alcohol use was less likely with a higher number of random BAL checks (RR 0.63) and with a longer duration of prelisting abstinence (RR 0.88). None of the patients with prelisting abstinence of more than 24 months had a positive screen. Other interventions to aid in patient selection and achieve alcohol abstinence have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have alcoholic hepatitis are almost never transplanted because the presence of alcoholic hepatitis implies recent alcohol abuse, and because some improve without transplantation. In principle, the chronic inflammatory state associated with alcoholic hepatitis has the potential to increase perioperative complications, although most studies found that long-term morbidity is related primarily to recurrent alcohol abuse rather than acute complications of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/5,6,41,42\">",
"     5,6,41,42",
"    </a>",
"    ]. Moreover, it is increasingly apparent that long-term morbidity and mortality are also linked to continued smoking, which accelerates cardiovascular and cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Smoking'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=see_link&amp;anchor=H418822015#H418822015\">",
"     \"Alcoholic hepatitis: Clinical manifestations and diagnosis\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some studies refute the notion that transplantation is never indicated in patients with acute alcoholic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Some authorities have suggested that the six-month period of abstinence be reconsidered in patients with alcoholic hepatitis and that attempts be made to develop methods to identify transplant candidates who are at low risk of recidivism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a French study, 26 patients with alcoholic hepatitis who were at high risk of death underwent liver transplantation after failing to respond to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/43\">",
"     43",
"    </a>",
"    ]. The patients selected had good social support, a contract for abstinence, no prior episodes of known alcoholic liver disease, and no evidence of severe psychiatric disease. The patients were compared with 26 matched controls with severe alcoholic hepatitis who did not undergo transplantation. The cumulative six-month survival rate was significantly higher in patients who underwent transplantation compared with those who did not (77 versus 23 percent). Survival at two years was also significantly higher in the transplantation group (71 versus 23 percent). Three of the patients who underwent transplantation resumed drinking, one at 720 days post-transplantation, one at 740 days, and one at 1140 days.",
"   </p>",
"   <p>",
"    Similarly, a study using the United Network for Organ Sharing (UNOS) database from 2004 to 2010 found that 11 patients who underwent transplantation for alcoholic hepatitis had similar outcomes as matched patients transplanted for alcoholic cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/44\">",
"     44",
"    </a>",
"    ]. At five years, graft and patient survival rates were 75 and 73 percent, respectively, for patients with alcoholic hepatitis, and the rates were 80 and 78 percent, respectively, for patients with alcoholic cirrhosis.",
"   </p>",
"   <p>",
"    These studies suggest that in carefully selected patients, transplantation may be lifesaving and have long-term success, but it remains highly controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role of live donor liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of live donor liver transplantation (LDLT) introduced difficult ethical questions regarding the indications and timing of transplantation for alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In principle, LDLT offers the advantage of no longer depending on the availability of a deceased donor organ. Thus, opponents of transplantation for acute alcoholic liver disease cannot argue that the procedure deprives another patient of a suitable organ. On the other hand, there are risks to the donor, and thus the procedure must only be undertaken when there is a likelihood of a good outcome and low risk of recidivism by the recipient.",
"   </p>",
"   <p>",
"    Most institutions apply the same criteria for patient selection and donor evaluation in LDLT as are used for deceased donor transplantation. However, the ethics surrounding LDLT continue to be hotly debated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25672?source=see_link\">",
"     \"Living donor liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RECIDIVISM AND MORTALITY AFTER TRANSPLANTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Predictors of recidivism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In appropriately selected patients, the alcohol recidivism rate generally ranges from 8 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/1,14,15,34,41,52-58\">",
"     1,14,15,34,41,52-58",
"    </a>",
"    ]. However, there are conflicting data on whether such patients can be identified in advance. Considerably more research is needed to better define predictors of relapse post-transplant. The following are illustrative of the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 54 studies found that poorer social support, a family alcohol history, and pretransplantation abstinence of &le;6 months correlated with relapse, but the strength of the correlation to any of these factors was poor [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At least two groups have proposed multivariate models to better predict relapse after transplant, incorporating readily definable behaviors and psychosocial factors [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/42,59\">",
"       42,59",
"      </a>",
"      ]. Further studies are needed to establish their validity.",
"     </li>",
"     <li>",
"      Other studies have identified several other variables associated with poor outcomes including repeated episodes of medical noncompliance, current illicit drug use, and a return to drinking after professional intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effect of recidivism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the effect of recidivism on patient compliance and outcome. While many patients resume some alcohol use after transplantation, their survival and overall compliance with immunosuppression may not be different from patients transplanted for other reasons.",
"   </p>",
"   <p>",
"    As an example, the rate of return to some type of drinking in three series ranged from 18 to 49 percent, but only 5 to 7 percent returned to excessive drinking [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/52,61,62\">",
"     52,61,62",
"    </a>",
"    ]. In one of these reports, all patients remained compliant with immunosuppressive regimens and on histologic examination the only alcohol-related finding was steatosis in three of eight recidivistic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, excessive drinking after liver transplantation may be associated with rapidly progressive liver injury and fatal alcoholic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Furthermore, at least one report suggested impaired survival after 10 years in patients who resumed drinking, possibly because of an increased risk of death from cancer and cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/65\">",
"     65",
"    </a>",
"    ]. Finally, the continued use of alcohol in patients post-transplantation might increase the likelihood that they will be lost to follow-up, leading to an underestimate of the impact of ethanol use on outcomes; however, to date there are no data to prove this contention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Independent of relapse, smoking remains a significant risk factor for post-transplant morbidity and mortality. Long-term follow-up of patients who have undergone OLT for alcoholic liver disease has shown an increased rate of lung, liver, and oropharyngeal cancer compared to patients transplanted for other indications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/60,66\">",
"     60,66",
"    </a>",
"    ]. It is likely that this association is due to the relatively high prevalence of smoking in this population combined with the impact of immunosuppression on tumor surveillance. One report found that up to 40 percent of patients who had undergone transplantation for alcoholic liver disease resumed smoking early in the posttransplant course, underscoring the need for continued counseling and monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing emphasis or insistence on enrollment of patients into smoking cessation programs has been advocated to reduce morbidity post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Some authorities have advocated removing patients from the transplant waiting list who continue to smoke despite these interventions. Roughly 20 percent of transplant centers report that they will refuse to list patients due to smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have addressed the success of post-OLT alcoholism treatment programs to prevent relapse. One uncontrolled study of alcoholism treatment in the post-OLT population revealed a 22 percent relapse rate of any drinking over a four-year period after requiring that all patients be followed by an addiction treatment psychiatrist [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/71\">",
"     71",
"    </a>",
"    ]. Historical controls revealed a relapse rate of 48 percent in their post-OLT patients before the alcoholism treatment program started [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/71\">",
"     71",
"    </a>",
"    ]. In the United Kingdom, all patients who undergo transplantation for alcoholic liver disease are followed by an addiction treatment psychiatrist [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5160/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Such a program is recommended but not mandatory in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      End-stage alcoholic liver disease was responsible for 18 percent of all orthotopic liver transplants between 1992 and 2001 in the United States. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy of liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transplantation is associated with one-, five-, and seven-year patient and graft survival of 84 and 81 percent (one year), 72 and 66 percent (five years), and 63 and 59 percent (seven years), respectively. This compares with five-year survival of approximately 23 percent without transplantation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy of liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An important determinant of success is that clinicians caring for patients with end-stage alcoholic liver disease consider transplantation as a potential option and refer their patients early to a transplant center for evaluation. We recommend that patients with end-stage alcoholic liver disease who are potential transplant candidates be referred for transplantation evaluation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy of liver transplantation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"       \"Patient selection for liver transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Successful transplantation in patients with end-stage alcoholic liver disease depends upon careful patient selection. No absolute interval of sobriety is required but most centers insist upon six months of sobriety plus enrollment in an alcohol rehabilitation program such as Alcoholics Anonymous. Exceptions are patients with alcoholic hepatitis; we suggest that patients with active alcoholic hepatitis NOT undergo transplantation because of a potentially increased risk of morbidity and mortality after transplantation, and a high likelihood of recidivism if there has not been a sufficient period of observed abstinence (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In appropriately selected patients, the alcohol recidivism rate after transplantation generally ranges from 8 to 20 percent. The accuracy of predictors of recidivism is incompletely understood but poor social support, a family alcohol history, and pretransplantation abstinence of &le;6 months are some of the predictors that may be important. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Predictors of recidivism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Up to 50 percent of patients who have undergone transplantation for alcoholic liver disease resume some degree of drinking, but only about 5 to 7 percent return to excessive drinking. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of recidivism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Smoking remains a significant risk factor for posttransplant morbidity and mortality. Long-term follow-up of patients who have undergone OLT for alcoholic liver disease has shown an increased rate of lung, liver, and oropharyngeal cancer compared with patients transplanted for other indications. We suggest that patients with alcoholic liver disease who smoke be enrolled in a smoking cessation program (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Smoking'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H387277900\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Jenny Sauk, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/1\">",
"      Moss AH, Siegler M. Should alcoholics compete equally for liver transplantation? JAMA 1991; 265:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/2\">",
"      Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl 2011; 17:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/3\">",
"      Cohen C, Benjamin M. Alcoholics and liver transplantation. The Ethics and Social Impact Committee of the Transplant and Health Policy Center. JAMA 1991; 265:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/4\">",
"      Longworth L, Young T, Buxton MJ, et al. Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transpl 2003; 9:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/5\">",
"      O'Grady JG. Liver transplantation alcohol related liver disease: (deliberately) stirring a hornet's nest! Gut 2006; 55:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/6\">",
"      De Gottardi A, Dumortier J. Transplantation for alcoholic liver disease. Gut 2007; 56:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/7\">",
"      Room R. British livers and British alcohol policy. Lancet 2006; 367:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/8\">",
"      Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 2006; 367:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/9\">",
"      Ponicki WR, Gruenewald PJ. The impact of alcohol taxation on liver cirrhosis mortality. J Stud Alcohol 2006; 67:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/10\">",
"      Andreasson S, Holder HD, Norstr&ouml;m T, et al. Estimates of harm associated with changes in Swedish alcohol policy: results from past and present estimates. Addiction 2006; 101:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/11\">",
"      Gelson W, Hoare M, Dawwas MF, et al. The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation 2011; 91:1240.",
"     </a>",
"    </li>",
"    <li>",
"     United Network for Organ Sharing (UNOS). Public data from UNOS/OPTN scientific registry file://www.unos.org (Accessed on March 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/13\">",
"      Starzl TE, Van Thiel D, Tzakis AG, et al. Orthotopic liver transplantation for alcoholic cirrhosis. JAMA 1988; 260:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/14\">",
"      Gish RG, Lee AH, Keeffe EB, et al. Liver transplantation for patients with alcoholism and end-stage liver disease. Am J Gastroenterol 1993; 88:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/15\">",
"      Berlakovich GA, Steininger R, Herbst F, et al. Efficacy of liver transplantation for alcoholic cirrhosis with respect to recidivism and compliance. Transplantation 1994; 58:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/16\">",
"      Osorio RW, Freise CE, Ascher NL, et al. Orthotopic liver transplantation for end-stage alcoholic liver disease. Transplant Proc 1993; 25:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/17\">",
"      Lucey MR, Merion RM, Henley KS, et al. Selection for and outcome of liver transplantation in alcoholic liver disease. Gastroenterology 1992; 102:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/18\">",
"      Stefanini GF, Biselli M, Grazi GL, et al. Orthotopic liver transplantation for alcoholic liver disease: rates of survival, complications and relapse. Hepatogastroenterology 1997; 44:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/19\">",
"      Bellamy CO, DiMartini AM, Ruppert K, et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001; 72:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/20\">",
"      Young TA, Neuberger J, Longworth L, et al. Survival gain after liver transplantation for patients with alcoholic liver disease: a comparison across models and centers. Transplantation 2003; 76:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/21\">",
"      Webb K, Shepherd L, Day E, et al. Transplantation for alcoholic liver disease: report of a consensus meeting. Liver Transpl 2006; 12:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/22\">",
"      Cowling T, Jennings LW, Goldstein RM, et al. Societal reintegration after liver transplantation: findings in alcohol-related and non-alcohol-related transplant recipients. Ann Surg 2004; 239:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/23\">",
"      Everhart JE, Lombardero M, Detre KM, et al. Increased waiting time for liver transplantation results in higher mortality. Transplantation 1997; 64:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/24\">",
"      Watt KD, McCashland TM. Transplantation in the alcoholic patient. Semin Liver Dis 2004; 24:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/25\">",
"      Julapalli VR, Kramer JR, El-Serag HB, American Association for the Study of Liver Diseases. Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center. Liver Transpl 2005; 11:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/26\">",
"      Vanlemmens C, Di Martino V, Milan C, et al. Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med 2009; 150:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/27\">",
"      Lucey MR, Brown KA, Everson GT, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997; 3:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/28\">",
"      Keeffe EB. Assessment of the alcoholic patient for liver transplantation: comorbidity, outcome, and recidivism. Liver Transpl Surg 1996; 2:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/29\">",
"      Vaillant GE. The natural history of alcoholism and its relationship to liver transplantation. Liver Transpl Surg 1997; 3:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/30\">",
"      Hoofnagle JH, Kresina T, Fuller RK, et al. Liver transplantation for alcoholic liver disease: executive statement and recommendations. Summary of a National Institutes of Health workshop held December 6-7, 1996, Bethesda, Maryland. Liver Transpl Surg 1997; 3:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/31\">",
"      O'Shea RS, Dasarathy S, McCullough AJ, et al. Alcoholic liver disease. Hepatology 2010; 51:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/32\">",
"      Webzell I, Ball D, Bell J, et al. Substance use by liver transplant candidates: an anonymous urinalysis study. Liver Transpl 2011; 17:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/33\">",
"      Kumar S, Stauber RE, Gavaler JS, et al. Orthotopic liver transplantation for alcoholic liver disease. Hepatology 1990; 11:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/34\">",
"      Osorio RW, Ascher NL, Avery M, et al. Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. Hepatology 1994; 20:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/35\">",
"      Bird GL, O'Grady JG, Harvey FA, et al. Liver transplantation in patients with alcoholic cirrhosis: selection criteria and rates of survival and relapse. BMJ 1990; 301:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/36\">",
"      Tandon P, Goodman KJ, Ma MM, et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol 2009; 104:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/37\">",
"      Weinrieb RM, Van Horn DH, McLellan AT, Lucey MR. Interpreting the significance of drinking by alcohol-dependent liver transplant patients: fostering candor is the key to recovery. Liver Transpl 2000; 6:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/38\">",
"      Everhart JE, Beresford TP. Liver transplantation for alcoholic liver disease: a survey of transplantation programs in the United States. Liver Transpl Surg 1997; 3:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/39\">",
"      Carbonneau M, Jensen LA, Bain VG, et al. Alcohol use while on the liver transplant waiting list: a single-center experience. Liver Transpl 2010; 16:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/40\">",
"      Georgiou G, Webb K, Griggs K, et al. First report of a psychosocial intervention for patients with alcohol-related liver disease undergoing liver transplantation. Liver Transpl 2003; 9:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/41\">",
"      Pfitzmann R, Schwenzer J, Rayes N, et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 2007; 13:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/42\">",
"      De Gottardi A, Spahr L, Gelez P, et al. A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years. Arch Intern Med 2007; 167:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/43\">",
"      Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/44\">",
"      Singal AK, Bashar H, Anand BS, et al. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology 2012; 55:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/45\">",
"      Brown RS Jr. Transplantation for alcoholic hepatitis--time to rethink the 6-month \"rule\". N Engl J Med 2011; 365:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/46\">",
"      John S, Chung RT. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2012; 366:478; author reply 479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/47\">",
"      Tamura S, Sugawara Y, Kukudo N. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2012; 366:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/48\">",
"      Di Martino V, Sheppard F, Vanlemmens C. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2012; 366:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/49\">",
"      Schiano TD, Kim-Schluger L, Gondolesi G, Miller CM. Adult living donor liver transplantation: the hepatologist's perspective. Hepatology 2001; 33:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/50\">",
"      Miller CM, Gondolesi GE, Florman S, et al. One hundred nine living donor liver transplants in adults and children: a single-center experience. Ann Surg 2001; 234:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/51\">",
"      Bramstedt KA, Jabbour N. When alcohol abstinence criteria create ethical dilemmas for the liver transplant team. J Med Ethics 2006; 32:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/52\">",
"      F&aacute;brega E, Crespo J, Casafont F, et al. Alcoholic recidivism after liver transplantation for alcoholic cirrhosis. J Clin Gastroenterol 1998; 26:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/53\">",
"      Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl 2008; 14:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/54\">",
"      Miguet M, Monnet E, Vanlemmens C, et al. Predictive factors of alcohol relapse after orthotopic liver transplantation for alcoholic liver disease. Gastroenterol Clin Biol 2004; 28:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/55\">",
"      Foster PF, Fabrega F, Karademir S, et al. Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation. Hepatology 1997; 25:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/56\">",
"      McCallum S, Masterton G. Liver transplantation for alcoholic liver disease: a systematic review of psychosocial selection criteria. Alcohol Alcohol 2006; 41:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/57\">",
"      Keeffe EB, Esquivel CO. Controversies in patient selection for liver transplantation. West J Med 1993; 159:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/58\">",
"      Jauhar S, Talwalkar JA, Schneekloth T, et al. Analysis of factors that predict alcohol relapse following liver transplantation. Liver Transpl 2004; 10:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/59\">",
"      Kelly M, Chick J, Gribble R, et al. Predictors of relapse to harmful alcohol after orthotopic liver transplantation. Alcohol Alcohol 2006; 41:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/60\">",
"      Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006; 7:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/61\">",
"      Gerhardt TC, Goldstein RM, Urschel HC, et al. Alcohol use following liver transplantation for alcoholic cirrhosis. Transplantation 1996; 62:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/62\">",
"      Schmeding M, Heidenhain C, Neuhaus R, et al. Liver transplantation for alcohol-related cirrhosis: a single centre long-term clinical and histological follow-up. Dig Dis Sci 2011; 56:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/63\">",
"      Conjeevaram HS, Hart J, Lissoos TW, et al. Rapidly progressive liver injury and fatal alcoholic hepatitis occurring after liver transplantation in alcoholic patients. Transplantation 1999; 67:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/64\">",
"      Pageaux GP, Bismuth M, Perney P, et al. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol 2003; 38:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/65\">",
"      Cuadrado A, F&aacute;brega E, Casafont F, Pons-Romero F. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 2005; 11:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/66\">",
"      Jain A, DiMartini A, Kashyap R, et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 2000; 70:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/67\">",
"      DiMartini A, Javed L, Russell S, et al. Tobacco use following liver transplantation for alcoholic liver disease: an underestimated problem. Liver Transpl 2005; 11:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/68\">",
"      Mu&ntilde;oz SJ. Tobacco use by liver transplant recipients: grappling with a smoking gun. Liver Transpl 2005; 11:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/69\">",
"      Bataller R. Time to ban smoking in patients with chronic liver diseases. Hepatology 2006; 44:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/70\">",
"      Ehlers SL, Rodrigue JR, Widows MR, et al. Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research. Liver Transpl 2004; 10:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/71\">",
"      Bj&ouml;rnsson E, Olsson J, Rydell A, et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand J Gastroenterol 2005; 40:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/72\">",
"      Bathgate AJ, UK Liver Transplant Units. Recommendations for alcohol-related liver disease. Lancet 2006; 367:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5160/abstract/73\">",
"      Kotlyar DS, Burke A, Campbell MS, Weinrieb RM. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. Am J Gastroenterol 2008; 103:734.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3608 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5160=[""].join("\n");
var outline_f5_2_5160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY OF LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alcohol abstinence and psychosocial factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role of live donor liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RECIDIVISM AND MORTALITY AFTER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Predictors of recidivism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effect of recidivism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment of relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H387277900\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=related_link\">",
"      Alcoholic hepatitis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22743?source=related_link\">",
"      Ethical issues in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25672?source=related_link\">",
"      Living donor liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=related_link\">",
"      Pathogenesis of alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=related_link\">",
"      Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_2_5161="Treatment of orthostatic and postprandial hypotension";
var content_f5_2_5161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of orthostatic and postprandial hypotension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/2/5161/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5161/contributors\">",
"     Horacio Kaufmann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5161/contributors\">",
"     Roy Freeman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5161/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/2/5161/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5161/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/2/5161/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5161/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/2/5161/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 22, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When autonomic reflexes are impaired or intravascular volume is markedly depleted, a significant reduction in blood pressure occurs upon standing (ie, orthostatic hypotension). Orthostatic hypotension can cause dizziness, syncope, and even angina or stroke. The prevalence of orthostatic hypotension varies from 5 to 20 percent in different reports. In the Cardiovascular Health study, for example, the prevalence of orthostatic hypotension was 18 percent in 5201 men and women age 65 years or older. Only 2 percent, however, complained of dizziness with standing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A related problem, postprandial hypotension - a fall in blood pressure occurring 15 to 90 minutes after meals - is common in older subjects. Among elderly residents of nursing homes, for example, one report noted that 24 to 36 percent had a 20 mmHg or greater fall in systolic blood pressure within 75 minutes after eating a meal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link\">",
"     \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the symptoms and treatment of patients with chronic symptomatic orthostatic hypotension and postprandial hypotension.",
"   </p>",
"   <p>",
"    Causes of orthostatic hypotension severe enough to induce symptoms of organ hypoperfusion include autonomic neuropathies (eg, diabetic or amyloid neuropathy, pure autonomic failure), some central nervous system disorders (eg, multiple system atrophy, Parkinson disease), and impaired baroreceptor function due to drugs or other causes. Orthostatic hypotension caused by acute hypovolemia is another major consideration. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link\">",
"     \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic orthostatic intolerance (COI) describes the association of lightheadedness, dizziness, faintness, or syncope that occurs with prolonged standing or upright posture. Younger patients have been described with COI who develop a variety of symptoms such as fatigue, lightheadedness, exercise intolerance, and cognitive impairment in the upright position. These symptoms are associated with an exaggerated tachycardia but little or no fall in blood pressure. This disorder, called the postural tachycardia syndrome (POTS) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29159?source=see_link\">",
"     \"Postural tachycardia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL RESPONSE TO STANDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;How autonomic failure leads to a fall in blood pressure and why some therapeutic modalities may be effective can be appreciated from a brief summary of the normal response to standing. Assumption of the upright posture results in the pooling of 500 to 1000 mL of blood in the lower extremities and splanchnic circulation, which initiates the following sequence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial decrease in venous return to the heart",
"     </li>",
"     <li>",
"      The ensuing reduction in ventricular filling results in diminished cardiac output and blood pressure",
"     </li>",
"     <li>",
"      The fall in blood pressure reduces the discharge of arterial baroreceptors; this initiates compensatory reflexes mediated by the central nervous system that increase sympathetic outflow and vasopressin release, and reduce vagal outflow",
"     </li>",
"     <li>",
"      The increase in sympathetic efferent activity raises peripheral vascular resistance, venous return, and cardiac output, thereby limiting the fall in blood pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With intact compensatory mechanisms, assumption of the erect posture normally leads to only a small fall in systolic blood pressure (5 to 10 mmHg), an increase in diastolic blood pressure (5 to 10 mmHg), and an increase in the pulse rate (10 to 25 beats per minute).",
"   </p>",
"   <p>",
"    Autonomic failure causes orthostatic hypotension by interfering with the reflex response (ie, the sympathetic vasoconstrictor outflow) to standing. Urinary sodium wasting and reduced extracellular fluid volume may be contributing factors. Norepinephrine normally stimulates sodium reabsorption in the proximal tubule; loss of this effect in autonomic insufficiency increases sodium excretion until a new steady state is achieved at a lower plasma volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=see_link&amp;anchor=H7#H7\">",
"     \"Chapter 8C: Regulation of renal Na+ excretion\", section on 'Sympathetic nervous system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthostatic hypotension is not necessarily the first symptom of autonomic failure, but it is the symptom that usually leads patients to seek medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/3\">",
"     3",
"    </a>",
"    ]. Affected patients typically present with lightheadedness and presyncopal complaints occurring in response to sudden postural change, meals, exertion, or prolonged standing. Complaints less easily recognized as hypotensive in origin, such as generalized weakness, fatigue, cognitive slowing, leg buckling, visual blurring, headache and neck pain, may also occur.",
"   </p>",
"   <p>",
"    Orthostatic hypotension can be incapacitating [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/4\">",
"     4",
"    </a>",
"    ]. Severely afflicted patients are unable to leave the supine position without experiencing presyncope or syncope (ie, loss of consciousness).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections on therapy are directed toward the patient with chronic orthostatic hypotension due to autonomic dysfunction. The patient with acute orthostasis due to volume depletion should be treated with volume replacement.",
"   </p>",
"   <p>",
"    Nonpharmacologic measures are important components of the therapy of chronic orthostatic hypotension. These include removal of offending agents, patient education, physical and dietary interventions, and avoiding precipitating factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Removal of offending medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition and removal of drugs which can cause orthostatic hypotension is the first management step. The most common offending agents are diuretics, antihypertensive (primarily sympathetic blockers) and antianginal drugs, and antidepressants (",
"    <a class=\"graphic graphic_table graphicRef76942 \" href=\"UTD.htm?26/13/26843\">",
"     table 1",
"    </a>",
"    ). Often, elderly patients with orthostatic hypotension have supine hypertension and have recently started taking antihypertensive agents. Many such patients present with symptoms of orthostatic hypotension (syncope or presyncope) shortly after initiation of antihypertensive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Patient education and physical maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education is very important for the management of chronic orthostatic hypotension. Throughout the day, patients are subject to a number of orthostatic demands for which there are simple and effective countermeasures. As a result, the time spent emphasizing practical management principles is of inestimable value. These measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arising slowly, in stages, from supine to seated to standing. This maneuver is most important in the morning, when orthostatic tolerance is lowest.",
"     </li>",
"     <li>",
"      Avoiding straining, coughing, and walking in hot weather; these activities reduce venous return and worsen orthostatic hypotension.",
"     </li>",
"     <li>",
"      Raising the head of the bed 10 to 20 degrees decreases renal perfusion, thereby activating the renin-angiotensin-aldosterone system and decreasing nocturnal diuresis. These changes relieve orthostasis by expanding extracellular fluid volume and may reduce end organ damage by reducing supine hypertension.",
"     </li>",
"     <li>",
"      The use of custom-fitted elastic stockings permits the application of graded pressure to the lower extremities and lower abdomen, thereby minimizing peripheral blood pooling. It is essential that such stockings extend to the waist since most peripheral pooling occurs in the splanchnic circulation. These stockings are poorly tolerated by many patients, particularly those with painful peripheral neuropathies or motor dysfunction. One report of ten patients found that compression stockings in patients with orthostatic hypotension and a history of falls reduced the average degree of orthostasis in the group as a whole, and abolished orthostatic dizziness in seven [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exercise may be beneficial when cardiovascular deconditioning rather than chronic autonomic failure is the cause of orthostatic hypotension. As an example, a small study of five elderly patients in whom tilt-table testing at baseline resulted in symptoms showed that an exercise regimen consisting of walking or climbing stairs for 30 to 45 minutes per day three times per week for six months resulted in symptom disappearance during a repeat tilt-table test [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another maneuver that may be effective is tensing the legs by crossing them while actively standing on both legs. In one series of seven patients with autonomic neuropathy, this procedure raised the cardiac output by 16 percent and the systemic blood pressure by 13 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Without leg-crossing, five of the patients reported dizziness within 10 minutes of standing up, leg-crossing allowed all to stand for 10 minutes or more [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/7\">",
"       7",
"      </a>",
"      ]. Squatting produced a similar benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Respiratory maneuvers are under investigation as a means of treating orthostatic hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/9\">",
"       9",
"      </a>",
"      ]. Increased negative inspiratory intrathoracic pressure may reduce orthostatic hypotension by augmenting venous return. Techniques such as inspiration through pursed lips, inspiratory sniffing, and use of an external device causing selective inspiratory obstruction were shown in 10 patients to improve standing blood pressure comparable to leg muscle tensing as long as hyperventilation was avoided.",
"     </li>",
"     <li>",
"      Isometric handgrip when standing was effective in reducing symptoms and minimizing decreases in blood pressure and cardiac output in a case series of 14 patients (age 15 to 22 years) with orthostatic hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Increased salt and water intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reduction in central blood volume associated with autonomic insufficiency (due to increased urinary sodium and water excretion) can be attenuated by increasing sodium and water intake [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. As an example, in a study of 11 patients with severe orthostatic hypotension due to autonomic failure, blood pressure increased significantly after drinking 480 mL of tap water in less than five minutes from",
"    <span class=\"nowrap\">",
"     83&plusmn;6/53&plusmn;3.4",
"    </span>",
"    mmHg at baseline, to",
"    <span class=\"nowrap\">",
"     114&plusmn;30/66&plusmn;18",
"    </span>",
"    mmHg 35 minutes later [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/11\">",
"     11",
"    </a>",
"    ]. After a meal, blood pressure declined less in patients who drank water during the meal than in patients who did not. High-sodium containing foods or salt tablets also may be prescribed. Another study found that water drinking prior to supine exercise improved orthostatic tolerance post-exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Postprandial factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with autonomic failure and even normal elderly are susceptible to significant falls in blood pressure in association with meals [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. Postprandial hypotension can be minimized by [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoiding large meals",
"     </li>",
"     <li>",
"      Ingesting meals low in carbohydrate",
"     </li>",
"     <li>",
"      Minimizing alcohol intake",
"     </li>",
"     <li>",
"      Avoiding activities or sudden standing immediately after eating.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonpharmacologic measures are often insufficient to prevent symptoms of orthostatic hypotension, particularly in patients with moderate to severe disease. Such patients often need pharmacologic intervention. Numerous agents from diverse pharmacological groups have been utilized (",
"    <a class=\"graphic graphic_table graphicRef59499 \" href=\"UTD.htm?28/45/29404\">",
"     table 2",
"    </a>",
"    ). Normotension cannot be perfectly restored. The therapeutic goal is to ameliorate symptoms while avoiding side effects. It is important to analyze symptoms rather than blood pressure values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FLUDROCORTISONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     Fludrocortisone",
"    </a>",
"    acetate (9-alpha-fluorohydrocortisone), a synthetic mineralocorticoid, is the medication of first choice for most patients with orthostatic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/15\">",
"     15",
"    </a>",
"    ]. This agent has a long duration of action, and is well-tolerated by most patients with chronic autonomic failure.",
"   </p>",
"   <p>",
"    The principal mode of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    is an increase in blood volume. Enhanced sensitivity of blood vessels to circulating catecholamines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/16\">",
"     16",
"    </a>",
"    ], and enhanced norepinephrine release from sympathetic neurons are also suggested. A pressor effect of fludrocortisone tends to persist due to increased peripheral vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    acetate is initiated at a dose of 0.1 mg per day which can eventually be increased to 1.0 mg per day; however, little benefit is obtained by an increase beyond 0.5 mg per day. Increments should not occur more rapidly than weekly. Patients treated with fludrocortisone must be carefully monitored for the development of edema or worsening seated or supine hypertension, which may necessitate discontinuation or dosage reduction. Potassium supplementation is usually required, particularly when higher doses are used.",
"   </p>",
"   <p>",
"    Patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    should be instructed in blood pressure recording and should provide to the clinician, for monitoring, a series of blood pressure recordings taken over several days including when supine, sitting, and standing upon awakening, before and one hour after lunch, and before retiring to bed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    acetate may be limited by supine hypertension resulting from the increase in peripheral vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/17\">",
"     17",
"    </a>",
"    ]. Other side effects include hypokalemia, ankle edema, and congestive heart failure. Edema is generally not a major problem, in the absence of some other sodium-retaining state, because of escape from the sodium-retaining effects of fludrocortisone. As an example, patients with primary aldosteronism do not typically develop edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, many elderly patients with autonomic dysfunction do have concurrent conditions that promote edema. Discontinuation of therapy due to side effects is common. In one study of 64 patients with orthostatic hypotension, one-third stopped taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    within six months due primarily to worsening supine hypertension, edema, and, congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SYMPATHOMIMETIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A direct or indirect sympathomimetic pressor agent may be added if the patient remains symptomatic despite treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    acetate. Pressor agents may be used alone in those unable to tolerate fludrocortisone acetate.",
"   </p>",
"   <p>",
"    The effectiveness of sympathomimetic agents is probably dependent upon the increase in adrenergic receptor number and affinity, and the reduction in baroreflex modulation that accompanies autonomic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/20\">",
"     20",
"    </a>",
"    ]. The available alpha-1 adrenoreceptor agonists include those with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both direct and indirect effects. These include ephedrine (25 to 50 mg three times a day),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      (30 to 60 mg three times a day) and phenylpropanolamine (12.5 to 25 mg three times a day) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Phenylpropanolamine has been associated with a small but significant increased risk of stroke, prompting the United States Food and Drug Administration to recommend its removal from the market.",
"     </li>",
"     <li>",
"      Direct effects alone, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      &nbsp;(see",
"      <a class=\"local\" href=\"#H11\">",
"       'Midodrine'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Indirect effects alone, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"       dextroamphetamine",
"      </a>",
"      sulphate [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. These are no longer used in the treatment of orthostatic hypotension because of intolerable CNS side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Midodrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral selective alpha-1-adrenergic agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    is used in the treatment of chronic orthostatic hypotension; it does not cross the blood brain barrier and has a pressor effect due to both arterial and venous constriction. The efficacy of midodrine in the treatment of orthostatic hypotension (and in neurocardiogenic syncope) has been shown in open-label and double-blind studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. As an example, in a randomized trial in 162 patients with chronic orthostatic hypotension, midodrine 10 mg TID was associated with greater improvement in lightheadedness and in standing systolic blood pressure than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     Midodrine",
"    </a>",
"    , the prodrug, is activated to de-glymidodrine, the active alpha agonist. Midodrine is rapidly absorbed from the gastrointestinal tract and reaches a peak plasma concentration in 20 to 40 minutes; the plasma half life is 30 minutes.",
"   </p>",
"   <p>",
"    Since patient sensitivity to this agent varies, the dose should be titrated from 2.5 mg to 10 mg three times a day. Potential side effects include pilomotor reactions, pruritus, supine hypertension, gastrointestinal complaints, and urinary retention. The sympathomimetic side effects, such as anxiety, tremulousness and tachycardia, that accompany the use of adrenergic agents that cross the blood brain barrier are avoided with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     Midodrine",
"    </a>",
"    should not be used in patients with severe organic heart disease, uncontrolled hypertension, or urinary retention. Supine hypertension, which occurs both as a consequence of baroreceptor denervation &mdash; even in untreated patients with autonomic failure &mdash; and as a side effect of antihypotensive treatment, often limits therapeutic intervention. As mentioned above, raising the head of the bed 10 to 20 degrees may protect the brain against supine hypertension.",
"   </p>",
"   <p>",
"    Patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    should be instructed in blood pressure recording and should provide to the clinician, for monitoring, a series of blood pressure recordings taken over several days including when supine, sitting, and standing upon awakening, before and one hour after lunch, and before retiring to bed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of all of the above medications may be complicated by tachyphylaxis, although efficacy may be regained after a short drug holiday. Combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    with an alpha agonist usually has synergistic effects and allows for lower dosage of both agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUPPLEMENTARY AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     Pyridostigmine",
"    </a>",
"    , nonsteroidal antiinflammatory drugs, caffeine, and erythropoietin may be used in combination therapy with first or second line agents in patients with persistent symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pyridostigmine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acetylcholine is a neurotransmitter in the autonomic ganglia. Acetylcholinesterase inhibition could thereby enhance ganglionic neurotransmission, increase the release of norepinephrine by postganglionic sympathetic nerves, and ameliorate orthostatic hypotension. Because postganglionic sympathetic nerves are activated mainly during orthostatic stress, acetylcholinesterase inhibition may ameliorate orthostatic hypotension without inducing supine hypertension, a common side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    and other sympathomimetics.",
"   </p>",
"   <p>",
"    There is limited evidence of efficacy for this treatment. In one double-blind, randomized, four-way crossover study in 58 patients, a single dose of 60 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    , an acetylcholinesterase inhibitor, alone or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    , resulted in a small reduction of orthostatic hypotension (mean diastolic BP fall of 27.2 mmHg versus 34 mmHg in placebo), without increasing supine blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/26\">",
"     26",
"    </a>",
"    ]. However, in a single-blind randomized crossover trial of 31 patients with severe autonomic failure, a single dose of 60 mg of pyridostigmine did not increase the standing diastolic blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NSAIDs are rarely effective as monotherapy, but can supplement treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    or a sympathomimetic agent. They probably act to limit the vasodilating effects of circulating prostaglandins and arachidonic acid derivatives. They may also increase blood volume and enhance vascular sensitivity to norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Caffeine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methylxanthine, caffeine, has a well-established pressor effect that is in part due to blockade of vasodilating adenosine receptors. Caffeine improves orthostatic hypotension and may attenuate postprandial hypotension in patients with autonomic failure. Typical doses are 100 to 250 mg three times a day, either as tablets or caffeinated beverages (one cup of coffee and tea contains approximately 85 and 50 mg of caffeine, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     Recombinant human erythropoietin",
"    </a>",
"    increases standing blood pressure and improves orthostatic tolerance in patients with the anemia that often occurs in autonomic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In one series of eight patients, for example, erythropoietin increased the mean hematocrit from 34 to 45 percent and the standing blood pressure from",
"    <span class=\"nowrap\">",
"     81/46",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     100/63",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/30\">",
"     30",
"    </a>",
"    ]. Orthostatic dizziness improved in six patients; three developed supine hypertension. The elevation in blood pressure may be mediated by increases in red cell mass and central blood volume and by direct or indirect neurohumoral effects on the vascular wall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=see_link\">",
"     \"Hypertension following erythropoietin in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A trial of erythropoietin should be used in all patients with orthostatic hypotension and anemia who have low serum erythropoietin concentrations.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     Recombinant human erythropoietin",
"    </a>",
"    , epoetin alpha, is administered subcutaneously or intravenously at doses between 25 to 75",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    three times a week until a hematocrit that approaches normal is attained. Lower maintenance doses (approximately 25",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    three times a week) may subsequently be used. Iron supplementation is usually required, particularly during the period when the hematocrit is increasing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     THIRD LINE AND EXPERIMENTAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients require third-line or experimental therapy to ameliorate the symptoms of orthostatic hypotension. Such agents include vasopressin analogues, yohimbine, somatostatin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    , dopamine antagonists, monoamine oxidase inhibitors, and dihydroxyphenylserine. Beta blockers and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    are no longer recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Vasopressin analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressin analogues have a limited role in orthostatic hypotension. Both V1 and V2 receptor agonists have been used. Their mechanism of action may be enhanced by supersensitivity to vasopressin among patients with autonomic failure because of reduced postural release of this hormone.",
"   </p>",
"   <p>",
"    V1 and V2 receptor agonists have different modes of action.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The synthetic vasopressin analogue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      (dDAVP) acts on the V2 receptors in the collecting tubules but has no V1 receptor vasoconstricting potential. dDAVP, which can be taken via the nasal or oral route, prevents nocturia and overnight weight loss and reduces the morning postural fall in blood pressure in patients with autonomic failure [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/32\">",
"       32",
"      </a>",
"      ]. Careful and continued monitoring of serum Na concentration is required. If hyponatremia develops, treatment with dDAVP should be stopped.",
"     </li>",
"     <li>",
"      The V1 receptor agonists, such as lysine-vasopressin nasal spray and intramuscular triglycyl-lysine vasopressin, may increase blood pressure and peripheral vascular resistance due to a direct vasopressor effect, thereby improving symptoms of orthostatic hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/33\">",
"       33",
"      </a>",
"      ]. No controlled clinical trial has been conducted and therefore the use of V1 receptor agonists cannot be recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Yohimbine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yohimbine is a centrally active, selective alpha-2 antagonist that increases sympathetic nervous system efferent output by blocking central",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    presynaptic alpha-2 receptors. In subjects with residual sympathetic nervous system outflow, yohimbine (8 mg TID) produces a modest pressor effect [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/34\">",
"     34",
"    </a>",
"    ]. Side effects include anxiety, tremor, palpitations, diarrhea, and supine hypertension. In a single-blind randomized crossover treatment trial in 31 patients with severe autonomic failure, a single dose of yohimbine (5.4 mg) was associated with an average 11 mm Hg improvement in standing diastolic blood pressure compared with placebo-treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients also reported an improvement in presyncopal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Somatostatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin and somatostatin analogues such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    attenuate the pancreatic and gastrointestinal hormone response to food ingestion and other stimuli by inhibiting the release of vasoactive gastrointestinal peptides. They also enhance cardiac output, and increase forearm and splanchnic vascular resistance. The net effect is attenuation of the fall in the postprandial blood pressure in patients with autonomic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/35\">",
"     35",
"    </a>",
"    ]. Subcutaneous doses of octreotide range from 25 to 200 &micro;g. Side-effects of nausea and abdominal cramps limit the use of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Dihydroergotamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     Dihydroergotamine",
"    </a>",
"    , an ergot alkaloid that interacts with alpha-adrenergic receptors, has a selective venoconstrictor effect. As a result, it may increase venous return in patients with orthostatic hypotension without producing a significant increase in peripheral vascular resistance. Although dihydroergotamine is an effective pressor intravenously and intramuscularly, low oral bioavailability results in an inconsistent effect when it is taken orally [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dihydroxyphenylserine",
"    </span>",
"    &nbsp;&mdash;&nbsp;DL and L-dihydroxyphenylserine (DOPS) are synthetic, non-physiologic, amino acid norepinephrine precursors that are decarboxylated by the ubiquitous L-amino acid decarboxylase to norepinephrine. The important role played by norepinephrine in the maintenance of upright blood pressure and the successful implementation of precursor therapy for Parkinson disease provide the rationale for the use of this agent to treat neurogenic orthostatic hypotension. Of the four stereoisomers, D- and L-threo-DOPS and D- and L-erythro-DOPS, only L-threo-DOPS is pharmacologically active.",
"   </p>",
"   <p>",
"    Since the conversion of DOPS to norepinephrine bypasses the dopamine beta-hydroxylation step of catecholamine synthesis, DOPS is the ideal therapeutic agent for patients with dopamine beta-hydroxylase deficiency; such individuals are unable to synthesize norepinephrine and epinephrine in the central and peripheral nervous system. This agent may also be of benefit in patients with familial amyloid polyneuropathy, Parkinson disease, multiple system atrophy, and pure autonomic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Dopamine antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dopamine antagonists,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    (which is not approved by the US FDA), may be effective in chronic orthostatic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/38\">",
"     38",
"    </a>",
"    ]. Most likely, these agents inhibit the vasodilating and natriuretic effect of dopamine or increase noradrenaline release by blocking prejunctional inhibitory dopamine receptors. These should not be used in patients with parkinsonism. The risk of tardive dyskinesia and other extrapyramidal side effects limits their long-term use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Monoamine oxidase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial reports of combination therapy consisting of the indirect acting agent tyramine (which releases norepinephrine from neuronal storage pools) and a monoamine oxidase inhibitor (which prevents the breakdown of the released norepinephrine) were optimistic. Unfortunately, this combination can cause severe supine hypertension, an unpredictable response, and, in some cases, fails to abolish orthostatic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ambulatory norepinephrine infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selected patients with refractory orthostatic hypotension due to primary autonomic failure, ambulatory, patient-controlled infusion of norepinephrine may be an effective therapy. In one series of six patients, four had a continued benefit from this therapy, without side effects, for up to 19 months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUPINE HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common problem in patients with orthostatic hypotension is the concurrent presence of supine hypertension. Drugs effective in managing hypertension may exacerbate orthostatic hypotension, while treatment of orthostatic hypotension may increase supine hypertension. In many such patients, the best that can be achieved is to maximize nonpharmacologic measures and to use drugs that might raise the supine blood pressure only to the degree that permits the patient to ambulate.",
"   </p>",
"   <p>",
"    To offset supine hypertension, patients should avoid lying down during the day, and, if tired, should rest in a seated position. As mentioned above, patients should sleep in a semisitting position. One strategy is to treat supine hypertension at night with a transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    patch (0.025 to 0.1",
"    <span class=\"nowrap\">",
"     mg/hour),",
"    </span>",
"    which is removed in the morning prior to the assumption of an upright position [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Significant hypotension may result in some patients, thus the dose must be individually tailored. To avoid syncope and dangerous falls, patients should be cautioned to be extremely careful if they must arise at night, since orthostatic symptoms will be exacerbated. The usefulness of this treatment has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TREATMENT OF POSTPRANDIAL HYPOTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal therapy of symptomatic postprandial hypotension has not been defined. The same principles noted above for orthostatic hypotension (such as avoidance of volume depletion and certain drugs) should also be applied to patients with postprandial symptoms. As an example, among 20 patients with postprandial hypotension and heart failure but preserved left ventricular systolic function, the successful withdrawal of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    in 13 significantly lessened the maximum fall in both the systolic (-25 to -11 mmHg, P&lt;0.001) and diastolic blood pressures (-18 to -9 mmHg, P=0.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following general suggestions may also be helpful in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eat small meals; it is also possible that low carbohydrate meals will minimize postprandial hypotension. Salt restriction should be avoided.",
"     </li>",
"     <li>",
"      Avoid standing up suddenly or standing still after meals. Patients should try to walk between meals; if this is not tolerated, then lying semirecumbent for 90 minutes after meals may be necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The somatostatin analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    can minimize postprandial hypotension, perhaps by increasing splanchnic vascular resistance, thereby preventing pooling of blood in the gut [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/2\">",
"     2",
"    </a>",
"    ]. However, octreotide must be given subcutaneously (50 &micro;g, 30 minutes before each meal), is expensive, and often leads to side effects such as diarrhea and pain at the injection site. It should therefore be reserved for the most severely symptomatic patients.",
"   </p>",
"   <p>",
"    Caffeine has also been thought to be effective in this disorder. However, a controlled trial in patients with postprandial syncope showed no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5161/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6546?source=see_link\">",
"       \"Patient information: Orthostatic hypotension (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial treatment of orthostatic hypotension should focus on nonpharmacologic measures: removal of offending medications, using elastic stockings, physical maneuvers, and exercise. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nonpharmacologic measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest step-wise pharmacologic treatment using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      for patients with disabling symptoms despite nonpharmacologic measures, followed by a sympathomimetic pressor agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      , for patients who remain symptomatic on or cannot tolerate fludrocortisone. Treatment should be graded to the patients&rsquo; symptoms and their impact on daily function. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Fludrocortisone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Midodrine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of other modalities may be beneficial (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Supplementary agents'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Caffeine in the morning is probably helpful to most patients",
"     </li>",
"     <li>",
"      A trial with recombinant erythropoietin should be attempted in patients with anemia",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs may be useful supplementary agents in those with refractory symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small number of patients have persistent orthostatic symptoms despite these modalities. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Third line and experimental agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When medications such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      are used, patients should be instructed in blood pressure recording. They should provide to the clinician, for monitoring, a series of blood pressure recordings taken over several days including when supine, sitting, and standing upon awakening, before and one hour after lunch, and before retiring to bed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Fludrocortisone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Midodrine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supine hypertension may be a treatment-limiting complication and may require specific interventions. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Supine hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postprandial hypotension may respond to similar nonpharmacologic measures. Smaller meals, with low carbohydrate and salt content may also ameliorate symptoms. Rare patients will require pharmacologic intervention. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Treatment of postprandial hypotension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/1\">",
"      Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992; 19:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/2\">",
"      Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med 1995; 122:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/3\">",
"      Position paper: Orthostatic hypotension, multiple system atrophy (the Shy Drager syndrome) and pure autonomic failure. J Auton Nerv Sys 1996; 58:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/4\">",
"      Benrud-Larson LM, Dewar MS, Sandroni P, et al. Quality of life in patients with postural tachycardia syndrome. Mayo Clin Proc 2002; 77:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/5\">",
"      Henry R, Rowe J, O'Mahony D. Haemodynamic analysis of efficacy of compression hosiery in elderly fallers with orthostatic hypotension. Lancet 1999; 354:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/6\">",
"      Carroll JF, Wood CE, Pollock ML, et al. Hormonal responses in elders experiencing pre-syncopal symptoms during head-up tilt before and after exercise training. J Gerontol A Biol Sci Med Sci 1995; 50:M324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/7\">",
"      van Lieshout JJ, ten Harkel AD, Wieling W. Physical manoeuvres for combating orthostatic dizziness in autonomic failure. Lancet 1992; 339:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/8\">",
"      Ten Harkel AD, van Lieshout JJ, Wieling W. Effects of leg muscle pumping and tensing on orthostatic arterial pressure: a study in normal subjects and patients with autonomic failure. Clin Sci (Lond) 1994; 87:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/9\">",
"      Thijs RD, Wieling W, van den Aardweg JG, van Dijk JG. Respiratory countermaneuvers in autonomic failure. Neurology 2007; 69:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/10\">",
"      Clarke DA, Medow MS, Taneja I, et al. Initial orthostatic hypotension in the young is attenuated by static handgrip. J Pediatr 2010; 156:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/11\">",
"      Shannon JR, Diedrich A, Biaggioni I, et al. Water drinking as a treatment for orthostatic syndromes. Am J Med 2002; 112:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/12\">",
"      Young TM, Mathias CJ. The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure. J Neurol Neurosurg Psychiatry 2004; 75:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/13\">",
"      Humm AM, Mason LM, Mathias CJ. Effects of water drinking on cardiovascular responses to supine exercise and on orthostatic hypotension after exercise in pure autonomic failure. J Neurol Neurosurg Psychiatry 2008; 79:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/14\">",
"      Lipsitz LA, Nyquist RP Jr, Wei JY, Rowe JW. Postprandial reduction in blood pressure in the elderly. N Engl J Med 1983; 309:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/15\">",
"      Campbell IW, Ewing DJ, Clarke BF. 9-Alpha-fluorohydrocortisone in the treatment of postural hypotension in diabetic autonomic neuropathy. Diabetes 1975; 24:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/16\">",
"      Davies IB, Bannister RG, Sever PS, Wilcox CS. Fludrocortisone in the treatment of postural hypotension: altered sensitivity to pressor agents [proceedings]. Br J Clin Pharmacol 1978; 6:444P.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/17\">",
"      Chobanian AV, Volicer L, Tifft CP, et al. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979; 301:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/18\">",
"      Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008; 7:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/19\">",
"      Hussain RM, McIntosh SJ, Lawson J, Kenny RA. Fludrocortisone in the treatment of hypotensive disorders in the elderly. Heart 1996; 76:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/20\">",
"      Davies B, Bannister R, Sever P. Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure. Limitations and hazards. Lancet 1978; 1:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/21\">",
"      Ghrist, DG, Brown, GE. Postural hypertension with syncope: Its successful treatment with ephedrine. Am J Med Sci 1928; 175:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/22\">",
"      Biaggioni I, Onrot J, Stewart CK, Robertson D. The potent pressor effect of phenylpropanolamine in patients with autonomic impairment. JAMA 1987; 258:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/23\">",
"      Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997; 277:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/24\">",
"      Kaufmann H, Brannan T, Krakoff L, et al. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 1988; 38:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/25\">",
"      Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: a role in the management of neurocardiogenic syncope. Heart 1998; 79:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/26\">",
"      Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006; 63:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/27\">",
"      Shibao C, Okamoto LE, Gamboa A, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2010; 56:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/28\">",
"      Kochar MS, Itskovitz HD. Treatment of idiopathic orthostatic hypotension (Shy-Drager syndrome) with indomethacin. Lancet 1978; 1:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/29\">",
"      Onrot J, Goldberg MR, Biaggioni I, et al. Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension. N Engl J Med 1985; 313:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/30\">",
"      Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 1993; 329:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/31\">",
"      Perera R, Isola L, Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res 1995; 5:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/32\">",
"      Mathias CJ, Fosbraey P, da Costa DF, et al. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed) 1986; 293:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/33\">",
"      Kochar MS. Hemodynamic effects of lysine-vasopressin in orthostatic hypotension. Am J Kidney Dis 1985; 6:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/34\">",
"      Onrot J, Goldberg MR, Biaggioni I, et al. Oral yohimbine in human autonomic failure. Neurology 1987; 37:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/35\">",
"      Hoeldtke RD, Israel BC. Treatment of orthostatic hypotension with octreotide. J Clin Endocrinol Metab 1989; 68:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/36\">",
"      Jennings G, Esler M, Holmes R. Treatment of orthostatic hypotension with dihydroergotamine. Br Med J 1979; 2:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/37\">",
"      Freeman R, Landsberg L. The treatment of orthostatic hypotension with dihydroxyphenylserine. Clin Neuropharmacol 1991; 14:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/38\">",
"      Lopes de Faria SR, Zanella MT, Andriolo A, et al. Peripheral dopaminergic blockade for the treatment of diabetic orthostatic hypotension. Clin Pharmacol Ther 1988; 44:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/39\">",
"      Oldenburg O, Mitchell A, N&uuml;rnberger J, et al. Ambulatory norepinephrine treatment of severe autonomic orthostatic hypotension. J Am Coll Cardiol 2001; 37:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/40\">",
"      Shannon J, Jordan J, Costa F, et al. The hypertension of autonomic failure and its treatment. Hypertension 1997; 30:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/41\">",
"      Jordan J, Shannon JR, Pohar B, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol 1999; 10:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/42\">",
"      van Kraaij DJ, Jansen RW, Bouwels LH, Hoefnagels WH. Furosemide withdrawal improves postprandial hypotension in elderly patients with heart failure and preserved left ventricular systolic function. Arch Intern Med 1999; 159:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5161/abstract/43\">",
"      Lipsitz LA, Jansen RW, Connelly CM, et al. Haemodynamic and neurohumoral effects of caffeine in elderly patients with symptomatic postprandial hypotension: a double-blind, randomized, placebo-controlled study. Clin Sci (Lond) 1994; 87:259.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5105 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-71969A6E96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5161=[""].join("\n");
var outline_f5_2_5161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL RESPONSE TO STANDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NONPHARMACOLOGIC MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Removal of offending medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patient education and physical maneuvers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Increased salt and water intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Postprandial factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FLUDROCORTISONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SYMPATHOMIMETIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Midodrine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUPPLEMENTARY AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pyridostigmine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Caffeine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      THIRD LINE AND EXPERIMENTAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Vasopressin analogues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Yohimbine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Somatostatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Dihydroergotamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dihydroxyphenylserine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Dopamine antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Monoamine oxidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ambulatory norepinephrine infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUPINE HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TREATMENT OF POSTPRANDIAL HYPOTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5105\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5105|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/13/26843\" title=\"table 1\">",
"      Causes of isolated autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/45/29404\" title=\"table 2\">",
"      Rx of orthostatic hypotension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=related_link\">",
"      Chapter 8C: Regulation of renal Na+ excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=related_link\">",
"      Hypertension following erythropoietin in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6546?source=related_link\">",
"      Patient information: Orthostatic hypotension (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29159?source=related_link\">",
"      Postural tachycardia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_2_5162="Anticoagulant therapy in non-ST elevation acute coronary syndromes";
var content_f5_2_5162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/2/5162/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5162/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5162/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5162/contributors\">",
"     A Michael Lincoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/2/5162/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5162/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5162/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/2/5162/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/2/5162/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/2/5162/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of an atherosclerotic plaque is the usual initiating event in an acute coronary syndrome (ACS). Persistent thrombotic occlusion at the site of plaque rupture results in acute myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombin activity at the site of plaque rupture may result in delayed or incomplete reperfusion of occluded vessels and contributes to reocclusion. Thrombin is a central mediator of clot formation through its activation of platelets, conversion of fibrinogen to fibrin, and activation of factor XIII, leading to fibrin cross-linking and clot stabilization. Anticoagulants, including heparins, direct thrombin inhibitors, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    interfere with the activity of thrombin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the evidence that supports the use of parenteral anticoagulant therapy in all patients with an acute non-ST elevation coronary syndrome (NSTEACS), which includes both unstable angina and acute non-ST elevation myocardial infarction (NSTEMI), and will provide recommendations for its use according to whether the patient receives reperfusion with percutaneous coronary intervention or no reperfusion therapy. Information regarding anticoagulant agents in ST elevation myocardial infarction and the role of antiplatelet therapy in NSTEACS is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ANTICOAGULANT AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three classes of anticoagulants that have been evaluated in the management of acute coronary syndromes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The heparins, including unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (UFH) and the low molecular weight heparins (LMWH), are indirect thrombin inhibitors that complex with antithrombin (AT, formerly known as AT III) and convert AT from a slow to a rapid inactivator of thrombin, factor Xa, and to a lesser extent, factors XIIa, XIa, and IXa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"       \"Overview of hemostasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There are a number of intrinsic limitations to UFH therapy in patients with acute MI. The most important is that the heparin-antithrombin (AT, formerly called antithrombin III) complex cannot bind or inactivate thrombin bound within a clot [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/1\">",
"       1",
"      </a>",
"      ]. Such clot-bound thrombin acts as an important thrombogenic stimulus at a site of coronary thrombosis, particularly after clot disruption by fibrinolytic agents [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/2\">",
"       2",
"      </a>",
"      ]. An additional concern with the administration of UFH has been heparin-induced thrombocytopenia (HIT). The risk is much lower but not absent with LMWH than with UFH and is not seen with the direct thrombin inhibitors or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link&amp;anchor=H36#H36\">",
"       \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Heparin-induced thrombocytopenia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      LMWH inactivates factor Xa, like UFH, but has a lesser effect on thrombin (",
"      <a class=\"graphic graphic_figure graphicRef64839 \" href=\"UTD.htm?35/16/36110\">",
"       figure 1",
"      </a>",
"      ). As a result, LMWH do not prolong the aPTT in a predictable fashion. They have a number of advantages over UFH, including a more predictable anticoagulant effect and a reduced likelihood of inducing immune-mediated thrombocytopenia.",
"     </li>",
"     <li>",
"      The direct thrombin inhibitors (eg, hirudin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/45/4823?source=see_link\">",
"       lepirudin",
"      </a>",
"      ) bind to and inactivate one or more of the active sites on the thrombin molecule [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H7#H7\">",
"       \"Anticoagulants other than heparin and warfarin\", section on 'Direct thrombin inhibitors'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The prototypic agent of this class, hirudin, is a peptide derived from the saliva of the medicinal leech. Hirudin selectively binds to and inhibits both the fibrinogen recognition and catalytic sites of thrombin. Peptide analogues of hirudin include bivalirudin (previously called hirulog), which also binds to the substrate recognition and catalytic sites of thrombin [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/4\">",
"       4",
"      </a>",
"      ], and the arginine derivative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"       argatroban",
"      </a>",
"      , which competitively inhibits the thrombin catalytic site. These drugs share a number of the following properties that make them attractive as potential therapeutic agents compared to UFH:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antithrombin is not required as a cofactor.",
"     </li>",
"     <li>",
"      Clot-bound thrombin can be inhibited.",
"     </li>",
"     <li>",
"      Circulating inhibitors do not inhibit their function.",
"     </li>",
"     <li>",
"      There is no appreciable binding to plasma proteins.",
"     </li>",
"     <li>",
"      There is no activation of platelets and, in contrast, these drugs inhibit thrombin-mediated platelet activation.",
"     </li>",
"     <li>",
"      Thrombin bound to fibrin derivatives is susceptible to inactivation by direct thrombin inhibitors, but is protected from inhibition by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/2\">",
"       2",
"      </a>",
"      ]. This may be particularly important after fibrinolysis, when there is a procoagulant state.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The synthetic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      pentasaccharide",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      acts through antithrombin to exclusively neutralize factor Xa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44408?source=see_link\">",
"       \"Therapeutic use of fondaparinux\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1267953\">",
"    <span class=\"h1\">",
"     ANTICOAGULANT VERSUS PLACEBO",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend anticoagulant therapy for all patients with non-ST elevation ACS. This is based on studies with UFH and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    (an LMWH), which found that anticoagulant therapy is superior to no anticoagulant therapy in these patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pooled analysis of 10 small trials of patients with non-ST elevation ACS demonstrated a significant short-term (seven days) reduction in death or MI with either UFH or LMWH plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      compared to aspirin alone (summary odds ratio 0.53, 95% CI 0.38-0.73) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/5\">",
"       5",
"      </a>",
"      ]. Subgroup analysis based on the presence or absence of myocardial infarction was not reported.",
"     </li>",
"     <li>",
"      The FRISC trial evaluated 1506 patients who were randomly assigned to either placebo or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/6\">",
"       6",
"      </a>",
"      ]. The rate of death or new MI was significantly lower in patients treated with dalteparin (1.8 versus 4.8 percent) and there was a reduced frequency of the need for revascularization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No large trials comparing direct thrombin inhibitors or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    to placebo have been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HEPARINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence provided in the section above confirms a benefit from anticoagulant therapy with either UFH or a LMWH compared to placebo. A number of trials have compared an LMWH, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , to unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with unstable angina or NSTEMI and found that enoxaparin leads to better outcomes in patients managed with a conservative strategy (medical therapy), whereas other LMWHs have generally not been found to be useful in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Enoxaparin versus UFH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , compared to unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH), has been evaluated in four large randomized trials. In these trials, the usual dose of enoxaparin was 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours and for UFH was 60",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    initial bolus, followed by an infusion of 12",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per hour (adjusted to a goal activated partial thromboplastin time [aPTT] of 1.5 to 2.0 times the upper limit of normal or 50 to 70 seconds). Treatment was generally started soon after the diagnosis and continued for two and eight days, unless otherwise noted.",
"   </p>",
"   <p>",
"    The following four trials had differing populations and co-interventions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ESSENCE trial compared the effectiveness",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      to continuous intravenous UFH in 3171",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      treated patients with unstable angina (angina at rest) or acute NSTEMI; therapy was given for a minimum of 48 hours to a maximum of eight days [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/7\">",
"       7",
"      </a>",
"      ]. Revascularization was not intended in this trial.",
"      <br/>",
"      <br/>",
"      At 30 days, enoxaparin therapy had a significant lower rate of a combined end point of death, MI, and recurrent angina (19.8 versus 23.3 percent with UFH) or a revascularization procedure (27.0 versus 32.2 percent). There was no difference between the two groups in the rates of major bleeding (6.5 versus 7.0 percent) or severe thrombocytopenia (0.4 versus 0.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/8\">",
"       8",
"      </a>",
"      ]. These benefits were maintained at one year for both the combined end point (32 versus 36 percent) and the need for repeat revascularization (36 versus 41 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/9\">",
"       9",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Approximately one-third of patients underwent percutaneous coronary revascularization or coronary artery bypass graft surgery.",
"     </li>",
"     <li>",
"      The benefits of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      compared to UFH in UA or NSTEMI were confirmed in the TIMI 11B trial of 3910",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      treated patients for whom revascularization was not intended [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/10\">",
"       10",
"      </a>",
"      ]. The incidence of the primary end point (death, MI, or urgent revascularization) was significantly lower with enoxaparin at eight days (12.4 versus 14.5 for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ). The benefit of enoxaparin was limited to patients with elevated levels of troponin I [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Phase A of the A to Z trial, 3987 patients with a non-ST elevation ACS (74 percent NSTEMI) were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and then randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      or UFH [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/12\">",
"       12",
"      </a>",
"      ]. An early invasive strategy was declared in 55 percent of the study subjects, at the discretion of the physician. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At seven days, there was no significant difference in the incidence of the primary end point (death, MI, or refractory ischemia) between the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      and UFH arms (8.4 versus 9.4 percent, respectively; hazard ratio 0.88; 95% CI 0.71-1.08). These findings met the prespecified criteria for non-inferiority and, although not significant, the 1 percent absolute reduction in the primary end point was consistent with the findings in the above trials performed without GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitors.",
"     </li>",
"     <li>",
"      An analysis of prespecified subgroups found no difference in outcome in the 55 percent of patients treated with an intended early invasive strategy (8.8 versus 8.5 percent). In contrast, there was a significant reduction in the primary end point with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (7.7 versus 10.6 percent) in the remaining patients who were treated with an intended early conservative strategy.",
"     </li>",
"     <li>",
"      The incidence of major bleeding was greater with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (0.9 versus 0.4 percent with UFH; p = .05), but there was no increase in transfusion rates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with non-ST ACS are treated with two oral antiplatelet regimens in addition to anticoagulant. Thus, the three trials presented above are not directly applicable to current care. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H43#H43\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The SYNERGY trial provides the best evidence with which to compare UFH to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      in patients who receive contemporary antiplatelet therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. This trial randomly assigned 10,027 patients with a non-ST elevation ACS for whom an early invasive management strategy was planned to open label enoxaparin or UFH. Concomitant medications in SYNERGY included",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (95 percent),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      (66 percent), and a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor (57 percent). Coronary angiography was performed in 92 percent of the SYNERGY patients; 47 percent underwent PCI and 19 percent underwent surgical revascularization. In many patients, anticoagulant therapy was stopped after PCI.",
"      <br/>",
"      <br/>",
"      The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There was no significant difference in the rate of the primary end point of death or nonfatal MI at 30 days or at six months with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (14.0 versus 14.5 percent and 17.6 versus 17.8 percent, enoxaparin compared to UFH). There was also no difference in death or nonfatal MI or in all-cause mortality at one year (7.4 versus 7.8 percent).",
"     </li>",
"     <li>",
"      There was a significant increase in in-hospital major bleeding with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (9.1 versus 7.6 percent for UFH).",
"     </li>",
"     <li>",
"      Both cardiovascular and bleeding outcomes were worse in patients initially treated with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      or UFH and then switched to the other agent compared to patients who did not switch.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results from SYNERGY suggest that, in patients with a non-ST elevation ACS who receive an oral platelet P2Y12 receptor blocker and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (and a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor in some cases) and undergo PCI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    and UFH have comparable efficacy. However, enoxaparin is associated with a statistically significant increase in major bleeding.",
"   </p>",
"   <p>",
"    A 2012 meta-analysis comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    to UFH included studies of patients with ST- and non-ST elevation ACS and stable angina and evaluated outcomes of mortality and major bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/15\">",
"     15",
"    </a>",
"    ]. Although there were trends toward lower rates of death and major bleeding with enoxaparin, we do not feel this meta-analysis should be used in the formulation of our recommendations due to the inclusion of STEMI patients and many stable patients, as well as other limitations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link&amp;anchor=H21647888#H21647888\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'UFH versus enoxaparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other LMWHs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other LMWHs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    have been compared to placebo, UFH, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    . These drugs have equivalent efficacy to UFH, may be less effective than enoxaparin, and may be associated with higher rates of major bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Nadroparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the FRAXIS trial of over 2300 patients with a non-ST elevation ACS,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    was compared to intravenous UFH, both given for six days given for either six or fourteen days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/16\">",
"     16",
"    </a>",
"    ]. There was no advantage to nadroparin compared to UFH in the incidence of the primary end point (cardiac death, MI, refractory angina, or recurrence of unstable angina at day 14). Furthermore, there was a significantly increased risk of major hemorrhage among those receiving nadroparin for fourteen days (3.5 versus 1.6 percent for UFH).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Tinzaparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     Enoxaparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    given for seven days were directly compared in the EVET trial of 438 patients with a non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/17\">",
"     17",
"    </a>",
"    ]. Enoxaparin therapy was associated with a significantly greater reduction in the recurrence of unstable angina at seven days (11.8 versus 19.3 percent) and the incidence at 30 days of recurrent angina (17.3 versus 26.1 percent) or MI (0.5 versus 2.8 percent). The benefit persisted at six months, as the enoxaparin group had significantly lower rates of death, MI, or recurrent angina (26 versus 44 percent) and death or MI (2.7 versus 6.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Dalteparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of longer-term therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    was evaluated in two trials: in FRIC, in which patients received either dalteparin or placebo for 45 days after six days of dalteparin or UFH; and in FRISC II, in which patients received dalteparin acutely and then dalteparin or placebo for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. There was no benefit of prolonged therapy in FRIC, which also failed to demonstrate better outcomes with dalteparin than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . FRISC II found no difference in death or MI at three or six months. There was a reduction in the combined end point of death, MI, or revascularization at three months, but not at six months. However, there was an increased incidence of intracranial hemorrhage with dalteparin (5 versus 0 with placebo).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100954409\">",
"    <span class=\"h2\">",
"     Heparin-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of immune-mediated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) is approximately 2.5 to 3.0 percent in patients exposed to UFH for more than four days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/21\">",
"     21",
"    </a>",
"    ]. The incidence is much lower in patients treated with UFH for less than four days (0.2 percent) and in those treated with LMWH (0.2 versus 2.6 percent with UFH in a meta-analysis of studies that mostly consisted of patients who had undergone orthopedic surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these observations, we suggest that the platelet count be measured serially in patients treated with UFH. In patients with a history of HIT, or in whom HIT develops or is suspected while on UFH therapy, the preferred anticoagulant is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H33\">",
"     'Bivalirudin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Heparins summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     Enoxaparin",
"    </a>",
"    and UFH appear to be of equal efficacy when patients with UA and NSTEMI are evaluated in the aggregate. However, patients who are managed by a conservative strategy (ESSENCE, TIMI 11B, and Phase A of the A to Z trials) appear to have fewer adverse cardiovascular events when treated with enoxaparin compared to UFH. In addition, enoxaparin is easier to administer (subcutaneous as opposed the intravenous route with UFH) and requires no laboratory monitoring.",
"   </p>",
"   <p>",
"    On the other hand, for patients undergoing an early invasive strategy, UFH may be preferable in patients at high bleeding risk due to the increased risk of bleeding (",
"    <a class=\"graphic graphic_table graphicRef50176 \" href=\"UTD.htm?2/55/2940\">",
"     table 1",
"    </a>",
"    ) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    seen in the SYNERGY trial. There is no evidence to support the use of other LMWHs in preference to enoxaparin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DIRECT THROMBIN INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of the direct thrombin inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    , inogatran, efegatran, hirudin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    [Hirulog]), have been evaluated in trials of patients with non-ST elevation ACS. A meta-analysis of early trials found a significantly lower risk of death or MI at 30 days with direct thrombin inhibitors compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (7.4 versus 8.2 percent with unfractionated heparin [UFH], odds ratio 0.91, 95% CI 0.84-0.99), which was primarily due to a reduction in MI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/22\">",
"     22",
"    </a>",
"    ]. The treatment benefit was seen with hirudin and bivalirudin, but not with inogatran or argatroban. The better outcome was significant only in patients who underwent early PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/23\">",
"     23",
"    </a>",
"    ]. Compared to UFH, the risk of major bleeding (",
"    <a class=\"graphic graphic_table graphicRef50176 \" href=\"UTD.htm?2/55/2940\">",
"     table 1",
"    </a>",
"    ) was increased with hirudin and reduced with bivalirudin; there was no difference in intracranial hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Bivalirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    , a synthetic congener of hirudin, was initially evaluated in trials of patients with unstable angina (TIMI 7 trial and the Bivalirudin Angioplasty Study, both of which were included in the meta-analysis discussed directly above) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. A majority of patients enrolled in these early trials did not receive either glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors or a platelet P2Y12 receptor blocker such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    (alone or with a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor) compared to UFH or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (both with a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor) was evaluated in the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial of almost 14,000 patients with moderate to high risk acute coronary syndromes (both ST-elevation myocardial infarction [STEMI] and non-ST elevation ACS; 40 percent of all patients had unstable angina) undergoing PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Prior to randomization, about 64 percent of patients were receiving either UFH or enoxaparin, while about 36 percent were receiving neither. Nearly 65 percent of patients were taking a P2Y12 receptor blocker (either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    ) at the time of angiography. The primary end point was a composite of death, MI, or unplanned revascularization for ischemia at 30 days.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     Bivalirudin",
"    </a>",
"    alone was noninferior to UFH or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    for the rate of ischemic complications at 30 days (7.8 versus 7.3 percent, relative risk 1.08, 95% CI 0.93-1.24), while the rate of major bleeding was significantly lower with bivalirudin (3.0 versus 5.7 percent, relative risk 0.53, 95% CI 0.43-0.65). The net clinical benefit, defined as the rate of ischemic complications minus the bleeding rate, was significantly better with bivalirudin (10.1 versus 11.7 percent at 30 days).",
"   </p>",
"   <p>",
"    A pre-specified analysis of 30-day and 1 year major bleeding rates revealed a progressive increase in the frequency of bleeding with age irrespective of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/28\">",
"     28",
"    </a>",
"    ]. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    was associated with a significantly lower rate of non-CABG major bleeding at all ages with the magnitude of the absolute difference greatest in patients &ge;75 years (5.8 versus 10.1 percent).",
"   </p>",
"   <p>",
"    The impact of switching from a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    was evaluated in a substudy of the ACUITY trial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients who were switched had similar outcomes compared to those not switched. This information is relevant to the extent that in many hospitals, UFH or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    is used as the first anticoagulant in most patients with non-ST elevation ACS, often due to the high cost of prolonged bivalirudin therapy.",
"   </p>",
"   <p>",
"    ACUITY also emphasized the importance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    pretreatment in patients given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    who are not treated with a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor. On subset analysis, ischemic outcomes tended to be worse if clopidogrel was not given before angiography or PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H25#H25\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Bivalirudin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    compared to UFH in patients with non-ST elevation MI were also evaluated in the ISAR-REACT 4 trial, which randomly assigned 1721 patients with non-ST elevation MI to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    plus GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor or bivalirudin immediately before PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/30\">",
"     30",
"    </a>",
"    ]. At 30 days, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the rate of the primary composite end point (death, large recurrent myocardial infarction, urgent target&ndash;vessel revascularization [TVR], or major bleeding) between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      plus GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      (10.9 versus 11.0 percent; relative risk 0.99, 95% CI 0.74-1.32).",
"     </li>",
"     <li>",
"      There was no significant difference in the rate of the secondary end point of death, any recurrent MI, or urgent TVR (12.8 versus 13.4 percent, respectively).",
"     </li>",
"     <li>",
"      There was significantly more major bleeding with UFH plus GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor (4.6 versus 2.6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Direct thrombin inhibitors summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the different direct thrombin inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    is the best studied agent and appears to have the best efficacy to safety profile. When compared to UFH (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    ) plus a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor in patients with moderate to high risk acute coronary syndromes undergoing PCI, it is as effective and is associated with a lower risk of bleeding (",
"    <a class=\"graphic graphic_table graphicRef50176 \" href=\"UTD.htm?2/55/2940\">",
"     table 1",
"    </a>",
"    ). The benefit of bivalirudin is preserved even in patients switched from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or enoxaparin. Bivalirudin has not been compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     Bivalirudin",
"    </a>",
"    has not been evaluated in patients managed with a conservative strategy and is thus not recommended in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     FONDAPARINUX",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     Fondaparinux",
"    </a>",
"    is a reasonable anticoagulant choice in ACS patients, particularly those at increased risk of bleeding (",
"    <a class=\"graphic graphic_table graphicRef50176 \" href=\"UTD.htm?2/55/2940\">",
"     table 1",
"    </a>",
"    ), based principally on the results of the OASIS-5 trial.",
"   </p>",
"   <p>",
"    In OASIS-5, 20,078 non-ST elevation ACS patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily) for a mean of six days (anticoagulant was generally stopped after PCI, if it was performed) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Over 60 percent of patients underwent catheterization and over 30 percent had percutaneous coronary intervention (PCI). Patients received weight-adjusted UFH if the last dose of enoxaparin was greater than six hours before the procedure. For patients who received an initial dose of subcutaneous fondaparinux and then underwent PCI, an additional dose was given intravenously (",
"    <a class=\"graphic graphic_table graphicRef57341 \" href=\"UTD.htm?33/39/34427\">",
"     table 2",
"    </a>",
"    ). After isolated reports of catheter thrombosis, a protocol amendment allowed for the addition of open-label UFH in patients receiving fondaparinux at the discretion of the investigator.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two groups had similar rates of the primary end point, defined as death, MI, or refractory ischemia at nine days (5.8 versus 5.7 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      ), and the secondary end point of death or MI (4.1 percent in both groups).",
"     </li>",
"     <li>",
"      At longer term follow-up, there was a reduction in the primary end point with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      at 30 days (2.9 versus 3.5 percent, hazard ratio 0.83, 95% CI 0.71-0.97) and six months (5.8 versus 6.5 percent, hazard ratio 0.89, 95% CI 0.81-1.00). These differences were entirely due to a significantly lower rate of death.",
"     </li>",
"     <li>",
"      The rate of major bleeding was significantly reduced with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      (2.2 versus 4.1 percent, HR 0.52, 95% CI 0.44-0.61). The benefits and risks were consistent among various subgroups, including age and sex, the spectrum of renal function, and whether or not revascularization was performed within nine days [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    relative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    was confirmed in two important prespecified subgroups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 6238 patients who underwent PCI,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      significantly reduced major bleeding at day nine (2.4 versus 5.1 percent, hazard ratio 0.46, 95% CI 0.35-0.61), with comparable rates of the combined end point of death, MI or stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       Fondaparinux",
"      </a>",
"      significantly reduced major bleeding in the 3630 patients who received glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitors and the 13,531 patients who received platelet P2Y12 receptor blockers (5.2 versus 8.2 percent, hazard ratio 0.46, 95% CI 0.35-0.61 and 3.4 versus 5.4 percent, hazard ratio 0.62, 95% CI 0.52-0.73 respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/34\">",
"       34",
"      </a>",
"      ]. Ischemic events were similar between the two treatment arms in these two subsets, as in the entire OASIS-5 population. In addition, these findings regarding safety and efficacy were similar in the 3246 patients who received both antiplatelet therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    was associated with a small but significant increase in catheter-related thrombi (in patients undergoing PCI) compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (0.9 versus 0.4 percent). The frequency of catheter related thrombi was significantly reduced in both groups in those patients who received open-label UFH before the procedure.",
"   </p>",
"   <p>",
"    The observation in the OASIS-5 trial of a small but significant increase in catheter-related thrombi, which was mitigated by the use of UFH, raises the question as to the optimal dose of UFH in such patients. This issue was directly addressed in the",
"    <span class=\"nowrap\">",
"     FUTURA/OASIS",
"    </span>",
"    8 trial in which 2026 high-risk patients with non-ST elevation acute coronary syndromes treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    and scheduled to undergo PCI within 72 hours were randomly assigned to either a standard dose UFH regimen (85",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    bolus with additional boluses based on an activated clotting time dosing algorithm) or a fixed low dose (50",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    without activated clotting time) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/35\">",
"     35",
"    </a>",
"    ]. For patients receiving a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, the UFH bolus in the standard-dose group was lowered to 50",
"    <span class=\"nowrap\">",
"     units/kg.",
"    </span>",
"   </p>",
"   <p>",
"    At 48 hours after PCI, there was no significant difference between low-dose and standard regimens in the rate of the primary composite endpoint of major bleeding, minor bleeding, or major vascular access-site complications (4.7 versus 5.8 percent, respectively). The composite secondary outcome of major bleeding at 48 hours with death, myocardial infarction, or target vessel revascularization within 30 days occurred more often in the low-dose group, nearly attaining statistical significance (5.8 versus 3.9 percent; odds ratio 1.51, 95% CI 1.00-2.28). Catheter thrombus rates were very low and not statistically different in the two groups (0.5 and 0.1 percent, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40089?source=see_link\">",
"     \"Periprocedural bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Fondaparinux summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The OASIS-5 trial established",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    as a reasonable anticoagulant option to UFH,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    for patients with non-ST elevation ACS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients managed with a conservative strategy, we prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      to unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      . Issues of cost and local practice may influence the choice between the two. We prefer fondaparinux to enoxaparin in patients at increased risk of bleeding (",
"      <a class=\"graphic graphic_table graphicRef50176 \" href=\"UTD.htm?2/55/2940\">",
"       table 1",
"      </a>",
"      ), based on the findings in OASIS-5.",
"     </li>",
"     <li>",
"      For those patients undergoing PCI in whom",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      was chosen as the initial anticoagulant, we recommend switching to standard dose UFH, with further dosing of the latter based on the activated clotting time, as was done in the",
"      <span class=\"nowrap\">",
"       FUTURA/OASIS",
"      </span>",
"      8 trial. Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      has not been evaluated in this setting, we believe that switching to bivalirudin, is also a reasonable anticoagulant strategy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H614024307\">",
"    <span class=\"h1\">",
"     APPROACH TO ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulant therapy should be given as soon as possible after diagnosis to all patients with non-ST elevation ACS. This recommendation for early use is based on the fact that this therapy was started within a few hours of diagnosis in all of the randomized trials. The choice between UFH,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    is determined by whether the patient is managed by an early invasive or a conservative approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H4#H4\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Early invasive versus conservative strategy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients managed with a conservative approach, we prefer either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      or UFH. Bivalirudin has not been adequately assessed in this population, and enoxaparin leads to fewer adverse cardiovascular events when compared to UFH. In addition, enoxaparin is easier to administer (subcutaneous as opposed to the intravenous route with UFH) and requires no laboratory monitoring. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Heparins summary'",
"      </a>",
"      above.) The choice between fondaparinux and enoxaparin may be determined by issues of cost and local practice. For patients at higher risk of bleeding, we prefer fondaparinux to enoxaparin.",
"     </li>",
"     <li>",
"      For patients managed with an early invasive strategy (angiography within 4 to 48 hours),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      , UFH, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      are all effective at reducing the rates of ischemic events. However, the risk of bleeding appears to be greater with enoxaparin than each of the other anticoagulants. The choice between bivalirudin, fondaparinux, enoxaparin, and UFH should be made based on issues of cost, risk of bleeding, and local practice. When fondaparinux is chosen, UFH (or bivalirudin) should be given before percutaneous coronary intervention; when UFH is chosen, we suggest switching from UFH to bivalirudin.",
"     </li>",
"     <li>",
"      For patients who will be referred to the catheterization laboratory for catheterization within four hours, usually due to patient instability for reasons such as refractory angina, heart failure, arrhythmia, or hemodynamic instability, we prefer UFH or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       Fondaparinux",
"      </a>",
"      makes less sense in this setting as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or bivalirudin would need to be added to fondaparinux soon after starting the latter. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Fondaparinux summary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who undergo an invasive approach, and who were started on either UFH or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      , we prefer switching to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Bivalirudin'",
"      </a>",
"      above.). We acknowledge that the use of bivalirudin after fondaparinux (which otherwise requires the use of UFH at the time of PCI) has not been formally studied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100954534\">",
"    <span class=\"h1\">",
"     ANTICOAGULANT REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167446349\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dosing schedules are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      UFH &mdash; Intravenous bolus of 60-70",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      (maximum dose 5000 units) followed by 12",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour intravenously to achieve an activated partial thromboplastin time of 50 to 75 seconds.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       Enoxaparin",
"      </a>",
"      &mdash; No loading dose is necessary. Dosing is 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      subcutaneously every 12 hours or for patients with an estimated creatinine clearance less than 30",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      subcutaneously daily.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       Fondaparinux",
"      </a>",
"      &mdash; 2.5 mg subcutaneously once daily in patients managed with a non-invasive strategy. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Fondaparinux'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       Bivalirudin",
"      </a>",
"      &mdash; Intravenous bolus of 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and an infusion of 0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour before angiography; if PCI is performed, an additional 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      bolus is given and the infusion rate is increased to 1.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who undergo PCI after initial medical therapy, subsequent dosing depends upon which anticoagulant was given initially:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If UFH was given, we continue with an additional bolus of UFH after sheath insertion with an activated clotting time (ACT) of 200 to 250 seconds if the patient is treated with a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor and 250 to 300 seconds if a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor has not been given and is not planned during PCI.",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      was initiated and two or more doses were given and the last dose was given less than eight hours earlier, we proceed without additional enoxaparin or UFH. If a patient was given only one dose or the last dose was more than eight hours earlier, we give an additional bolus of enoxaparin (0.3 mg) or give UFH according to the above protocol. It may be better to continue with enoxaparin, especially if anticoagulation may be continued after the procedure, since extrapolation from SYNERGY suggests that switching to UFH may be associated with an increased risk of death or MI at 30 days. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Enoxaparin versus UFH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      was initiated, UFH in standard dose (50",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      bolus, with an ACT goal of greater than 200 seconds) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      in standard dose is given. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Fondaparinux'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167446356\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of anticoagulant therapy depends on the initial management strategy. Although the optimal treatment length has not been determined, the following represent commonly employed regimens in clinical practice (which we consider reasonable):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients undergoing PCI, anticoagulant therapy is stopped at the end of the procedure in uncomplicated cases. Continuation of anticoagulation beyond the times suggested above should be undertaken only if:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The PCI is complicated and there is an ongoing risk or recurrent ischemia.",
"     </li>",
"     <li>",
"      There is evidence of high risk for systemic or venous thromboembolism (anterior STEMI, severe left ventricular dysfunction, heart failure, history of systemic or pulmonary embolus, or echocardiographic evidence of mitral or left ventricular thrombus) or a preexistent rational for long term anticoagulation, such as patients with prosthetic heart valves or atrial fibrillation.",
"     </li>",
"     <li>",
"      In cases where a platelet P2Y12 receptor blocker has been given just before PCI and there is a concern about less than optimal antithrombotic effect. Under these circumstances, it is reasonable to continue a full infusion dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      for up to four hours after the procedure. This extended use of bivalirudin was used in the first randomized trial of Hirulog (bivalirudin) in patients with unstable angina and allowed for in the ACUITY, HORIZONS-AMI trials, and REPLACE-2 trials [",
"      <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/4,27,36,37\">",
"       4,27,36,37",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Bivalirudin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H25#H25\">",
"       \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Bivalirudin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link&amp;anchor=H21647881#H21647881\">",
"       \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Bivalirudin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients undergoing a non-invasive (conservative) strategy, UFH has been continued two to five days in most trials. We suggest a minimum of 48 hours for the duration of UFH; longer is reasonable in patients at low risk of bleeding (",
"      <a class=\"graphic graphic_table graphicRef50176 \" href=\"UTD.htm?2/55/2940\">",
"       table 1",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       Fondaparinux",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      have been continued for the duration of hospitalization (up to eight days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100953299\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the use of anticoagulant therapy in patients with non-ST elevation ACS are available from the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association (2012) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/38\">",
"     38",
"    </a>",
"    ], and the European Society of Cardiology (2010, 2011) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/2/5162/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Each of the guidelines makes a strong recommendation for the use of anticoagulant therapy in all patients with acute coronary syndromes (ACS).",
"   </p>",
"   <p>",
"    The following are important points made by in these guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      From the American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart Association:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients in whom an invasive strategy is selected, a strong recommendation is made for the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      , unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      . For patients undergoing urgent (immediate angiography), bivalirudin or UH is preferred.",
"     </li>",
"     <li>",
"      Among patients in whom a conservative strategy is selected, a strong recommendation is made for the use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      , or UFH, with the first two preferred to the latter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      From the European Society of Cardiology:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       Fondaparinux",
"      </a>",
"      , UFH,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      are given a strong recommendation for patients at medium to high risk of ischemia patients undergoing an invasive approach. The one exception was patients at very high ischemic risk, such as those with persistent angina, hemodynamic instability, or refractory arrhythmias, for whom UFH or bivalirudin is preferred.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       Fondaparinux",
"      </a>",
"      is preferred to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      , which is preferred to UFH, for patients managed with a conservative approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulant therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    prevents thrombus related ischemic events in patients with non-ST elevation acute coronary syndromes (ACS), which includes unstable angina and non-ST elevation myocardial infarction (NSTEMI). The following are our recommendations for the use of anticoagulants in patients with non-ST elevation ACS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend anticoagulant therapy for all patients (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1267953\">",
"       'Anticoagulant versus placebo'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      This recommendation is made for patients irrespective of whether an invasive or a conservative approach is taken. Anticoagulant therapy should be given as soon as possible after diagnosis and should be given in conjunction with recommended antiplatelet therapy. (See",
"      <a class=\"local\" href=\"#H614024307\">",
"       'Approach to anticoagulation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H43#H43\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients managed with an early invasive strategy (angiography within 4 to 48 hours), we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      or UFH as opposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) or to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). When fondaparinux is chosen, UFH (or bivalirudin) should be given before percutaneous coronary intervention.",
"     </li>",
"     <li>",
"      For patients who will be referred to the catheterization laboratory within four hours (usually due to patient instability for reasons such as refractory angina, heart failure, arrhythmia, or hemodynamic instability), we recommend UFH or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      as opposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H614024307\">",
"       'Approach to anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients in whom a conservative (non-invasive) strategy is planned, we recommend either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      in preference to either unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Heparins summary'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H40\">",
"       'Fondaparinux summary'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H37\">",
"       'Direct thrombin inhibitors summary'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H614024307\">",
"       'Approach to anticoagulation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The choice between fondaparinux and enoxaparin should be guided by issues of cost and local practice. For patients at higher risk of bleeding (",
"      <a class=\"graphic graphic_table graphicRef50176 \" href=\"UTD.htm?2/55/2940\">",
"       table 1",
"      </a>",
"      ), we suggest fondaparinux (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Enoxaparin versus UFH'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H40\">",
"       'Fondaparinux summary'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dosing schedules and duration of therapy for these anticoagulants are discussed above. (See",
"    <a class=\"local\" href=\"#H100954534\">",
"     'Anticoagulant regimens'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/1\">",
"      Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/2\">",
"      Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/3\">",
"      Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/4\">",
"      Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/5\">",
"      Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/6\">",
"      Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996; 347:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/7\">",
"      Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/8\">",
"      Berkowitz SD, Stinnett S, Cohen M, et al. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 2001; 88:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/9\">",
"      Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000; 36:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/10\">",
"      Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/11\">",
"      Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 2000; 36:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/12\">",
"      Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004; 292:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/13\">",
"      Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/14\">",
"      Mahaffey KW, Cohen M, Garg J, et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 2005; 294:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/15\">",
"      Silvain J, Beygui F, Barth&eacute;l&eacute;my O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012; 344:e553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/16\">",
"      Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999; 20:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/17\">",
"      Michalis LK, Katsouras CS, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003; 146:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/18\">",
"      Katsouras C, Michalis LK, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months. Am Heart J 2005; 150:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/19\">",
"      Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/20\">",
"      Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet 1999; 354:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/21\">",
"      Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/22\">",
"      Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002; 359:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/23\">",
"      Sinnaeve PR, Simes J, Yusuf S, et al. Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. Eur Heart J 2005; 26:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/24\">",
"      Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 1995; 92:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/25\">",
"      Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/26\">",
"      Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/27\">",
"      Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/28\">",
"      Lopes RD, Alexander KP, Manoukian SV, et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 53:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/29\">",
"      White HD, Chew DP, Hoekstra JW, et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008; 51:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/30\">",
"      Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/31\">",
"      Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/32\">",
"      Fox KA, Bassand JP, Mehta SR, et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 2007; 147:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/33\">",
"      Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007; 50:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/34\">",
"      Jolly SS, Faxon DP, Fox KA, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol 2009; 54:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/35\">",
"      FUTURA/OASIS-8 Trial Group, Steg PG, Jolly SS, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 2010; 304:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/36\">",
"      Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/37\">",
"      Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/38\">",
"      Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/39\">",
"      Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/2/5162/abstract/40\">",
"      Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31:2501.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 93 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5162=[""].join("\n");
var outline_f5_2_5162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF ANTICOAGULANT AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1267953\">",
"      ANTICOAGULANT VERSUS PLACEBO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HEPARINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Enoxaparin versus UFH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other LMWHs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Nadroparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Tinzaparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Dalteparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100954409\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Heparins summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DIRECT THROMBIN INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Bivalirudin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Direct thrombin inhibitors summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      FONDAPARINUX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Fondaparinux summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H614024307\">",
"      APPROACH TO ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100954534\">",
"      ANTICOAGULANT REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H167446349\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H167446356\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100953299\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/93\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/93|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/16/36110\" title=\"figure 1\">",
"      Mechanisms of action of heparin LMW heparin and fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/93|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/55/2940\" title=\"table 1\">",
"      Algorithm for predicting peri-procedural bleeding during PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/39/34427\" title=\"table 2\">",
"      Fondaparinux in ACS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40089?source=related_link\">",
"      Periprocedural bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44408?source=related_link\">",
"      Therapeutic use of fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_2_5163="Hay Ison criteria for diagnosis of bacterial vaginosis";
var content_f5_2_5163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hay Ison criteria for diagnosis of bacterial vaginosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Grade 0: No bacteria present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 1: Lactobacillus morphotypes predominate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 2: Mixed flora with some lactobacilli present, but gardnerella or mobiluncus morphotypes also present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 3*: Predominantly gardnerella and/or mobiluncus morphotypes. Few or absent lactobacilli.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 4: Gram-positive cocci predominate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *Grade 3 is diagnostic of bacterial vaginosis.",
"    </div>",
"    <div class=\"reference\">",
"     Source: Ison CA, Hay PE. Validation of a simplified grading of Gram stained vaginal smears for use in genitourinary medicine clinics. Sex Transm Infect 2002; 78:413.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5163=[""].join("\n");
var outline_f5_2_5163=null;
var title_f5_2_5164="Signs dehydration PI";
var content_f5_2_5164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs and symptoms of dehydration in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mild",
"        <br/>",
"        (3-5 percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Moderate",
"        <br/>",
"        (6-9 percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe",
"        <br/>",
"        (&ge;10 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulse",
"       </td>",
"       <td>",
"        Full, normal rate",
"       </td>",
"       <td>",
"        Rapid",
"       </td>",
"       <td>",
"        Rapid and weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systolic pressure",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal to low",
"       </td>",
"       <td>",
"        Very low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respirations",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Deep, rate may be increased",
"       </td>",
"       <td>",
"        Deep, rapid rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral tissues",
"       </td>",
"       <td>",
"        Tacky or slightly dry",
"       </td>",
"       <td>",
"        Dry",
"       </td>",
"       <td>",
"        Parched",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant fontanelle (soft spot in skull)",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Sunken",
"       </td>",
"       <td>",
"        Markedly sunken",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyes",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Sunken",
"       </td>",
"       <td>",
"        Markedly sunken",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Cool",
"       </td>",
"       <td>",
"        Cool, mottled, blue-tinged hands/feet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine output",
"       </td>",
"       <td>",
"        Mildly reduced",
"       </td>",
"       <td>",
"        Markedly reduced",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic signs",
"       </td>",
"       <td>",
"        Increased thirst",
"       </td>",
"       <td>",
"        Listlessness, irritability",
"       </td>",
"       <td>",
"        Grunting, lethargy, coma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5164=[""].join("\n");
var outline_f5_2_5164=null;
var title_f5_2_5165="Echinocandins PK";
var content_f5_2_5165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected pharmacokinetic characteristics of the echinocandins in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Caspofungin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Micafungin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anidulafungin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elimination half-life adult* (hours)",
"       </td>",
"       <td>",
"        27-50",
"       </td>",
"       <td>",
"        14-17.2",
"       </td>",
"       <td>",
"        40-50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolism",
"       </td>",
"       <td>",
"        Hepatic: slow peptide hydrolysis and N-acetylation, with some spontaneous degradation to peptide product",
"       </td>",
"       <td>",
"        Hepatic: catechol-O-methytransferase (COMT) and to a lesser extent, CYP1A2, 2B6, 2C and 3A4",
"       </td>",
"       <td>",
"        Not metabolized: undergoes slow spontaneous degradation to inactive metabolites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dosage adjustment for hepatic insufficiency",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Mild (Child-Pugh 5-6): none",
"         </li>",
"         <li>",
"          Moderate (Child-Pugh 7-9): decrease maintenance dose to 35 mg/day",
"         </li>",
"         <li>",
"          Severe (Child-Pugh &gt;9): no data",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Mild and Moderate (Child-Pugh 5-9): none",
"         </li>",
"         <li>",
"          Severe (Child-Pugh &gt;9): no data",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Not necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dosage adjustment for renal insufficiency",
"       </td>",
"       <td>",
"        Not necessary",
"       </td>",
"       <td>",
"        Not necessary",
"       </td>",
"       <td>",
"        Not necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug interactions",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Cyclosporine increases caspofungin AUC by ~35 percent",
"         </li>",
"         <li>",
"          Potent inducers of metabolism (eg, rifampin, efavirenz, nevirapine, phenytoin, dexamethasone, carbemazepine) reduce caspofungin AUC by 15-30 percent",
"         </li>",
"         <li>",
"          Caspofungin reduces tacrolimus AUC by ~20 percent",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CSF penetration (percent of plasma)",
"       </td>",
"       <td>",
"        &lt;0.1",
"       </td>",
"       <td>",
"        &lt;0.1",
"       </td>",
"       <td>",
"        &lt;0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fraction urine excretion (percent)",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein binding (percent)",
"       </td>",
"       <td>",
"        96-97",
"       </td>",
"       <td>",
"        99.8",
"       </td>",
"       <td>",
"        84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vd (L/kg)",
"       </td>",
"       <td>",
"        0.14",
"       </td>",
"       <td>",
"        0.22-0.24",
"       </td>",
"       <td>",
"        0.50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AUC: area under curve; CYP: cytochrome P; N/A: not applicable; CSF: cerebrospinal fluid; Vd: volume of distribution.",
"     <br>",
"      * Half-life of caspofungin and micafungin may be reduced in young children and infants compared with adults due to more rapid clearance.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Sources:",
"     <br>",
"      <ol>",
"       <li>",
"        US FDA-approved product information.",
"       </li>",
"       <li>",
"        Stone, JA, Holland, SD, Wickersham, PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739.",
"       </li>",
"       <li>",
"        Stone, JA, Xu, X, Winchell, GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48:815.",
"       </li>",
"       <li>",
"        Dodds Ashley, E, Lewis, R, Lewis, J, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43 Suppl 1:S28.",
"       </li>",
"       <li>",
"        Sucher, AJ, Chahine, EB, Balcer, HE. Echinocandins: the newest class of antifungals. Ann Pharmacotherapy 2009; 43:1647.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5165=[""].join("\n");
var outline_f5_2_5165=null;
var title_f5_2_5166="Postnatal evaluation of severe bilateral prenatal hydronephrosis";
var content_f5_2_5166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postnatal evaluation of severe bilateral prenatal hydronephrosis*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 413px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     US: ultrasound; VCUG: voiding cystourethrogram.",
"     <br/>",
"     * If the premature hydronephrosis is mild to moderate (&lt;15 mm, third trimester) and there are no other findings suggestive of renal disease (ie, ureter, ureterocele, thickened bladder, renal cysts, or renal echogenecity), evaluation can be performed after seven days of life.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_2_5166=[""].join("\n");
var outline_f5_2_5166=null;
var title_f5_2_5167="Contents: Primary care rheumatology";
var content_f5_2_5167=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care rheumatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care rheumatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Arthritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/24/1416\">",
"           Asymptomatic hyperuricemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/46/13033\">",
"           Clinical features of rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/49/4890\">",
"           Clinical manifestations and diagnosis of gout",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/49/12056\">",
"           Clinical manifestations of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/32/33287\">",
"           Diagnosis and classification of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/55/6010\">",
"           Diagnosis and differential diagnosis of rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/7/3193\">",
"           Diagnostic imaging of joint pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/14/28904\">",
"           Evaluation of the adult with monoarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/15/34039\">",
"           Evaluation of the adult with polyarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/11/39098\">",
"           General principles of management of rheumatoid arthritis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/42/5800\">",
"           Hemarthrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/52/23368\">",
"           Joint aspiration or injection in adults: Technique and indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/30/2538\">",
"           Nonpharmacologic therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/41/42648\">",
"           Origin and utility of measurement of rheumatoid factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/33/1558\">",
"           Pathogenesis and diagnosis of viral arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/23/14714\">",
"           Pharmacologic therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29370\">",
"           Risk factors for and possible causes of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/50/11049\">",
"           Septic arthritis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/56/20360\">",
"           Synovial fluid analysis and the diagnosis of septic arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/24/17800\">",
"           Treatment of acute gout",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/62/3047\">",
"           Uric acid nephrolithiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7621\">",
"           Weight-resistance exercises in patients with osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/19/5427\">",
"           Weight-resistance training in patients with osteoarthritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Muscle disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/4/26694\">",
"           Approach to the patient with muscle weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/44/6856\">",
"           Drug-induced myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/40/23173\">",
"           Glucocorticoid-induced myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/24/29060\">",
"           Muscle examination in the evaluation of weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rheumatic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/32/13832\">",
"           Clinical manifestations and diagnosis of polymyalgia rheumatica",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/48/6921\">",
"           Clinical manifestations and diagnosis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/33/18969\">",
"           Clinical manifestations of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/48/28425\">",
"           Diagnosis of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/50/34599\">",
"           Diagnosis of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/7/3193\">",
"           Diagnostic imaging of joint pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/5/80\">",
"           Episcleritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13130\">",
"           Erythema nodosum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26263\">",
"           Evaluation of a tick bite for possible Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/54/28520\">",
"           Measurement and clinical significance of antinuclear antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/18/4392\">",
"           Musculoskeletal ultrasonography: Clinical applications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/37/6745\">",
"           NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38393\">",
"           NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/19/1336\">",
"           NSAIDs: Mechanism of action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17177\">",
"           Nonselective NSAIDs: Overview of adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33382\">",
"           Overview of the use of immunosuppressive and disease-modifying drugs in the rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/45/39641\">",
"           Pregnancy in women with systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/54/27498\">",
"           Treatment of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/26/34217\">",
"           Treatment of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/41/40598\">",
"           Treatment of polymyalgia rheumatica",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/16/23817\">",
"           Uveitis: Etiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/10/10407\">",
"           Uveitis: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Soft tissue disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/45/14041\">",
"           Bursitis: An overview of clinical manifestations, diagnosis, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/7/9335\">",
"           Clinical evaluation of musculoskeletal chest pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/15/42230\">",
"           Clinical manifestations and diagnosis of carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8056\">",
"           Clinical manifestations and diagnosis of fibromyalgia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/49/35608\">",
"           Differential diagnosis of fibromyalgia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/22/23911\">",
"           Etiology of carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/24/1418\">",
"           Evaluation of the patient with neck pain and cervical spine disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/9/2201\">",
"           Major causes of musculoskeletal chest pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/18/4392\">",
"           Musculoskeletal ultrasonography: Clinical applications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/60/1991\">",
"           Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4711\">",
"           Nocturnal leg cramps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/30/42472\">",
"           Overview of soft tissue rheumatic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/40/44681\">",
"           Plantar fasciitis and other causes of heel pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1030\">",
"           Posterior and medial ankle tendinopathies not involving the Achilles tendon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/3/32822\">",
"           Surgery for carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/1/7194\">",
"           Temporomandibular joint dysfunction syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/62/44008\">",
"           Treatment of carpal tunnel syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Spinal disease and back pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/10/18601\">",
"           Approach to the diagnosis and evaluation of low back pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/21/12633\">",
"           Diagnostic testing for low back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/21/13658\">",
"           Treatment of acute low back pain",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-EFA98743D5-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_2_5167=[""].join("\n");
var outline_f5_2_5167=null;
